METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS

BACKGROUND OF THE INVENTION

(1) Field of the Invention:

5

10

15

20

25

30

[0001] The present invention relates generally to the use of an enzyme inhibitor alone and in combination with an antidepressant agent for the treatment or prevention of psychiatric disorders, and in particular to the use of a cyclooxygenase-2 inhibitor alone and in combination with an antidepressant agent.

(2) Description of the Related Art:

[0002] Many people in the United States and around the world suffer from some form or combination of psychiatric disorders. A broad spectrum of psychiatric disorders has now been recognized, many of which have overlapping and interacting etiologies. Two of the most widespread and prevalent of the psychiatric disorders are depression (unipolar disorder or major depressive disorder) and manic depression (bipolar disorder).

[0003] The most common category of psychiatric disorders is mood disorders, accounting for 25% of patients in public mental institutions, 65% of psychiatric outpatients, and 10% of all patients seen in nonpsychiatric medical settings. Mood disorders are a group of typically recurrent illnesses characterized by pervasive disturbances, psychomotor dysfunction and vegetative symptoms, including depression, manic depression, dysthymic disorders, and cyclothymic disorder. Some type of mood disorder affects 20% of women and 12% of men during their lifetime, with a major part of these figures representing subjects suffering from depression. See *The Merck Manual of Diagnosis & Therapy, Beers & Brakow, 17th edition,* Published by Merck Research Labs, *Sec. 15, Chap. 189, Psychiatric Disorders, Mood Disorders* (1999).

[0004] A subject suffering from depression may display a variety of symptoms and moods. The mood of a subject suffering from depression can generally be depressed, irritable, anxious, miserable, morbid, preoccupied with guilt, self-degenerating, indecisive, helpless, hopeless, or any combination thereof. The subject may also have social withdrawal, recurrent thoughts of death or suicide, sleep disorders, decreased ability to concentrate, diminished interest in usual activities, or any combination of these symptoms.

5

10

15

20

25

30

[0005] While the exact cause of depression and other mood disorders is unknown, it has been suggested that impaired limbic-diencephalic function is the final pathway causing mood disorders. Also, cholinergic, catecholaminergic (noradrenergic or dopaminergic) and serotonergic (5-HT) neurotransmission imbalances have been implicated as a cause of many mood disorders. Most antidepressant agents are directed toward these systems as a treatment or prevention of psychiatric disorders.

[0006] Other causes of mood disorders can be stressors that provoke affective episodes either psychologically or biologically. Traumatic life events, especially separations, commonly precede depressive and manic depressive episodes. This type of mood disorder may arise in a subject with any type of personality, although, such events may trigger depression symptoms from manifesting in a subject suffering from a subtle mood disorder rather than its cause.

[0007] Some subjects suffering from one or more psychiatric disorders also have signs of physical pain, sickness, headaches, or other physical conditions. Subjects diagnosed with one or more psychiatric disorders are often treated as outpatients, although other patients require full-time supervision and treatment. Antidepressant agents play a large role in this treatment, usually in combination with supportive therapy. Many different types of antidepressant agents with varying functionalities have emerged over the years and are used as pharmaceutical therapies. See Ables, A., et al., Am. Fam. Physician 67(3):547-54 (2003). These

antidepressant agents are helpful to the patient by helping to treat and prevent the emergence of symptoms associated with the psychiatric disorder. See Hegarty K. et al., Aust. Fam. Physician 32(4):229-34, 236-7, 239 (2003). In fact, symptom remission is usually the goal of treatment of a subject suffering from a psychiatric disorder.

5

10

15

20

25

30

[0008] An example of one of the most prevalently prescribed antidepressant agents is the compound sertraline (Zoloft®). Sertraline was initially introduced for the treatment of depression, but it is now used to treat a wide variety of psychiatric disorders. See Khouzam H., et al., Compr. Ther. 29(1):47-53 (2003). Sertraline acts as a selective serotonin reuptake inhibitor (SSRI). However, it is structurally unrelated to other SSRIs, tricyclic, tetracyclic, or other available antidepressant agents.

[0009] Even after treatment with an antidepressant agent, a subject suffering from depression often continues to have symptoms. See Menza M., et al., J. Clin. Psychiatry 64(5):516-23 (2003).

[0010] Some subjects also develop physical side effects during treatment with an antidepressant agent. These side effects may include sexual dysfunction, sickness, headaches, pain, sleep disorders, physical dependence and addiction to the antidepressant agent, and other adverse side effects. Also, many subjects suffering from depression do not respond as expected to conventional treatment with antidepressant drugs.

[0011] Moreover, the treatment of psychiatric disorders with only antidepressant agents fails to address all the underlying causes of psychiatric disorders. This is problematic because some psychiatric disorders are thought to arise, in part, from the release of inflammatory mediators formed within the brain. For example, several clinical studies have suggested that depression may be accompanied by an activation of the inflammatory response system. See Tiemeier, H., et al., Epidemiology 14(1):103-7 (2003). Another study reported that an association exists between depression and the presence of low-grade systemic inflammation. See Danner, M., et al., Psychosom. Med. 65(3):347-56

(2003). Conventional antidepressants fail to address this inflammatory aspect of psychiatric disorders.

5

10

15

20

25

30

Inhibitors of the cyclooxygenase-2 (Cox-2) enzyme have been increasingly recognized as having beneficial effects on inflammation. For example, typical of the development of many inflammatory symptoms is upregulation of the Cox-2 enzyme. Cox-2 is an enzyme produced by an inducible gene, which is responsible for the biosynthesis of prostaglandins in inflammatory cells. Inflammation causes the induction of the Cox-2 enzyme, leading to the release of prostanoids (prostaglandin E2), which sensitize peripheral nociceptor terminals and produce localized inflammation and edema. See e.g., Samad, T., et al., Nature 410(6827):471-5 (2001).

[0013] Historically, physicians have treated inflammation-related disorders with a regimen of nonsteroidal anti-inflammatory drugs (NSAIDS), such as, for example, aspirin and ibuprofen. Undesirably, however, some NSAIDS are known to cause gastrointestinal (GI) bleeding or ulcers in patients undergoing consistent long term regimens of NSAID therapy. See Henry, D., et al., Lancet 337:730 (1991).

[0014] A reduction of unwanted side effects of common NSAIDS was made possible by the discovery that two cyclooxygenases are involved in the transformation of arachidonic acid as the first step in the prostaglandin synthesis pathway. These enzymes exist in two forms and have been termed cyclooxygenase-1 (Cox-1) and cyclooxygenase-2 (Cox-2). See Needleman, P. et al., J. Rheumatol. 24, Suppl. 49:6-8 (1997).

[0015] Cox-1 is a constitutive enzyme responsible for the biosynthesis of prostaglandins in the gastric mucosa and in the kidney. Cox-2 is an enzyme that is produced by an inducible gene that is responsible for the biosynthesis of prostaglandins in inflammatory cells. Inflammation causes the induction of Cox-2, leading to the release of prostanoids (prostaglandin E2), which sensitize peripheral nociceptor terminals and produce localized pain hypersensitivity, inflammation, and oedema. See Samad, T., et al., Nature 410(6827):471-5 (2001).

[0016] Many common NSAIDs are now known to be inhibitors of both Cox-1 and Cox-2. Accordingly, when administered in sufficiently high levels, these NSAIDs not only alleviate the inflammatory consequences of Cox-2 activity, but also inhibit the beneficial gastric maintenance activities of Cox-1.

5

10

15

20

25

30

[0017] Research into the area of arachidonic acid metabolism has resulted in the discovery of compounds that selectively inhibit the Cox-2 enzyme to a greater extent than the activity of Cox-1. The Cox-2 selective inhibitors are believed to offer advantages that include the capacity to prevent or reduce inflammation while avoiding harmful side effects associated with the inhibition of Cox-1. Thus, Cox-2 selective inhibitors have shown great promise for use in therapies -- especially in therapies that require maintenance administration, such as for pain and inflammation control.

[0018] While Cox-2 inhibitors have been described heretofore for treating pain and inflammation, they have not been described for the treatment or prevention of psychiatric disorders.

Despite the recent advances that have been made in [0019] understanding psychiatric disorders, they remain notoriously difficult to treat or prevent. Although significant progress has been made in the field of antidepressant agents, a continuing need still exists for better antidepressant agents that also have fewer side-effects and a more targeted functionality. From the foregoing, it can be seen that a need exists for improved methods and therapeutic compositions to treat psychiatric disorders. It would also be useful to provide an improved method and composition for reducing the symptoms associated with psychiatric disorders. Likewise, methods and compositions that improve patient outcomes following treatment with antidepressant agents would be desirable. Also, methods and compositions that reduce dosages or reduce unwanted side effects in conventional treatments for psychiatric disorders are desirable. Finally, methods and compositions that improve the efficacy of treating psychiatric disorders that are resistant in a

particular subject to known methods of therapy alone would also be desirable.

5

10

15

20

25

30

SUMMARY OF THE INVENTION

[0020] Briefly, therefore, the present invention is directed to a novel method of treating or preventing a psychiatric disorder in a subject comprising administering to the subject at least one Cox-2 inhibitor.

[0021] The present invention is also directed to a novel method of treating or preventing a psychiatric disorder in a subject comprising administering to the subject at least one Cox-2 inhibitor in combination with an antidepressant agent.

[0022] The present invention is also directed to a novel therapeutic composition comprising a Cox-2 inhibitor and an antidepressant agent.

[0023] The present invention is also directed to a novel pharmaceutical comprising a Cox-2 inhibitor, an antidepressant agent, and a pharmaceutically acceptable carrier.

[0024] The present invention is also directed to a novel kit for preventing or treating psychiatric disorders in a subject that is in need of such prevention or treatment, the kit comprising one dosage form comprising a Cox-2 inhibitor and a second dosage form comprising an antidepressant agent.

present invention, therefore, may be noted the provision of improved methods, therapeutic compositions, pharmaceutical compositions, and kits for the prevention or treatment of psychiatric disorders such as depression. Other advantages achieved by the present invention include improved methods, compositions, and kits for reducing both the inflammation and depression symptoms that may be associated with psychiatric disorders. Still other advantages achieved by the present invention include methods, compositions, and kits that improve patient recurrences of psychiatric symptoms. In addition, the present invention provides methods, compositions, and kits that reduce dosages or reduce

unwanted side effects in conventional treatments for psychiatric disorders. Finally, the present invention provides methods and compositions that improve the efficacy of treating a psychiatric disorder that is considered resistant or intractable to known methods of therapy alone.

5

10

15

20

25

30

DETAILED DESCRIPTION

[0026] In accordance with the present invention, it has been discovered that the treatment and/or prevention of psychiatric disorders, including such disorders as depression and manic depression, is provided by a therapy comprising a Cox-2 inhibitor alone or in combination with an antidepressant agent.

[0027] For purposes of the present invention, the novel therapy comprising at least one Cox-2 inhibitor alone or in combination with at least one antidepressant agent is useful for the purpose of preventing or treating psychiatric disorders. The present therapy is also useful for the purpose of preventing or treating psychiatric disorders in a subject that is in need of such prevention or treatment.

The therapy of the present invention is useful, for example, to reduce such psychiatric disorder symptoms as a mood that is depressed, irritable, anxious, miserable, morbid, preoccupied with guilt, self-degenerating, indecisive, helpless, hopeless, or any combination of the foregoing. The subject may also have social withdrawal, recurrent thoughts of death or suicide, sleep disorders, decreased ability to concentrate, diminished interest in usual activities, or any combination of these symptoms. The therapy of the present invention would also be useful to prevent the occurrence of such symptoms.

[0029] The methods and compositions of the present invention are also useful to reduce the number of hospitalizations of subjects suffering from a chronic psychiatric disorder.

[0030] The administration of a Cox-2 inhibitor alone or in combination with at least one antidepressant agent for the prevention or treatment of a psychiatric disorder is an unexpectedly effective treatment

and preventative therapy. Such administration is effective for improving the symptoms of a psychiatric disorder while avoiding or reducing certain disadvantages of current treatments. The therapy of a Cox-2 inhibitor alone or in combination with at least one antidepressant agent is also useful for decreasing the required number of separate dosages, thus, potentially improving patient compliance.

5

10

15

20

25

30

[0031] Therapies comprising at least one Cox-2 inhibitor alone or in combination with at least one antidepressant agent are useful not only for improving psychiatric disorder symptoms and shortening recovery times, but also for reducing or eliminating the dosages of antidepressant agents that are normally required. The elimination of or administration of lower dosages of antidepressant agents provides a reduction in side effects corresponding to such antidepressant agents.

[0032] Another embodiment of the present invention is a combination therapy for treating or preventing psychiatric disorders and psychiatric disorder symptoms in a subject in need of such treatment and prevention comprising at least one Cox-2 inhibitor and at least one antidepressant agent.

[0033] Such administration is effective for improving the symptoms of psychiatric disorders while avoiding or reducing certain disadvantages of current treatments. The combination therapy of a Cox-2 inhibitor and an antidepressant agent is also useful for decreasing the required number of separate dosages, thus, potentially improving patient compliance. For example, in one embodiment, the combination therapy of the present invention is useful for reducing the dosing frequency of conventional antidepressant treatment agents. One antidepressant agent, buproprion (Wellbutrin®), is typically dosed three to four times daily. Dosing three to four times daily may become problematic for a subject suffering from a neurodegenerative symptom, such as short term memory loss or from seriously ill subjects who have difficulty complying with multiple doses/day. Thus, administering the combination therapy of the present invention to a

subject undergoing dosing with buproprion may reduce the required number of separate doses normally prescribed with buproprion.

[0034] Combination therapies comprising Cox-2 inhibitors and antidepressant agents are useful not only for improving psychiatric disorder symptoms and shortening recovery times, but also for reducing the dosages of conventional antidepressant agents that are normally required.

5

10

15

20

25

30

[0035] For example, the combination therapy is effective for lowering the dosages of antidepressant agents that are normally prescribed as a monotherapy. The administration of lower dosages of antidepressant agents provides a reduction in side effects corresponding to such agents. Reduced dosages of antidepressant agents are beneficial where normal dosages often exhibit harmful side effects, for example, with such conventional antidepressant agents as fluoxetine (Prozac®). In some patients, fluoxetine causes sexual dysfunction, which can lead to reduced patient compliance with the treatment regimen.

[0036] The administration of a Cox-2 inhibitor in combination with an antidepressant agent is an effective treatment for psychiatric disorders and psychiatric disorder-related symptoms, and in preferred embodiments, is superior to the use of either agent alone.

[0037] Moreover, in one embodiment, the combination therapy demonstrates a synergistic efficacy for treating and preventing psychiatric disorders and psychiatric disorder-related complications that is greater than what would be expected from simply combining the two therapies.

[0038] The term "synergistic" refers to the combination of a Cox-2 inhibitor and an antidepressant agent as a combined therapy having an efficacy for the prevention and treatment of psychiatric disorders that is greater than what would be expected merely from the sum of their individual effects.

[0039] The synergistic effects of the embodiments of the present invention's combination therapy encompass additional advantages for the treatment and prevention of psychiatric disorders. Such additional

advantages include, but are not limited to, lowering the required dose of antidepressant agents, reducing the side effects of antidepressant agents, and rendering those agents more tolerable to subjects in need of psychiatric disorder therapy.

5

10

15

20

25

30

[0040] As used herein, the phrases "combination therapy", "coadministration", "co-administering", "administration with", "administering", "combination", or "co-therapy", when referring to the embodiment of the present invention that comprises the use of a Cox-2 inhibitor in combination with an antidepressant agent, are intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co-administration of these agents in a substantially simultaneous manner. Thus, the Cox-2 inhibitor and antidepressant agent may be administered in one therapeutic dosage form, such as in a single capsule, tablet, or injection, or in two separate therapeutic dosage forms, such as in separate capsules, tablets, or injections.

[0041] Sequential administration of such treatments encompasses both relatively short and relatively long periods between the administration of each of the drugs of the present method. However, for purposes of the present invention, the second drug is administered while the first drug is still having an efficacious effect on the subject.

[0042] Preferably, the second of the two drugs is to be given to the subject within the therapeutic response time of the first drug to be administered. For example, the combination therapy of the present invention encompasses administration of a Cox-2 inhibitor to the subject and the later administration of an antidepressant agent, as long as the antidepressant agent is administered to the subject while the Cox-2 inhibitor is still present in the subject at a level, which in combination with the level of the antidepressant agent is therapeutically effective, and vice versa.

[0043] As used herein, the term "therapeutic response time" means the duration of time that a compound is present or detectable within a subject's body at therapeutic concentrations.

5

10

15

20

25

30

[0044] As used herein, the term "monotherapy" is intended to embrace administration of a Cox-2 inhibitor to a subject suffering from a psychiatric disorder as a single therapeutic treatment without any additional therapeutic treatment comprising an antidepressant agent. However, the Cox-2 inhibitor may still be administered in multiple dosage forms. Thus, the Cox-2 inhibitor may be administered in one therapeutic dosage form, such as in a single capsule, tablet, or injection, or in two separate therapeutic dosage forms, such as in separate capsules, tablets, or injections.

[0045] In one embodiment, the present invention provides a method for treating or preventing psychiatric disorders in a subject in need of such treatment or prevention.

[0046] In another embodiment, the present invention provides a method for preventing psychiatric disorders in a subject comprising administering to the subject a Cox-2 inhibitor alone or in combination with an antidepressant agent.

[0047] As used herein, the terms "to prevent", "preventing", or "prevention" refer to any reduction, no matter how slight, of a subject's predisposition or risk for developing a psychiatric disorder. This definition includes either preventing the onset of a psychiatric disorder altogether or preventing the onset of a preclinically evident stage of a psychiatric disorder in individuals at risk.

[0048] In yet another embodiment, the present invention provides a method for treating psychiatric disorders in a subject comprising administering to the subject a Cox-2 inhibitor alone or in combination with an antidepressant agent.

[0049] As used herein, the terms "treating", "treatment", "treated", or "to treat," mean to alleviate symptoms, eliminate the cause of symptoms either on a temporary or permanent basis, or to alter or slow the

appearance of symptoms or symptom worsening. The term "treatment" includes alleviation or elimination of the cause of the symptoms associated with, but not limited to, any of the psychiatric disorders or psychiatric disorder-related symptoms described herein.

[0050] Without being bound by this or any other theory, it is believed that a therapy comprising a Cox-2 inhibitor alone or in combination with an antidepressant agent is efficacious for preventing or treating psychiatric disorders and psychiatric disorder-related symptoms.

5

10

15

20

25

30

[0051] The combination therapy embodiment of the present invention also provides for the treatment of psychiatric disorder-related symptoms, which may arise indirectly from having a psychiatric disorder, by treating the underlying psychiatric disorder itself. For example, if a subject is suffering from a psychiatric disorder-related symptom, such as a depressed mood, the treatment of the underlying psychiatric disorder, such as depression, by the methods and compositions of the present invention will likewise improve the symptoms of the associated complication.

[0052] The present invention encompasses a novel method of preventing or treating psychiatric disorders and psychiatric disorder-related symptoms in a subject that is in need of such prevention or treatment comprising administering to the subject at least one Cox-2 inhibitor. In a second embodiment, the present invention encompasses a novel method of preventing or treating psychiatric disorders and psychiatric disorder-related symptoms in a subject that is in need of such prevention or treatment comprising administering to the subject at least one Cox-2 inhibitor and one or more antidepressant agents.

[0053] A component of the present invention is a Cox-2 inhibitor.
[0054] Inhibitors of the cyclooxygenase pathway in the metabolism of arachidonic acid used in the prevention and treatment of psychiatric disorders may inhibit enzyme activity through a variety of mechanisms. By the way of example, the inhibitors used in the methods described herein

may block the enzyme activity directly by acting as a substrate for the enzyme.

5

10

15

20

25

30

[0055] The terms "cyclooxygenase-2 inhibitor", or "Cox-2 inhibitor", which can be used interchangeably herein, embrace compounds which inhibit the Cox-2 enzyme regardless of the degree of inhibition of the Cox-1 enzyme, and include pharmaceutically acceptable salts of those compounds. Thus, for purposes of the present invention, a compound is considered a Cox-2 inhibitor irrespective of whether the compound inhibits the Cox-2 enzyme to an equal, greater, or lesser degree than the Cox-1 enzyme.

In one embodiment of the present invention, it is preferred that the Cox-2 inhibitor compound is a non-steroidal anti-inflammatory drug (NSAID). Therefore, preferred materials that can serve as the Cox-2 inhibitor of the present invention include non-steroidal anti-inflammatory drug compounds, a pharmaceutically acceptable salt thereof, or a pure (-) or (+) optical isomeric form thereof.

Examples of NSAID compounds that are useful in the [0057] present invention include acemetacin, acetyl salicylic acid, alclofenac, alminoprofen, azapropazone, benorylate, benoxaprofen, bucloxic acid, carprofen, choline magnesium trisalicylate, clidanac, clopinac, dapsone, diclofenac, diflunisal, droxicam, etodolac, fenoprofen, fenbufen, fenclofenec, fentiazac, floctafenine, flufenisal, flurbiprofen, (r)-flurbiprofen, (s)-flurbiprofen, furofenac, feprazone, flufenamic acid, fluprofen, ibufenac, ibuprofen, indometacin, indomethacin, indoprofen, isoxepac, isoxicam, ketoprofen, ketorolac, miroprofen, piroxicam, meloxicam, mefenamic, mefenamic acid, meclofenamic acid, meclofen, nabumetone, naproxen, niflumic acid, oxaprozin, oxipinac, oxyphenbutazone, phenylbutazone, podophyllotoxin derivatives, proglumetacin, piprofen, pirprofen, prapoprofen, salicylic acid, salicylate, sudoxicam, suprofen, sulindac, tenoxicam, tiaprofenic acid, tiopinac, tioxaprofen, tolfenamic acid, tolmetin, zidometacin, zomepirac, and 2-fluoro-a-methyl[1,1'-biphenyl]-4-acetic acid, 4-(nitrooxy)butyl ester.

[0058] In a preferred embodiment, the Cox-2 inhibitor is a Cox-2 selective inhibitor. The term "Cox-2 selective inhibitor" embraces compounds which selectively inhibit the Cox-2 enzyme over the Cox-1 enzyme, and also include pharmaceutically acceptable salts and prodrugs of those compounds.

5

10

15

20

25

30

[0059] In practice, the selectivity of a Cox-2 inhibitor varies depending upon the condition under which the test is performed and on the inhibitors being tested. However, for the purposes of this specification, the selectivity of a Cox-2 inhibitor can be measured as a ratio of the in vitro or in vivo IC50 value for inhibition of Cox-1, divided by the IC50 value for inhibition of Cox-2 (Cox-1 IC50/Cox-2 IC50). A Cox-2 selective inhibitor is any inhibitor for which the ratio of Cox-1 IC50 to Cox-2 IC50 is greater than 1. In preferred embodiments, this ratio is greater than 2, more preferably greater than 5, yet more preferably greater than 10, still more preferably greater than 50, and more preferably still greater than 100.

[0060] As used herein, the term "IC50" refers to the concentration of a compound that is required to produce 50% inhibition of cyclooxygenase activity. Preferred Cox-2 selective inhibitors of the present invention have a Cox-2 IC50 of less than about 1 μ M, more preferred of less than about 0.5 μ M, and even more preferred of less than about 0.2 μ M.

[0061] Preferred Cox-2 selective inhibitors have a Cox-1 IC50 of greater than about 1 μ M, and more preferably of greater than 20 μ M. Such preferred selectivity may indicate an ability to reduce the incidence of common NSAID-induced side effects.

[0062] Also included within the scope of the present invention are compounds that act as prodrugs of Cox-2-selective inhibitors. As used herein in reference to Cox-2 selective inhibitors, the term "prodrug" refers to a chemical compound that can be converted into an active Cox-2 selective inhibitor by metabolic or simple chemical processes within the body of the subject. One example of a prodrug for a Cox-2 selective inhibitor is parecoxib, which is a therapeutically effective prodrug of the tricyclic Cox-2 selective inhibitor valdecoxib. An example of a preferred

Cox-2 selective inhibitor prodrug is sodium parecoxib. A class of prodrugs of Cox-2 inhibitors is described in U.S. Patent No. 5,932,598.

[0063] The Cox-2 selective inhibitor of the present invention can be, for example, the Cox-2 selective inhibitor meloxicam, Formula B-1 (CAS registry number 71125-38-7), or a pharmaceutically acceptable salt or prodrug thereof.

5

10

15

20

25

[0064] In another embodiment of the invention the Cox-2 selective inhibitor can be the Cox-2 selective inhibitor RS 57067, 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3(2H)-pyridazinone, Formula B-2 (CAS registry number 179382-91-3), or a pharmaceutically acceptable salt or prodrug thereof.

[0065] As used herein, the term "alkyl", either alone or within other terms such as "haloalkyl" and "alkylsulfonyl"; embraces linear or branched radicals having one to about twenty carbon atoms. Lower alkyl radicals have one to about ten carbon atoms. The number of carbon atoms can also be expressed as " C_1 - C_5 ", for example. Examples of lower alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secbutyl, tert-butyl, pentyl, isoamyl, hexyl, octyl and the like.

[0066] The term "alkenyl" refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains at least

one double bond. The alkenyl radicals may be optionally substituted with groups such as those defined below. Examples of suitable alkenyl radicals include propenyl, 2-chloropropylenyl, buten-1yl, isobutenyl, penten-1yl, 2-methylbuten-1-yl, 3-methylbuten-1-yl, hexen-1-yl, 3-hydroxyhexen-1-yl, hepten-1-yl, octen-1-yl, and the like.

5

10

15

20

25

30

[0067] The term "alkynyl" refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains one or more triple bonds, such radicals preferably containing 2 to about 6 carbon atoms, more preferably from 2 to about 3 carbon atoms. The alkynyl radicals may be optionally substituted with groups such as described below. Examples of suitable alkynyl radicals include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, pentyn-2-yl, 4-methoxypentyn-2-yl, 3-methylbutyn-1-yl, hexyl-1-yl, hexyn-2-yl, hexyn-3-yl, 3,3-dimethylbutyn-1-yl radicals, and the like.

[0068] The term "oxo" means a single double-bonded oxygen.

[0069] The terms "hydrido", "-H", or "hydrogen", denote a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical, or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH₂ -) radical.

[0070] The term "halo" means halogens such as fluorine, chlorine, and bromine or iodine atoms. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl, and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have a bromo, chloro, or a fluoro atom within the radical. Dihalo alkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals and polyhaloalkyl radicals may have more than two of the same halo atoms or a combination of different halo radicals.

[0071] The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals.

[0072] The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms, such as methoxy radical. The term "alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" or "alkoxyalkyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro, or bromo, to provide "haloalkoxy" or "haloalkoxyalkyl" radicals. Examples of "alkoxy" radicals include methoxy, butoxy, and trifluoromethoxy.

[0073] The term "aryl", whether used alone or with other terms, means a carbocyclic aromatic system containing one, two, or three rings wherein such rings may be attached together in a pendent manner, or may be fused. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronapthyl, indane, and biphenyl. The term "heterocyclyl" means a saturated or unsaturated mono- or multi-ring carbocycle wherein one or more carbon atoms are replaced by N, S, P, or O. This includes, for example, structures such as:

$$Z^3$$
 ,or Z^3

5

10

15

20

25

30

where Z, Z^1 , Z^2 , or Z^3 is C, S, P, O, or N, with the proviso that one of Z, Z^1 , Z^2 , or Z^3 is other than carbon, but is not O or S when attached to another Z atom by a double bond or when attached to another O or S atom. Furthermore, the optional substituents are understood to be attached to Z, Z^1 , Z^2 , or Z^3 only when each is C. The term "heterocycle" also includes fully saturated ring structures, such as piperazinyl, dioxanyl, tetrahydrofuranyl, oxiranyl, aziridinyl, morpholinyl, pyrrolidinyl, piperidinyl, thiazolidinyl, and others.

[0074] The term "heteroaryl" embraces unsaturated heterocyclic radicals. Examples of unsaturated heterocyclic radicals include thienyl, pyrryl, furyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, pyranyl, and tetrazolyl. The term also embraces

radicals where heterocyclic radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like.

[0075] The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals –SO₂–. "Alkylsulfonyl", embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. The term "arylsulfonyl" embraces sulfonyl radicals substituted with an aryl radical. The term "aminosulfonyl" denotes a sulfonyl radical substituted with an amine radical, forming a sulfonamide (–SO₂-NH₂).

[0076] The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes $-CO_2$ -H. The term "carboxyalkyl" embraces radicals having a carboxyradical as defined above, attached to an alkyl radical. The term "carbonyl", whether used alone or with other terms, such as "alkylcarbonyl", denotes -(C=O) -. The term "alkylcarbonyl" embraces radicals having a carbonyl radical substituted with an alkyl radical. An example of an "alkylcarbonyl" radical is CH_3 -(CO) -. The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl (C=O) radical. Examples of such "alkoxycarbonyl" radicals include $(CH_3)_3$ -C-O-C=O) - and -(O=)C-OCH $_3$. The term "amino", whether used alone or with other terms, such as "aminocarbonyl", denotes $-NH_2$.

[0077] The term "heterocycloalkyl" embraces heterocyclic-substituted alkyl radicals such as pyridylmethyl and thienylmethyl. The terms "aralkyl", or "arylalkyl" embrace aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The terms benzyl and phenylmethyl are interchangeable. The term "cycloalkyl" embraces radicals having three to ten carbon atoms, such as cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. The term "cycloalkenyl" embraces unsaturated radicals having three to ten carbon

atoms, such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and cycloheptenyl.

The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. An example of "alkylthio" is methylthio, (CH₃ –S–). The term "alkylsulfinyl" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent –S(–O) – atom. The term "acyl", whether used alone, or within a term such as "acylamino", denotes a radical provided by the residue after removal of hydroxyl from an organic acid.

5

10

15

20

25

[0079] The term "cyano", used either alone or with other terms, such as "cyanoalkyl", refers to C≡N. The term "nitro" denotes –NO₂.

[0080] In one embodiment of the invention the Cox-2 selective inhibitor is of the chromene/chroman structural class, which encompasses substituted benzopyrans or substituted benzopyran analogs, as well as substituted benzothiopyrans, dihydroquinolines, or dihydronaphthalenes having the structure of any one of the general Formulas I, II, III, IV, V, and VI, shown below, and including, by way of non-limiting example, the structures disclosed in Table 1, and the diastereomers, enantiomers, racemates, tautomers, salts, esters, amides and prodrugs thereof.

[0081] Benzopyrans that can serve as a Cox-2 selective inhibitor of the present invention include substituted benzopyran derivatives that are described in U.S. Patent Nos. 6,271,253 and 6,492,390. One such class of compounds is defined by the general formula shown below in formula I:

$$R^4 \frac{A^2}{A^3} A \qquad \qquad R^3$$

wherein X¹ is selected from O, S, CR^c R^b and NR^a;

wherein R^a is selected from hydrido, C₁ –C₃ –alkyl, (optionally substituted phenyl)-C₁ –C₃ –alkyl, acyl and carboxy-C₁ –C₆ –alkyl; wherein each of R^b and R^c is independently selected from hydrido, C₁ –C₃ –alkyl, phenyl-C₁ –C₃ –alkyl, C₁ –C₃ –perfluoroalkyl, chloro, C₁ –C₆

–alkylthio, C_1 – C_6 –alkoxy, nitro, cyano and cyano- C_1 – C_3 –alkyl; or wherein CR^b R^c forms a 3-6 membered cycloalkyl ring;

5

10

15

20

25

30

wherein \mathbb{R}^1 is selected from carboxyl, aminocarbonyl, C_1 – C_6 – alkylsulfonylaminocarbonyl and C_1 – C_6 –alkoxycarbonyl;

wherein \mathbb{R}^2 is selected from hydrido, phenyl, thienyl, C_1 – C_6 –alkyl and C_2 – C_6 –alkenyl;

wherein \mathbb{R}^3 is selected from C_1 – C_3 –perfluoroalkyl, chloro, C_1 – C_6 – alkylthio, C_1 – C_6 –alkoxy, nitro, cyano and cyano- C_1 – C_3 –alkyl;

wherein R⁴ is one or more radicals independently selected from hydrido, halo, C₁ –C₆ –alkyl, C₂ –C₆ –alkenyl, C₂ –C₆ –alkynyl, halo-C₂ –C₆ -alkynyl, aryl-C₁ --C₃ -alkyl, aryl-C₂ --C₆ -alkynyl, aryl-C₂ --C₆ -alkenyl, C₁ $-C_6$ –alkoxy, methylenedioxy, C_1 – C_6 –alkylthio, C_1 – C_6 –alkylsulfinyl, aryloxy, arylthio, arylsulfinyl, heteroaryloxy, $C_1 - C_6$ -alkoxy- $C_1 - C_6$ -alkyl, aryl-C₁ –C₆ –alkyloxy, heteroaryl-C₁ –C₆ –alkyloxy, aryl-C₁ –C₆ –alkoxy-C₁ $-C_6$ -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -haloalkoxy, C_1 - C_6 -haloalkylthio, $C_1 - C_6$ -haloalkylsulfinyl, $C_1 - C_6$ -haloalkylsulfonyl, $C_1 - C_3$ -(haloalkyl-1 - C_3 -hydroxyalkyl, C_1 - C_6 -hydroxyalkyl, hydroxyimino- C_1 - C_6 -alkyl, C_1 -C₆ –alkylamino, arylamino, aryl-C₁ –C₆ –alkylamino, heteroarylamino, heteroaryl-C₁ –C₆ –alkylamino, nitro, cyano, amino, aminosulfonyl, C₁ –C₆ -alkylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aryl-C₁ -C₆ –alkylaminosulfonyl, heteroaryl-C₁ –C₆ –alkylaminosulfonyl, heterocyclylsulfonyl, $C_1 - C_6$ –alkylsulfonyl, aryl- $C_1 - C_6$ –alkylsulfonyl, optionally substituted aryl, optionally substituted heteroaryl, aryl-C1 -C6 alkylcarbonyl, heteroaryl-C₁ –C₆ –alkylcarbonyl, heteroarylcarbonyl, arylcarbonyl, aminocarbonyl, $C_1 - C_1$ -alkoxycarbonyl, formyl, $C_1 - C_6$ haloalkylcarbonyl and C₁ -C₆ -alkylcarbonyl; and

wherein the A ring atoms A^1 , A^2 , A^3 and A^4 are independently selected from carbon and nitrogen with the proviso that at least two of A^1 , A^2 , A^3 and A^4 are carbon;

or wherein R⁴ together with ring A forms a radical selected from naphthyl, quinolyl, isoquinolyl, quinolizinyl, quinoxalinyl and dibenzofuryl, or an isomer or pharmaceutically acceptable salt thereof.

[0082] Another class of benzopyran derivatives that can serve as the Cox-2 selective inhibitor of the present invention includes compounds having the structure of formula II:

10

5

$$R^{8} \frac{D_{6}^{2}}{D_{3}^{3}} \frac{D_{5}^{1}}{D_{5}^{3}} \frac{R^{5}}{D_{5}^{3}}$$

wherein X² is selected from O, S, CR^c R^b and NR^a;

wherein R^a is selected from hydrido, $C_1 - C_3$ –alkyl, (optionally substituted phenyl)- $C_1 - C_3$ –alkyl, alkylsulfonyl, phenylsulfonyl, benzylsulfonyl, acyl and carboxy- $C_1 - C_6$ –alkyl;

wherein each of R^b and R^c is independently selected from hydrido, $C_1 - C_3$ –alkyl, phenyl- $C_1 - C_3$ –alkyl, $C_1 - C_3$ –perfluoroalkyl, chloro, $C_1 - C_6$ –alkylthio, $C_1 - C_6$ –alkoxy, nitro, cyano and cyano- $C_1 - C_3$ –alkyl;

or wherein $CR^c R^b$ form a cyclopropyl ring;

20

15

wherein R^5 is selected from carboxyl, aminocarbonyl, $C_1 - C_6 - C_6$ alkylsulfonylaminocarbonyl and $C_1 - C_6$ —alkoxycarbonyl; wherein R^6 is selected from hydrido, phenyl, thienyl, $C_2 - C_6$ —alkynyl and $C_2 - C_6$ —alkenyl;

25

wherein R^7 is selected from C_1 – C_3 –perfluoroalkyl, chloro, C_1 – C_6 – alkylthio, C_1 – C_6 –alkoxy, nitro, cyano and cyano- C_1 – C_3 –alkyl; wherein R^8 is one or more radicals independently selected from hydrido, halo, C_1 – C_6 –alkyl, C_2 – C_6 –alkenyl, C_2 – C_6 –alkynyl, halo- C_2 – C_6 –alkynyl, aryl- C_1 – C_3 –alkyl, aryl- C_2 – C_6 –alkynyl, aryl- C_2 – C_6 –alkylsulfinyl, — C_6 –alkylsulfinyl, —

 $O(CF_2)_2 \ O---, \ aryloxy, \ arylthio, \ arylsulfinyl, \ heteroaryloxy, \ C_1-C_6-alkoxy-C_1-C_6-alkyl, \ aryl-C_1-C_6-alkyloxy, \ heteroaryl-C_1-C_6-alkyloxy, \ aryl-C_1-C_6-alkyloxy, \ aryl-C_1-C_6-alkoxy-C_1-C_6-alkyl, \ C_1-C_6-haloalkyl, \ C_1-C_6-haloalkylsulfonyl, \ C_1-C_6-haloalkylsulfonyl, \ C_1-C_6-haloalkylsulfonyl, \ C_1-C_3-(haloalkyl-C_1-C_3-hydroxyalkyl), \ C_1-C_6-hydroxyalkyl, \ hydroxyimino-C_1-C_6-alkyl, \ C_1-C_6-alkylamino, \ aryl-C_1-C_6-alkylamino, \ heteroarylamino, \ heteroaryl-C_1-C_6-alkylaminosulfonyl, \ arylaminosulfonyl, \ heteroarylaminosulfonyl, \ aryl-C_1-C_6-alkylaminosulfonyl, \ heteroaryl-C_1-C_6-alkylaminosulfonyl, \ heteroaryl-C_1-C_6-alkylaminosulfonyl, \ aryl-C_1-C_6-alkylaminosulfonyl, \ aryl-C_1-C_6-alkylaminosulfonyl, \ heteroaryl-C_1-C_6-alkylaminosulfonyl, \ heteroaryl-C_1-C_6-alkylaminosulfonyl,$

wherein the D ring atoms D^1 , D^2 , D^3 and D^4 are independently selected from carbon and nitrogen with the proviso that at least two of D^1 , D^2 , D^3 and D^4 are carbon; or

wherein R⁸ together with ring D forms a radical selected from naphthyl, quinolyl, isoquinolyl, quinolizinyl, quinoxalinyl and dibenzofuryl; or an isomer or pharmaceutically acceptable salt thereof.

[0083] Other benzopyran Cox-2 selective inhibitors useful in the practice of the present invention are described in U.S. Patent Nos. 6,034,256 and 6,077,850. The general formula for these compounds is shown in formula III:

$$\mathbb{R}^{12} \longrightarrow \mathbb{E}$$

$$\mathbb{R}^{10}$$

$$\mathbb{R}^{11}$$

5

10

15

20

25

wherein X^3 is selected from the group consisting of O or S or NR^a; wherein R^a is alkyI;

wherein R⁹ is selected from the group consisting of H and aryl; wherein R¹⁰ is selected from the group consisting of carboxyl, aminocarbonyl, alkylsulfonylaminocarbonyl and alkoxycarbonyl; wherein R¹¹ is selected from the group consisting of haloalkyl, alkyl, aralkyl, cycloalkyl and aryl optionally substituted with one or more radicals selected from alkylthio, nitro and alkylsulfonyl; and

5

10

15


20

25

wherein R¹² is selected from the group consisting of one or more radicals selected from H, halo, alkyl, aralkyl, alkoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, haloalkyl, haloalkoxy, alkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, nitro, amino, aminosulfonyl, alkylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl, heteroaralkylaminosulfonyl, heterocyclosulfonyl, alkylsulfonyl, hydroxyarylcarbonyl, nitroaryl, optionally substituted aryl, optionally substituted heteroaryl, aralkylcarbonyl, heteroarylcarbonyl, arylcarbonyl, aminocarbonyl, and alkylcarbonyl; or

wherein R¹² together with ring E forms a naphthyl radical; or an isomer or pharmaceutically acceptable salt thereof; and including the diastereomers, enantiomers, racemates, tautomers, salts, esters, amides and prodrugs thereof.

[0084] A related class of compounds useful as Cox-2 selective inhibitors in the present invention is described by Formulas IV and V below:



wherein X^4 is selected from O or S or NR^a ;

wherein R^a is alkyl;

wherein R¹³ is selected from carboxyl, aminocarbonyl, alkylsulfonylaminocarbonyl and alkoxycarbonyl;

wherein R¹⁴ is selected from haloalkyl, alkyl, aralkyl, cycloalkyl and aryl optionally substituted with one or more radicals selected from alkylthio, nitro and alkylsulfonyl; and

wherein R¹⁵ is one or more radicals selected from hydrido, halo, alkyl, aralkyl, alkoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, haloalkyl, haloalkoxy, alkylamino, arylamino, aralkylamino, heteroarylalkylamino, nitro, amino, aminosulfonyl, alkylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, haloalkylaminosulfonyl, heteroaralkylaminosulfonyl, heterocyclosulfonyl, aralkylaminosulfonyl, optionally substituted aryl, optionally substituted heteroaryl, aralkylcarbonyl, heteroarylcarbonyl, arylcarbonyl, aminocarbonyl, and alkylcarbonyl;

or wherein R¹⁵ together with ring G forms a naphthyl radical; or an isomer or pharmaceutically acceptable salt thereof.

[0085] Formula V is:

$$R^{18}$$
 A X^{5} R^{17} V

wherein:

5

10

15

25

X⁵ is selected from the group consisting of O or S or NR^b; R^b is alkyl;

R¹⁶ is selected from the group consisting of carboxyl, aminocarbonyl, alkylsulfonylaminocarbonyl and alkoxycarbonyl;

R¹⁷ is selected from the group consisting of haloalkyl, alkyl, aralkyl, cycloalkyl and aryl, wherein haloalkyl, alkyl, aralkyl, cycloalkyl, and aryl each is independently optionally substituted with one or more radicals selected from the group consisting of alkylthio, nitro and alkylsulfonyl; and

R¹⁸ is one or more radicals selected from the group consisting of hydrido, halo, alkyl, aralkyl, alkoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, haloalkyl, haloalkoxy, alkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, nitro, amino, aminosulfonyl, alkylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl, heteroaralkylaminosulfonyl, heterocyclosulfonyl, alkylsulfonyl, optionally substituted aryl, optionally substituted heteroaryl, aralkylcarbonyl, heteroarylcarbonyl, arylcarbonyl, aminocarbonyl, and alkylcarbonyl; or wherein R¹⁸ together with ring A forms a naphthyl radical;

5

10

15

20

25

30

or an isomer or pharmaceutically acceptable salt thereof.

[0086] The Cox-2 selective inhibitor may also be a compound of Formula V, wherein:

X⁵ is selected from the group consisting of oxygen and sulfur;

R¹⁶ is selected from the group consisting of carboxyl, lower alkyl, lower aralkyl and lower alkoxycarbonyl;

R¹⁷ is selected from the group consisting of lower haloalkyl, lower cycloalkyl and phenyl; and

R¹⁸ is one or more radicals selected from the group of consisting of hydrido, halo, lower alkyl, lower alkoxy, lower haloalkyl, lower haloalkoxy, lower alkylamino, nitro, amino, aminosulfonyl, lower alkylaminosulfonyl, 5-membered heteroarylalkylaminosulfonyl, 6-membered heteroarylalkylaminosulfonyl, lower aralkylaminosulfonyl, 5-membered nitrogen-containing heterocyclosulfonyl, 6-membered nitrogen-containing heterocyclosulfonyl, lower alkylsulfonyl, optionally substituted phenyl, lower aralkylcarbonyl, and lower alkylcarbonyl; or

wherein R¹⁸ together with ring A forms a naphthyl radical; or an isomer or pharmaceutically acceptable salt thereof.

[0087] The Cox-2 selective inhibitor may also be a compound of Formula V, wherein:

X⁵ is selected from the group consisting of oxygen and sulfur; R¹⁶ is carboxyl;

R¹⁷ is lower haloalkyl; and

R¹⁸ is one or more radicals selected from the group consisting of hydrido, halo, lower alkyl, lower haloalkyl, lower haloalkoxy, lower alkylamino, amino, aminosulfonyl, lower alkylaminosulfonyl, 5-membered heteroarylalkylaminosulfonyl, 6-membered heteroarylalkylaminosulfonyl, lower aralkylaminosulfonyl, lower alkylsulfonyl, 6-membered nitrogencontaining heterocyclosulfonyl, optionally substituted phenyl, lower aralkylcarbonyl, and lower alkylcarbonyl; or wherein R¹⁸ together with ring A forms a naphthyl radical;

10

15

5

or an isomer or pharmaceutically acceptable salt thereof.

[0088] The Cox-2 selective inhibitor may also be a compound of Formula V, wherein:

X⁵ is selected from the group consisting of oxygen and sulfur; R¹⁶ is selected from the group consisting of carboxyl, lower alkyl, lower aralkyl and lower alkoxycarbonyl;

R¹⁷ is selected from the group consisting of fluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl,

heptafluoropropyl, difluoroethyl, difluoropropyl, dichloroethyl,

dichloropropyl, difluoromethyl, and trifluoromethyl; and

20

R¹⁸ is one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, iodo, methyl, ethyl, isopropyl, *tert*-butyl, butyl, isobutyl, pentyl, hexyl, methoxy, ethoxy, isopropyloxy, tertbutyloxy, trifluoromethyl, difluoromethyl, trifluoromethoxy, amino, N,N-dimethylamino, N,N-diethylamino, N-phenylmethylaminosulfonyl, N-phenylethylaminosulfonyl, N-(2-furylmethyl)aminosulfonyl, nitro, N,N-dimethylaminosulfonyl, N-methylaminosulfonyl, N-ethylsulfonyl, 2,2-dimethylethylaminosulfonyl, N,N-dimethylaminosulfonyl, N-(2-methylpropyl)aminosulfonyl, N-morpholinosulfonyl, methylsulfonyl,

benzylcarbonyl, 2,2-dimethylpropylcarbonyl, phenylacetyl and phenyl; or

30

25

wherein R² together with ring A forms a naphthyl radical; or an isomer or pharmaceutically acceptable salt thereof.

[0089] The Cox-2 selective inhibitor may also be a compound of Formula V, wherein:

X⁵ is selected from the group consisting of oxygen and sulfur;

R¹⁶ is selected from the group consisting of carboxyl, lower alkyl, lower aralkyl and lower alkoxycarbonyl;

R¹⁷ is selected from the group consisting trifluoromethyl and pentafluoroethyl; and

R¹⁸ is one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, iodo, methyl, ethyl, isopropyl, *tert*-butyl, methoxy, trifluoromethyl, trifluoromethoxy, N-phenylmethylaminosulfonyl, N-phenylethylaminosulfonyl, N-(2-furylmethyl)aminosulfonyl, N,N-dimethylaminosulfonyl, N-methylaminosulfonyl, N-(2,2-dimethylethyl)aminosulfonyl, dimethylaminosulfonyl, 2-methylpropylaminosulfonyl, N-morpholinosulfonyl, methylsulfonyl, benzylcarbonyl, and phenyl; or wherein R¹⁸ together with ring A forms a naphthyl radical; or an isomer or prodrug thereof.

[0090] The Cox-2 selective inhibitor of the present invention can also be a compound having the structure of Formula VI:

$$R^{21}$$
 CO_2H R^{22} R^{19}

20

25

5

10

15

wherein:

X⁶ is selected from the group consisting of O and S;

R¹⁹ is lower haloalkyl;

R²⁰ is selected from the group consisting of hydrido, and halo;

R²¹ is selected from the group consisting of hydrido, halo, lower alkyl, lower haloalkoxy, lower alkoxy, lower aralkylcarbonyl, lower

dialkylaminosulfonyl, lower alkylaminosulfonyl, lower aralkylaminosulfonyl, lower heteroaralkylaminosulfonyl, 5-membered nitrogen-containing heterocyclosulfonyl, and 6- membered nitrogen-containing heterocyclosulfonyl;

5

R²² is selected from the group consisting of hydrido, lower alkyl, halo, lower alkoxy, and aryl; and

R²³ is selected from the group consisting of the group consisting of hydrido, halo, lower alkyl, lower alkoxy, and aryl; or an isomer or prodrug thereof.

10

[0091] The Cox-2 selective inhibitor can also be a compound of having the structure of Formula VI, wherein:

X⁶ is selected from the group consisting of O and S;

R¹⁹ is selected from the group consisting of trifluoromethyl and pentafluoroethyl;

15

20

R²⁰ is selected from the group consisting of hydrido, chloro, and fluoro;

R²¹ is selected from the group consisting of hydrido, chloro, bromo, fluoro, iodo, methyl, tert-butyl, trifluoromethoxy, methoxy, benzylcarbonyl, dimethylaminosulfonyl, isopropylaminosulfonyl, methylaminosulfonyl, benzylaminosulfonyl, phenylethylaminosulfonyl,

methylpropylaminosulfonyl, methylsulfonyl, and morpholinosulfonyl;

R²² is selected from the group consisting of hydrido, methyl, ethyl, isopropyl, tert-butyl, chloro, methoxy, diethylamino, and phenyl; and

R²³ is selected from the group consisting of hydrido, chloro, bromo, fluoro, methyl, ethyl, tert-butyl, methoxy, and phenyl; or an isomer or prodrug thereof.

25

Table 1. Examples of Chromene Cox-2 Selective Inhibitors

Compound Number	Structural Formula
B-3	O ₂ N OH CF ₃ 6-Nitro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid
B-4	C1 OH CF ₃
	6-Chloro-8-methyl-2-trifluoromethyl-2H-1- benzopyran-3-carboxylic acid
B-5	C1 OH OH
	((S)-6-Chloro-7-(1,1-dimethylethyl)-2-(trifluoromethyl-2H-1-benzopyran-3-carboxylic acid
B-6	OH CF ₃
	2-Trifluoromethyl-2H-naphtho[2,3-b]pyran-3- carboxylic acid

Compound Number	Structural Formula
B-7	O_2N $C1$ OH OH CF_3
	6-Chloro-7-(4-nitrophenoxy)-2-(trifluoromethyl)-2H-1-benzopyran-3- carboxylic acid
B-8	C1 OH CF ₃
	((S)-6,8-Dichloro-2-(trifluoromethyl)-2H-1-benzopyran- 3-carboxylic acid
B-9	C1 OH
	6-Chloro-2-(trifluoromethyl)-4-phenyl-2H-1-benzopyran- 3-carboxylic acid
B-10	HO CF ₃
	6-(4-Hydroxybenzoyl)-2-(trifluoromethyl)-2H-1- benzopyran-3-carboxylic acid

Compound Number	Structural Formula
B-11	F ₃ C S OH
	2-(Trifluoromethyl)-6-[(trifluoromethyl)thio]-2H-1-benzothiopyran- 3-carboxylic acid
B-12	C1 OH CF ₃
	6,8-Dichloro-2-trifluoromethyl-2H-1-benzothiopyran- 3-carboxylic acid
B-13	OH CF ₃
	6-(1,1-Dimethylethyl)-2-(trifluoromethyl)-2H-1- benzothiopyran-3-carboxylic acid
B-14	F OH CF3
	6,7-Difluoro-1,2-dihydro-2-(trifluoromethyl)-3- quinolinecarboxylic acid

Compound Number	Structural Formula
B-15	G-Chloro-1,2-dihydro-1-methyl-2-(trifluoromethyl)-3-
	quinolinecarboxylic acid
B-16	C1 OH CF3
	6-Chloro-2-(trifluoromethyl)-1,2-dihydro[1,8]naphthyridine- 3-carboxylic acid
B-17	C1 OH CF3
	((S)-6-Chloro-1,2-dihydro-2-(trifluoromethyl)-3- quinolinecarboxylic acid
B-18	OH FF F
	(2S)-6,8-dimethyl-2-(trifluoromethyl)-2H-chromene- 3-carboxylic acid

Compound Number	Structural Formula
B-19	(2S)-8-ethyl-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid
B-20	CI O O O F F F
	(2S)-6-chloro-5,7-dimethyl-2-(trifluoromethyl)-2H- chromene-3-carboxylic acid

[0092] In preferred embodiments the chromene Cox-2 inhibitor is selected from (S)-6-chloro-7-(1,1-dimethylethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, (2S)-6,8-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, (2S)-6-chloro-8-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, (2S)-8-ethyl-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, (2S)-6-chloro-5,7-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, and mixtures thereof.

5

10

[0093] In a preferred embodiment of the invention the Cox-2 inhibitor can be selected from the class of tricyclic Cox-2 selective inhibitors represented by the general structure of formula **VII**:

$$\begin{array}{c|c}
 & & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & &$$

wherein:

5

10

15

20

25

Z¹ is selected from the group consisting of partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

R²⁴ is selected from the group consisting of heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R²⁴ is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

R²⁵ is selected from the group consisting of methyl or amino; and R²⁶ is selected from the group consisting of a radical selected from H, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl. heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N- arylaminocarbonyl, N-alkyl-Narylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, Narylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, Narylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; or a prodrug thereof.

[0094] In a preferred embodiment of the invention the tricyclic Cox-2 selective inhibitor represented by the above Formula VII is selected from the group of compounds, illustrated in Table 2, which includes celecoxib (B-21), valdecoxib (B-22), deracoxib (B-23), rofecoxib (B-24), etoricoxib (MK-663; B-25), JTE-522 (B-26), or prodrugs thereof.

5

10

[0095] Additional information about selected examples of the tricyclic Cox-2 selective inhibitors discussed above can be found as follows: celecoxib (CAS RN 169590-42-5, C-2779, SC-58653, and in U.S. Patent No. 5,466,823); deracoxib (CAS RN 169590-41-4); rofecoxib (CAS RN 162011-90-7); compound B-24 (U.S. Patent No. 5,840,924); compound B-26 (WO 00/25779); and etoricoxib (CAS RN 202409-33-4, MK-663, SC-86218, and in WO 98/03484).

[0096] Table 2. Examples of Tricyclic Cox-2 Selective Inhibitors

Compound Number	Structural Formula
B-21	H_2N CF_3
B-22	H_2N S H_3C N

Compound Number	Structural Formula
B-23	H ₂ N CHF ₂
B-24	H ₃ C S
B-25	H ₃ C S CH ₃
B-26	H_2N S O O N CH_3

[0097] In a more preferred embodiment of the invention, the Cox-2 selective inhibitor is selected from the group consisting of celecoxib, rofecoxib and etoricoxib.

[0098] In a preferred embodiment, parecoxib (See, U.S. Patent No. 5,932,598), having the structure shown in B-27, and which is a therapeutically effective prodrug of the tricyclic Cox-2 selective inhibitor valdecoxib, B-22, (See, U.S. Patent No. 5,633,272), may be advantageously employed as the Cox-2 inhibitor of the present invention.

[0100] A preferred form of parecoxib is sodium parecoxib.

[0101] Another tricyclic Cox-2 selective inhibitor useful in the present invention is the compound ABT-963, having the formula B-28 shown below, that has been previously described in International Publication Number WO 00/24719.

[0102] In a further embodiment of the invention, the Cox-2 inhibitor can be selected from the class of phenylacetic acid derivative Cox-2 selective inhibitors represented by the general structure of formula **VIII**:

B-28

20

15

5

10

wherein:

R²⁷ is methyl, ethyl, or propyl;

5 R²⁸ is chloro or fluoro;

R²⁹ is hydrogen, fluoro, or methyl;

R³⁰ is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxyl;

R³¹ is hydrogen, fluoro, or methyl; and

R³² is chloro, fluoro, trifluoromethyl, methyl, or ethyl,

provided that R²⁸, R²⁹, R³⁰ and R³¹ are not all fluoro when R²⁷ is ethyl and R³⁰ is H.

[0103] An exemplary phenylacetic acid derivative Cox-2 selective inhibitor that is described in WO 99/11605 is a compound that has the structure shown in formula **VIII**,

15 wherein:

R²⁷ is ethyl;

R²⁸ and R³⁰ are chloro;

R²⁹ and R³¹ are hydrogen; and

R³² is methyl.

20 **[0104]** Another phenylacetic acid derivative Cox-2 selective inhibitor is a compound that has the structure shown in formula **VIII**,

wherein: R²⁷ is propyl;

R²⁸ and R³⁰ are chloro;

R²⁹ and R³¹ are methyl; and R³² is ethyl.

[0105] Another phenylacetic acid derivative Cox-2 selective inhibitor that is disclosed in WO 02/20090 is a compound that is referred to as COX-189 (also termed lumiracoxib; CAS Reg. No. 220991-20-8), having the structure shown in formula **VIII**,

wherein:

5

15

20

R²⁷ is methyl;

R²⁸ is fluoro;

10 R³² is chloro; and

R²⁹, R³⁰, and R³¹ are hydrogen.

[0106] Compounds having a structure similar to that shown in formula VIII, that can serve as the Cox-2 selective inhibitor of the present invention, are described in U.S. Patent Nos. 6,451,858, 6,310,099, 6,291,523, and 5,958,978.

[0107] Other Cox-2 selective inhibitors that can be used in the present invention have the general structure shown in formula IX, where the J group is a carbocycle or a heterocycle. Preferred embodiments have the structure:

wherein:

 X^7 is O; J is 1-phenyl; R^{33} is 2-NHSO₂CH₃; R^{34} is 4-NO₂; and there is no R^{35} group, (nimesulide), or

 X^7 is O; J is 1-oxo-inden-5-yl; R^{33} is 2-F; R^{34} is 4-F; and R^{35} is 6-

NHSO₂CH₃, (flosulide); or X^7 is O; J is cyclohexyl; R^{33} is 2-NHSO₂CH₃; R^{34} is 5-NO₂; and there is no R^{35} group, (NS-398); or

 X^7 is S; J is 1-oxo-inden-5-yl; R^{33} is 2-F; R^{34} is 4-F; and R^{35} is 6-N⁻SO₂CH₃ · Na⁺, (L-745337); or

X⁷ is S; J is thiophen-2-yl; R³³ is 4-F; there is no R³⁴ group; and R³⁵ is 5-NHSO₂CH₃, (RWJ-63556); or

 X^7 is O; J is 2-oxo-5(R)-methyl-5-(2,2,2-trifluoroethyl)furan-(5H)-3-yl; R^{33} is 3-F; R^{34} is 4-F; and R^{35} is 4-(p-SO₂CH₃)C₆H₄, (L-784512).

5

10

15

20

[0108] The Cox-2 selective inhibitor NS-398, also known as N-(2-cyclohexyloxynitrophenyl) methane sulfonamide (CAS RN 123653-11-2), having a structure as shown below in formula B-29, has been described in, for example, Yoshimi, N. *et al.*, in *Japanese J. Cancer Res.*, *90(4):*406 – 412 (1999).

[0109] An evaluation of the anti-inflammatory activity of the Cox-2 selective inhibitor, RWJ 63556, in a canine model of inflammation, was described by Kirchner *et al.*, in *J Pharmacol Exp Ther 282*, 1094-1101 (1997).

[0110] Materials that can serve as the Cox-2 selective inhibitor of the present invention include diarylmethylidenefuran derivatives that are described in U.S. Patent No. 6,180,651. Such diarylmethylidenefuran derivatives have the general formula shown below in formula **X**:

$$Q^2$$
 M R^{39} R^{38} R^{36} R^{37}

wherein:

5

10

15

the rings T and M independently are a phenyl radical, a naphthyl radical, a radical derived from a heterocycle comprising 5 to 6 members and possessing from 1 to 4 heteroatoms, or a radical derived from a saturated hydrocarbon ring having from 3 to 7 carbon atoms; at least one of the substituents Q¹, Q², L¹ or L² is an —S(O)_n —R group, in

which n is an integer equal to 0, 1 or 2 and R is a lower alkyl radical having 1 to 6 carbon atoms, a lower haloalkyl radical having 1 to 6 carbon atoms, or an $-SO_2NH_2$ group;

and is located in the para position,

the others independently being a hydrogen atom, a halogen atom, a lower alkyl radical having 1 to 6 carbon atoms, a trifluoromethyl radical, or a lower O-alkyl radical having 1 to 6 carbon atoms, or Q^1 and Q^2 or L^1 and L^2 are a methylenedioxy group; and

R³⁶, R³⁷, R³⁸ and R³⁹ independently are a hydrogen atom, a halogen atom, a lower alkyl radical having 1 to 6 carbon atoms, a lower haloalkyl radical having 1 to 6 carbon atoms, or an aromatic radical selected from the group consisting of phenyl, naphthyl, thienyl, furyl and pyridyl; or,

20 R³⁶, R³⁷ or R³⁸, R³⁹ are an oxygen atom; or R³⁶, R³⁷ or R³⁸, R³⁹, together with the carbon atom to which they are attached, form a saturated hydrocarbon ring having from 3 to 7 carbon atoms;

or an isomer or prodrug thereof.

[0111] Particular diarylmethylidenefuran derivatives that can serve as the Cox-2 selective inhibitor of the present invention include, for example, N-(2-cyclohexyloxynitrophenyl)methane sulfonamide, and (E)-4-[(4-methylphenyl)(tetrahydro-2-oxo-3-furanylidene) methyl]benzenesulfonamide.

[0112] Other Cox-2 selective inhibitors that are useful in the present invention include darbufelone (Pfizer), CS-502 (Sankyo), LAS 34475 (Almirall Profesfarma), LAS 34555 (Almirall Profesfarma), S-33516 (Servier), SD 8381 (Pharmacia, described in U.S. Patent No. 6,034,256), BMS-347070 (Bristol Myers Squibb, described in U.S. Patent No. 6,180,651), MK-966 (Merck), L-783003 (Merck), T-614 (Toyama), D-1367 (Chiroscience), L-748731 (Merck), CT3 (Atlantic Pharmaceutical), CGP-28238 (Novartis), BF-389 (Biofor/Scherer), GR-253035 (Glaxo Wellcome), 6-dioxo-9H-purin-8-yl-cinnamic acid (Glaxo Wellcome), and S-2474 (Shionogi).

[0113] Compounds that may act as Cox-2 selective inhibitors of the present invention include multibinding compounds containing from 2 to 10 ligands covaniently attached to one or more linkers, as described in U.S. Patent No. 6,395,724.

[0114] Conjugated linoleic, as described in U.S. Patent No. 6,077,868, is useful as a Cox-2 selective inhibitor in the present invention. [0115] Compounds that can serve as a Cox-2 selective inhibitor of the present invention include heterocyclic aromatic oxazole compounds that are described in U.S. Patents 5,994,381 and 6,362,209. Such heterocyclic aromatic oxazole compounds have the formula shown below in formula XI:

$$\mathbb{R}^{40}$$
 \mathbb{R}^{41}
 \mathbb{R}^{42}
 \mathbb{R}^{42}
wherein:

5

10

15

20

25

Z² is an oxygen atom;

one of R⁴⁰ and R⁴¹ is a group of the formula

$$R^{45}$$
 R^{45} R^{45} R^{47} R^{46}

wherein:

5

10

15

R⁴³ is lower alkyl, amino or lower alkylamino; and

R⁴⁴, R⁴⁵, R⁴⁶ and R⁴⁷ are the same or different and each is hydrogen atom, halogen atom, lower alkyl, lower alkoxy, trifluoromethyl, hydroxyl or amino, provided that at least one of R⁴⁴, R⁴⁵, R⁴⁶ and R⁴⁷ is not hydrogen atom, and the other is an optionally substituted cycloalkyl, an optionally substituted heterocyclic group or an optionally substituted aryl; and

R³⁰ is a lower alkyl or a halogenated lower alkyl, and a pharmaceutically acceptable salt thereof.

[0116] Cox-2 selective inhibitors that are useful in the method and compositions of the present invention include compounds that are described in U.S. Patent Nos. 6,080,876 and 6,133,292, and described by formula **XII**:

$$\mathbb{R}^{48} \mathrm{O}_2 \mathrm{S}$$

wherein:

 Z^3 is selected from the group consisting of linear or branched C_1 – C_6 alkyl, linear or branched C_1 – C_6 alkoxy, unsubstituted, mono-, di- or trisubstituted phenyl or naphthyl wherein the substituents are selected from the group consisting of hydrogen, halo, C_1 – C_3 alkoxy, C_1 – C_3 fluoroalkyl C_1 – C_3 alkyl, and – CO_2 H;

R⁴⁸ is selected from the group consisting of NH₂ and CH₃,

 R^{49} is selected from the group consisting of C_1 – C_6 alkyl unsubstituted or substituted with C_3 – C_6 cycloalkyl, and C_3 – C_6 cycloalkyl;

 R^{50} is selected from the group consisting of C_1 – C_6 alkyl unsubstituted or substituted with one, two or three fluoro atoms, and C_3 – C_6 cycloalkyl; with the proviso that R^{49} and R^{50} are not the same.

[0117] Pyridines that are described in U.S. Patent Nos. 6,596,736, 6,369,275, 6,127,545, 6,130,334, 6,204,387, 6,071,936, 6,001,843 and 6,040,450, and can seve as Cox-2 selective inhibitors of the present invention, have the general formula described by formula XIII:

$$R^{52}$$
 $XIII$

wherein:

5

10

15

20

25

R⁵¹ is selected from the group consisting of CH₃, NH₂, NHC(O)CF₃, and NHCH₃;

 Z^4 is a mono-, di-, or trisubstituted phenyl or pyridinyl (or the N-oxide thereof), wherein the substituents are selected from the group consisting of hydrogen, halo, $C_1 - C_6$ alkoxy, $C_1 - C_6$ alkylthio, CN, $C_1 - C_6$ alkyl, $C_1 - C_6$ fluoroalkyl, N_3 , $-CO_2R^{53}$, hydroxyl, $-C(R^{54})(R^{55})$ —OH, $-C_1 - C_6$ alkyl- $-C_2$ — $-C_6$ fluoroalkoxy;

 R^{52} is selected from the group consisting of halo, C_1 – C_6 alkoxy, C_1 – C_6 alkylthio, CN, C_1 – C_6 alkyl, C_1 – C_6 fluoroalkyl, N_3 , — CO_2R^{57} , hydroxyl,

— $C(R^{58})(R^{59})$ —OH, — C_1 – C_6 alkyl-CO₂— R^{60} , C_1 – C_6 fluoroalkoxy, NO₂, NR⁶¹R⁶², and NHCOR⁶³;

 R^{53} , R^{54} , R^{55} , R^{56} , R^{57} , R^{58} , R^{59} , R^{60} , R^{61} , R^{62} , and R^{63} , are each independently selected from the group consisting of hydrogen and $C_1 - C_6$ alkyl;

or R⁵⁴ and R⁵⁵, R⁵⁸ and R⁵⁹, or R⁶¹ and R⁶² together with the atom to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6, or 7 atoms.

[0118] Materials that can serve as the Cox-2 selective inhibitor of the present invention include diarylbenzopyran derivatives that are described in U.S. Patent No. 6,340,694. Such diarylbenzopyran derivatives have the general formula shown below in formula XIV:

$$R^{64}$$
 R^{65}
 R^{66}
 R^{66}

wherein:

5

10

20

25

15 X⁸ is an oxygen atom or a sulfur atom;

 R^{64} and R^{65} , identical to or different from each other, are independently a hydrogen atom, a halogen atom, a C_1 – C_6 lower alkyl group, a trifluoromethyl group, an alkoxy group, a hydroxyl group, a nitro group, a nitrile group, or a carboxyl group;

 R^{66} is a group of a formula: $S(O)_n R^{68}$ wherein n is an integer of $0\sim2$, R^{68} is a hydrogen atom, a $C_1 - C_6$ lower alkyl group, or a group of a formula: NR^{69} R^{70} wherein R^{69} and R^{70} , identical to or different from each other, are independently a hydrogen atom, or a $C_1 - C_6$ lower alkyl group; and R^{67} is oxazolyl, benzo[b]thienyl, furanyl, thienyl, naphthyl, thiazolyl, indolyl, pyrolyl, benzofuranyl, pyrazolyl, pyrazolyl substituted with a $C_1 - C_6$ lower

alkyl group, indanyl, pyrazinyl, or a substituted group represented by the following structures:

$$R^{71}$$
 R^{72}
 R^{73}
 R^{76}
 R^{76}

5 wherein:

10

15

 R^{71} through R^{75} , identical to or different from one another, are independently a hydrogen atom, a halogen atom, a C_1 – C_6 lower alkyl group, a trifluoromethyl group, an alkoxy group, a hydroxyl group, a hydroxyl group, a nitro group, a group of a formula: $S(O)_n R^{68}$, a group of a formula: NR^{69} R^{70} , a trifluoromethoxy group, a nitrile group a carboxyl group, an acetyl group, or a formyl group,

wherein n, R^{68} , R^{69} and R^{70} have the same meaning as defined by R^{66} above; and

 R^{76} is a hydrogen atom, a halogen atom, a C_1 – C_6 lower alkyl group, a trifluoromethyl group, an alkoxy group, a hydroxyl group, a trifluoromethoxy group, a carboxyl group, or an acetyl group.


[0119] Materials that can serve as the Cox-2 selective inhibitor of the present invention include 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines that are described in U.S. Patent No. 6,376,519. Such 1-(4-

sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines have the formula shown below in formula **XV**:

$$Z^{5}$$
 N
 N
 SO_2NH_2

wherein:

 X^9 is selected from the group consisting of C_1 – C_6 trihalomethyl, preferably trifluoromethyl; C_1 – C_6 alkyl; and an optionally substituted or di-substituted phenyl group of formula **XVI**:



10 wherein:

15

 R^{77} and R^{78} are independently selected from the group consisting of hydrogen, halogen, preferably chlorine, fluorine and bromine; hydroxyl; nitro; C_1 – C_6 alkyl, preferably C_1 – C_3 alkyl; C_1 – C_6 alkoxy, preferably C_1 – C_3 alkoxy; carboxy; C_1 – C_6 trihaloalkyl, preferably trihalomethyl, most preferably trifluoromethyl; and cyano; Z^5 is selected from the group consisting of substituted and unsubstituted aryl.

[0120] Compounds useful as Cox-2 selective inhibitors of the present invention include heterocycles that are described in U.S. Patent No. 6,153,787. Such heterocycles have the general formulas shown below in formulas XVII and XVIII:

5

wherein:

 R^{79} is a mono-, di-, or tri-substituted C_1 – C_{12} alkyl, or a mono-, or an unsubstituted or mono-, di- or tri-substituted linear or branched C_2 – C_{10} alkenyl, or an unsubstituted or mono-, di- or tri-substituted linear or branched C_2 – C_{10} alkynyl, or an unsubstituted or mono-, di- or tri-substituted C_3 – C_{12} cycloalkenyl, or an unsubstituted or mono-, di- or tri-substituted C_5 – C_{12} cycloalkynyl, wherein the substituents are selected from the group consisting of halo selected from F, CI, Br, and I, OH, CF₃, C_3 – C_6 cycloalkyl, =O,dioxolane, CN;

1

15

10

R⁸⁰ is selected from the group consisting of CH₃, NH₂, NHC(O)CF₃, and NHCH₃;

 R^{81} and R^{82} are independently selected from the group consisting of hydrogen and C_1 – C_{10} alkyl; or

20

R⁸¹ and R⁸² together with the carbon to which they are attached form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms.

[0121] Formula XVIII is:

$$(O)_2SH_3C$$
 H_3C
 CH_3

wherein X¹⁰ is fluoro or chloro.

[0122] Materials that can serve as the Cox-2 selective inhibitor of the present invention include 2,3,5-trisubstituted pyridines that are described in U.S. Patent No. 6,046,217. Such pyridines have the general formula shown below in formula XIX:

$$R^{84} \qquad XIX$$

$$R^{85} \qquad R^{87} \qquad R^{89} \qquad QR^{91}$$

$$R^{86} \qquad R^{88} \qquad R^{90}$$

or a pharmaceutically acceptable salt thereof,

10 wherein:

15

5

X¹¹ is selected from the group consisting of O, S, and a bond;

n is 0 or 1;

 R^{83} is selected from the group consisting of CH_3 , NH_2 , and $\mathsf{NHC}(\mathsf{O})\mathsf{CF}_3$;

 R^{84} is selected from the group consisting of halo, C_1 – C_6 alkoxy, C_1 – C_6 alkylthio, CN, C_1 – C_6 alkyl, C_1 – C_6 fluoroalkyl, N_3 , — CO_2 R^{92} ,

hydroxyl, — $C(R^{93})(R^{94})$ —OH, — C_1 — C_6 alkyl- CO_2 — R^{95} , C_1 — C_6 fluoroalkoxy, NO_2 , NR^{96} R^{97} , and $NHCOR^{98}$;

 R^{85} to R^{89} are independently selected from the group consisting of hydrogen and C_1 – C_6 alkyl; or

 R^{85} and R^{89} , or R^{89} and R^{90} together with the atoms to which they are attached form a carbocyclic ring of 3, 4, 5, 6 or 7 atoms, or R^{85} and R^{87} are joined to form a bond.

[0123] Compounds that are useful as the Cox-2 selective inhibitor of the present invention include diaryl bicyclic heterocycles that are described in U.S. Patent No. 6,329,421. Such diaryl bicyclic heterocycles have the general formula shown below in formula **XX**:

$$R^{101} A^6 = A^5$$
 $R^{102} A^8$
 X^{12}
 R^{100}

and pharmaceutically acceptable salts thereof wherein:

15 $-A^5=A^6-A^7=A^8$ is selected from the group consisting of

5

10

(b)
$$-CH_2 - CH_2 - CH_2 - C(O)$$
, $-CH_2 - CH_2 - C(O)$ $-CH_2 - CH_2$, $-CH_2 - CH_2$,

(c)
$$-CH_2 - CH_2 - C(O)$$
, $-CH_2 - C(O)$ $-CH_2$, $-C(O)$ $-CH_2$

25 (f)
$$-C(R^{105})_2 -O-C(O)-, -C(O)-O-C(R^{105})_2 -, -O-C(O)-$$

 $C(R^{105})_2 -, -C(R^{105})_2 -C(O)-O-,$

- (h) —CH=N—CH=CH—,
- (i) —CH=CH—N=CH—,
- (j) —CH=CH—CH=N—,
- (k) —N=CH—CH=N—,
- 5 (I) —N=CH—N=CH—,
 - (m) —CH=N—CH=N—,
 - (n) -S -CH = N -,
 - (o) —S—N=CH—,
 - (p) —N=N—NH—,
- 10 (q) —CH=N—S—, and
 - (r) —N=CH—S—;

R⁹⁹ is selected from the group consisting of S(O)₂CH₃, S(O)₂NH₂,

S(O)₂NHCOCF₃, S(O)(NH)CH₃, S(O)(NH)NH₂, S(O)(NH)NHCOCF₃,

 $P(O)(CH_3)OH$, and $P(O)(CH_3)NH_2$;

- 15 R¹⁰⁰ is selected from the group consisting of
 - (a) $C_1 C_6$ alkyl,
 - (b) C₃ –C₇ cycloalkyl,
 - (c) mono- or di-substituted phenyl or naphthyl wherein the substituent is selected from the group consisting of
- 20 (1) hydrogen,
 - (2) halo, including F, Cl, Br, I,
 - (3) $C_1 C_6$ alkoxy,
 - (4) $C_1 C_6$ alkylthio,
 - (5) CN,
- 25 (6) CF_3 ,
 - (7) C₁ –C₆ alkyl,
 - $(8) N_3$,
 - (9) $--CO_2 H$,
 - (10) — CO_2 — C_1 – C_4 alkyl,
- 30 (11) —C(R^{103})(R^{104})—OH,
 - (12) — $C(R^{103})(R^{104})$ —O— C_1 – C_4 alkyl, and
 - (13) — C_1 – C_6 alkyl- CO_2 — R^{106} ;

(d) mono- or di-substituted heteroaryl wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one hetero atom which is S, O, or N, and optionally 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2, 3, or 4 additional N atoms; said substituents are selected from the group consisting of

- (1) hydrogen,
- (2) halo, including fluoro, chloro, bromo and iodo,
- (3) $C_1 C_6$ alkyl,
- 10 (4) $C_1 C_6$ alkoxy,

5

- (5) $C_1 C_6$ alkylthio,
- (6) CN,
- $(7) CF_3,$
- (8) N_3 ,

15 (9)
$$-C(R^{103})(R^{104})$$
—OH, and (10) $-C(R^{103})(R^{104})$ —O—C₁ $-C_4$ alkyl;

- (e) benzoheteroaryl which includes the benzo fused analogs of (d); R^{101} and R^{102} are the substituents residing on any position of $-A^5=A^6$ $A^7=A^8$ and are selected independently from the group consisting of
- 20 (a) hydrogen,
 - (b) CF₃,
 - (c) CN,
 - (d) $C_1 C_6$ alkyl,
 - (e) $-Q^3$ wherein Q^3 is Q^4 , CO_2 H, $C(R^{103})(R^{104})OH$,
- 25 (f) —O—Q⁴,
 - (g) —S— Q^4 , and
 - (h) optionally substituted:
 - $(1) C_1 C_5$ alkyl- Q^3 ,
 - (2) --O--C₁ -C₅ alkyl-Q³,
- 30 (3) —S— C_1 – C_5 alkyl- Q^3 ,
 - $(4) C_1 C_3$ alkyl-O- C_{1-3} alkyl-Q³,
 - (5) — $C_1 C_3$ alkyl-S— C_{1-3} alkyl- Q^3 ,

(6) —
$$C_1 - C_5$$
 alkyl- $O - Q^4$,

$$(7) - C_1 - C_5$$
 alkyl-S $- Q^4$,

wherein the substituent resides on the alkyl chain and the substituent is C_1 – C_3 alkyl, and Q^3 is Q^4 , CO_2 H, $C(R^{103})(R^{104})OH$ Q^4 is CO_2 — C_1 – C_4 alkyl, tetrazolyl-5-yl, or $C(R^{103})(R^{104})O$ — C_1 – C_4 alkyl;

 R^{103} , R^{104} and R^{105} are each independently selected from the group consisting of hydrogen and C_1 – C_6 alkyl; or

R¹⁰³ and R¹⁰⁴ together with the carbon to which they are attached form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms, or two R¹⁰⁵ groups on the same carbon form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms;

R¹⁰⁶ is hydrogen or C₁ –C₆ alkyl;

R¹⁰⁷ is hydrogen, C₁ —C₆ alkyl or aryl;

$$X^7$$
 is O, S, NR^{107} , CO, $C(R^{107})_2$, $C(R^{107})(OH)$, — $C(R^{107})=C(R^{107})$ —; — $C(R^{107})=N$ —; or — $N=C(R^{107})$ —.

[0124] Compounds that may act as Cox-2 selective inhibitors include salts of 5-amino or a substituted amino 1,2,3-triazole compound that are described in U.S. Patent No. 6,239,137. The salts are of a class of compounds of formula XXI:

wherein:

5

10

15

20

R¹⁰⁸ is:

$$-(CH_2)_p$$
 X^{13}
 $(R^{112})_m$

wherein:

5

10

15

p is 0 to 2; m is 0 to 4; and n is 0 to 5;

X¹³ is O, S, SO, SO₂, CO, CHCN, CH₂ or C=NR¹¹³ where R¹¹³ is hydrogen, loweralkyl, hydroxyl, loweralkoxy, amino, loweralkylamino, diloweralkylamino or cyano;

R¹¹¹ and R¹¹² are independently halogen, cyano, trifluoromethyl, loweralkanoyl, nitro, loweralkyl, loweralkoxy, carboxy, lowercarbalkoxy, trifluoromethoxy, acetamido, loweralkylthio, loweralkylsulfinyl, loweralkylsulfonyl, trichlorovinyl, trifluoromethylthio, trifluoromethylsulfinyl, or trifluoromethylsulfonyl;

R¹⁰⁹ is amino, mono or diloweralkyl amino, acetamido, acetimido, ureido, formamido, or guanidino; and

R¹¹⁰ is carbamoyl, cyano, carbazoyl, amidino or N-hydroxycarbamoyl; wherein the loweralkyl, loweralkyl containing, loweralkoxy and loweralkanoyl groups contain from 1 to 3 carbon atoms.

[0125] Pyrazole derivatives such as those described in U.S. Patent 6,136,831 can serve as a Cox-2 selective inhibitor of the present invention. Such pyrazole derivatives have the formula shown below in formula XXII:

20 wherein:

R¹¹⁴ is hydrogen or halogen;

R¹¹⁵ and R¹¹⁶ are each independently hydrogen, halogen, lower alkyl, lower alkoxy, hydroxyl or lower alkanoyloxy;

R¹¹⁷ is lower haloalkyl or lower alkyl;

X¹⁴ is sulfur, oxygen or NH; and

Z⁶ is lower alkylthio, lower alkylsulfonyl or sulfamoyl; or a pharmaceutically acceptable salt thereof.

[0126] Materials that can serve as a Cox-2 selective inhibitor of the present invention include substituted derivatives of benzosulphonamides that are described in U.S. Patent 6,297,282. Such benzosulphonamide derivatives have the formula shown below in formula XXIII:

10 wherein:

5

15

20

25

X¹⁵ denotes oxygen, sulphur or NH;

R¹¹⁸ is an optionally unsaturated alkyl or alkyloxyalkyl group, optionally mono- or polysubstituted or mixed substituted by halogen, alkoxy, oxo or cyano, a cycloalkyl, aryl or heteroaryl group optionally mono- or polysubstituted or mixed substituted by halogen, alkyl, CF₃, cyano or alkoxy;

 R^{119} and R^{120} , independently from one another, denote hydrogen, an optionally polyfluorised alkyl group, an aralkyl, aryl or heteroaryl group or a group $(CH_2)_n - X^{16}$; or

R¹¹⁹ and R¹²⁰, together with the N- atom, denote a 3 to 7-membered, saturated, partially or completely unsaturated heterocycle with one or more heteroatoms N, O or S, which can optionally be substituted by oxo, an alkyl, alkylaryl or aryl group, or a group (CH₂)_n—X¹⁶;

 X^{16} denotes halogen, NO₂, —OR¹²¹, —COR¹²¹, —CO₂ R¹²¹, —OCO₂ R¹²¹, —OCO₂ R¹²¹, —CN, —CONR¹²¹ OR¹²², —CONR¹²¹ R¹²², —SR¹²¹, —S(O)R¹²¹, —S(O)₂ R¹²¹, —NR¹²¹ R¹²², —NHC(O)R¹²¹, —NHS(O)₂ R¹²¹;

n denotes a whole number from 0 to 6;

R¹²³ denotes a straight-chained or branched alkyl group with 1-10 C-atoms, a cycloalkyl group, an alkylcarboxyl group, an aryl group, aralkyl group, a heteroaryl or heteroaralkyl group which can optionally be monoor polysubstituted or mixed substituted by halogen or alkoxy;

- R^{124} denotes halogen, hydroxyl, a straight-chained or branched alkyl, alkoxy, acyloxy or alkyloxycarbonyl group with 1 to 6 carbon atoms, which can optionally be mono- or polysubstituted by halogen, NO₂, —OR¹²¹, COR¹²¹, —CO₂ R¹²¹, —COO₂ R¹²¹, —CN, —CONR¹²¹ OR¹²², —CONR¹²¹ R¹²², —SR¹²¹, —S(O)R¹²¹, —S(O)₂ R¹²¹, —NR¹²¹ R¹²², —NHC(O)R¹²¹, —
- NHS(O)₂ R¹²¹, or a polyfluoroalkyl group;

 R¹²¹ and R¹²², independently from one another, denote hydrogen, alkyl, aralkyl or aryl; and

 m denotes a whole number from 0 to 2;

and the pharmaceutically-acceptable salts thereof.

15 **[0127]** Compounds that are useful as Cox-2 selective inhibitors of the present invention include phenyl heterocycles that are described in U.S. Patent Nos. 5,474,995 and 6,239,173. Such phenyl heterocyclic compounds have the formula shown below in formula **XXIV**:

- or pharmaceutically acceptable salts thereof wherein: X^{17} — Y^1 — Z^7 -is selected from the group consisting of
 - (a) —CH₂ CH₂ CH₂ —,

5

- (b) ---C(O)CH2 CH2 ---,
- (c) ---CH₂ CH₂ C(O)---,

(d)
$$-CR^{129}$$
 (R^{129}) $-O-C(O)$,

(f)
$$-CH_2 -NR^{127} -CH_2 -$$

(g)
$$-CR^{129}$$
 (R^{129}) $-NR^{127}$ $-C(O)$ -,

5 (h)
$$-CR^{128}=CR^{128'}-S-$$
,

(I)
$$-N=CR^{128}-O-$$
,

10 (m)
$$-O-CR^{128} = N-$$

(p)
$$-S-CR^{128}=N-$$
,

(g)
$$-C(O)-NR^{127}-CR^{129}(R^{129'})-$$
,

when side b is a double bond, and sides a and c are single bonds; and X^{17} — Y^{1} — Z^{7} -is selected from the group consisting of

(c)
$$=N-S-CH=$$
,

(d) =
$$CH$$
— S — N =,

$$(f) = CH - O - N = ,$$

$$(h) = N - O - N = ,$$

when sides a and c are double bonds and side b is a single bond;

 R^{125} is selected from the group consisting of

(a)
$$S(O)_2 CH_3$$
,

30 (b)
$$S(O)_2 NH_2$$
,

(d)
$$S(O)(NH)CH_3$$
,

- (e) $S(O)(NH)NH_2$,
- (f) $S(O)(NH)NHC(O)CF_3$,
- (g) P(O)(CH₃)OH, and
- (h) P(O)(CH₃)NH₂;
- 5 R¹²⁶ is selected from the group consisting of
 - (a) $C_1 C_6$ alkyl,
 - (b) C_3 , C_4 , C_5 , C_6 , and C_7 , cycloalkyl,
 - (c) mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituent is selected from the group consisting of
- 10 (1) hydrogen,
 - (2) halo,
 - (3) $C_1 C_6$ alkoxy,
 - (4) $C_1 C_6$ alkylthio,
 - (5) CN,
- 15 (6) CF_3 ,

25

30

- (7) C₁ –C₆ alkyl,
- (8) N_3 ,
- $(9) CO_2 H$,
- (10) — CO_2 — C_1 – C_4 alkyl,
- 20 (11) — $C(R^{129})(R^{130})$ —OH,
 - (12) — $C(R^{129})(R^{130})$ —O— C_1 – C_4 alkyl, and
 - $(13) C_1 C_6$ alkyl $-CO_2 R^{129}$;
 - (d) mono-, di- or tri-substituted heteroaryl wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one hetero atom which is S, O, or N, and optionally 1, 2, or 3 additionally N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2, 3, or 4 additional N atoms; said substituents are selected from the group consisting of
 - (1) hydrogen,
 - (2) halo, including fluoro, chloro, bromo and iodo,
 - (3) $C_1 C_6$ alkyl,
 - (4) $C_1 C_6$ alkoxy,

- (5) $C_1 C_6$ alkylthio,
- (6) CN,
- (7) CF₃,
- (8) N_3 ,

5 (9)
$$-C(R^{129})(R^{130})$$
 OH, and

(10) —
$$C(R^{129})(R^{130})$$
— O — C_1 — C_4 alkyl;

(e) benzoheteroaryl which includes the benzo fused analogs of (d);

R¹²⁷ is selected from the group consisting of

- (a) hydrogen,
- 10 (b) CF₃,
 - (c) CN,
 - (d) $C_1 C_6$ alkyl,
 - (e) hydroxyl C₁ −C₆ alkyl,
 - (f) —C(O)— $C_1 C_6$ alkyl,
- 15 (g) optionally substituted:
 - (1) — C_1 – C_5 alkyl- Q^5 ,
 - (2) $-C_1 C_5$ alkyl-O- $C_1 C_3$ alkyl-Q⁵,
 - (3) $-C_1 C_3$ alkyl-S- $-C_1 C_3$ alkyl-Q⁵,
 - $(4) C_1 C_5$ alkyl $O Q^5$, or
- 20 (5) $-C_1 C_5$ alkyl-S $-Q^5$,

wherein the substituent resides on the alkyl and the substituent is C_1 – C_3 alkyl;

(h) $-Q^5$;

R¹²⁸ and R¹²⁸ are each independently selected from the group consisting

- 25 of
 - (a) hydrogen,
 - (b) CF₃,
 - (c) CN,
 - (d) $C_1 C_6$ alkyl,
- 30 (e) $-Q^5$,
 - (f) —O—Q⁵;
 - (a) $-S-Q^5$, and

- (h) optionally substituted:
 - (1) — C_1 – C_5 alkyl- Q^5 ,
 - (2) $--O-C_1-C_5$ alkyl-Q⁵,
 - (3) —S— C_1 – C_5 alkyl- Q^5 ,
 - $(4) C_1 C_3$ alkyl $O C_1 C_3$ alkyl Q^5 ,
 - $(5) C_1 C_3$ alkyl-S- $C_1 C_3$ alkyl- Q^5 ,
 - (6) $-C_1 C_5$ alkyl-O- $-Q^5$,
 - $(7) C_1 C_5$ alkyl-S- Q^5 ,

wherein the substituent resides on the alkyl and the substituent is $C_1 - \frac{1}{2}$

10 C₃ alkyl, and

5

R¹²⁹, R¹²⁹, R¹³⁰, R¹³¹ and R¹³² are each independently selected from the group consisting of

- (a) hydrogen,
- (b) $C_1 C_6$ alkyl;
- or R¹²⁹ and R¹³⁰ or R¹³¹ and R¹³² together with the carbon to which they are attached form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms;
 - Q^5 is CO_2 H, CO_2 — C_1 — C_4 alkyl, tetrazolyl-5-yl, $C(R^{131})(R^{132})(OH)$, or $C(R^{131})(R^{132})(O-C_1-C_4$ alkyl);
- provided that when X—Y—Z is —S— CR^{128} = CR^{128} , then R^{128} and R^{128} are other than CF_3 .

[0128] An exemplary phenyl heterocycle that is disclosed in U.S. Patent No. 6,239,173 is 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(2H)-furanone.

25 **[0129]** Bicycliccarbonyl indole compounds such as those described in U.S. Patent No. 6,303,628 are useful as Cox-2 selective inhibitors of the present invention. Such bicycliccarbonyl indole compounds have the formula shown below in formula **XXV**:

$$(X^{19})_n$$
 $(CH_2)_q$
 $(CH_2)_r$
 $(CH_2)_m$

or the pharmaceutically acceptable salts thereof wherein:

 A^9 is $C_1 - C_6$ alkylene or $-NR^{133}$ —; Z^8 is $C(=L^3)R^{134}$, or SO_2 R^{135} ;

5 Z^9 is CH or N;

10

 Z^{10} and Y^2 are independently selected from —CH₂ —, O, S and —N—R¹³³; m is 1, 2 or 3;

q and r are independently 0, 1 or 2;

 X^{18} is independently selected from halogen, $C_1 - C_4$ alkyl, halo-substituted $C_1 - C_4$ alkyl, hydroxyl, $C_1 - C_4$ alkoxy, halo-substituted $C_1 - C_4$ alkoxy, $C_1 - C_4$ alkylthio, nitro, amino, mono- or di-($C_1 - C_4$ alkyl)amino and cyano; n is 0, 1, 2, 3 or 4;

L³ is oxygen or sulfur;

 R^{133} is hydrogen or $C_1 - C_4$ alkyl;

- 15 R¹³⁴ is hydroxyl, C₁ –C₆ alkyl, halo-substituted C₁ –C₆ alkyl, C₁ –C₆ alkoxy, halo-substituted C₁ –C₆ alkoxy, C₃ –C₇ cycloalkoxy, C₁ –C₄ alkyl(C₃ –C₇ cycloalkoxy), —NR¹³⁶ R¹³⁷, C₁ –C₄ alkylphenyl-O— or phenyl-O—, said phenyl being optionally substituted with one to five substituents independently selected from halogen, C₁ –C₄ alkyl, hydroxyl, C₁ –C₄ alkoxy and nitro;
- R^{135} is C_1 – C_6 alkyl or halo-substituted C_1 – C_6 alkyl; and R^{136} and R^{137} are independently selected from hydrogen, C_{1-6} alkyl and halo-substituted C_1 – C_6 alkyl.

[0130] Materials that can serve as a Cox-2 selective inhibitor of the present invention include benzimidazole compounds that are described in U.S. Patent No. 6,310,079. Such benzimidazole compounds have the formula shown below in formula **XXVI**:

$$(X^{21})_n$$
 CR^{140} CR^{139} R^{138} $XXVI$

or a pharmaceutically acceptable salt thereof, wherein:

A¹⁰ is heteroaryl selected from:

5

10

15

20

25

a 5-membered monocyclic aromatic ring having one hetero atom selected from O, S and N and optionally containing one to three N atom(s) in addition to said hetero atom, or

a 6-membered monocyclic aromatic ring having one N atom and optionally containing one to four N atom(s) in addition to said N atom; and said heteroaryl being connected to the nitrogen atom on the benzimidazole through a carbon atom on the heteroaryl ring;

 X^{20} is independently selected from halo, C_1 – C_4 alkyl, hydroxyl, C_1 – C_4 alkoxy, halo-substituted C_1 – C_4 alkyl, hydroxyl-substituted C_1 – C_4 alkyl, $(C_1$ – C_4 alkoxy) $(C_1$ – C_4 alkyl, halo-substituted $(C_1$ – C_4 alkoxy, amino, $(C_1$ – C_4 alkyl)amino, $(C_1$ – C_4 alkyl)amino, $(C_1$ – C_4 alkyl)amino] $(C_1$ – $(C_4$ alkyl)amino] $(C_1$ – $(C_4$ alkyl)amino] $(C_1$ – $(C_4$ alkyl)amino, $(C_1$ – $(C_4$ alkoxy)amino]amino, $(C_1$ – $(C_4$ alkyl)amino]carbonyl, $(C_1$ – $(C_4$ alkyl)amino]carbonyl, $(C_1$ – $(C_4$ alkyl)amino]carbonyl, $(C_1$ – $(C_4$ alkyl)amino]carbonyl, $(C_1$ – $(C_4$ alkyl)amino]sulfonyl, $(C_1$ – $(C_4$ alkyl)amino]su

 X^{21} is independently selected from halo, C_1 – C_4 alkyl, hydroxyl, C_1 – C_4 alkyl, hydroxyl-substituted C_1 – C_4 alkyl,

 $(C_1 - C_4 \text{ alkoxy})C_1 - C_4 \text{ alkyl}$, halo-substituted $C_1 - C_4 \text{ alkoxy}$, amino, N-($C_1 - C_4 \text{ alkyl}$)amino, N, N-di($C_1 - C_4 \text{ alkyl}$)amino, [N-($C_1 - C_4 \text{ alkyl}$)amino] $C_1 - C_4 \text{ alkyl}$, [N, N-di($C_1 - C_4 \text{ alkyl}$)amino] $C_1 - C_4 \text{ alkyl}$, N-($C_1 - C_4 \text{ alkyl}$)amino, N-($C_1 - C_4 \text{ alkyl}$)-N-($C_1 - C_4 \text{ alkanoyl}$) amino, N-[($C_1 - C_4 \text{ alkyl}$)sulfonyl]amino, N-[(halo-sub stituted $C_1 - C_4 \text{ alkyl}$)sulfonyl]amino, $C_1 - C_4 \text{ alkanoyl}$, carboxy, ($C_1 - C_4 \text{ alkoxy}$)hydroxyl, cabamoyl, [N-($C_1 - C_4 \text{ alkyl}$) amino]carbonyl, [N, N-di($C_1 - C_4 \text{ alkyl}$)amino]carbonyl, N-carbomoylamino, cyano, nitro, mercapto, ($C_1 - C_4 \text{ alkyl}$)thio, ($C_1 - C_4 \text{ alkyl}$)sulfonyl, aminosulfonyl, [N-($C_1 - C_4 \text{ alkyl}$)amino]sulfonyl and [N, N-di($C_1 - C_4 \text{ alkyl}$)amino]sulfonyl;

5

10

15

20

25

30


R¹³⁸ is selected from hydrogen; straight or branched C₁ –C₄ alkyl optionally substituted with one to three substituent(s) wherein said substituents are independently selected from halo, hydroxyl, C₁ --C₄ alkoxy, amino, N-(C₁ -C₄ alkyl)amino and N, N-di(C₁ -C₄ alkyl)amino; C₃ -C₈ cycloalkyl optionally substituted with one to three substituent(s) wherein said substituents are indepently selected from halo, C₁ -C₄ alkyl, hydroxyl, $C_1 - C_4$ alkoxy, amino, $N-(C_1 - C_4 \text{ alkyl})$ amino and N, N-di($C_1 - C_4$ alkyl)amino; C₄ -C₈ cycloalkenyl optionally substituted with one to three substituent(s) wherein said substituents are independently selected from halo, $C_1 - C_4$ alkyl, hydroxyl, $C_1 - C_4$ alkoxy, amino, N-($C_1 - C_4$ alkyl)amino and N, N-di(C₁ -C₄ alkyl)amino; phenyl optionally substituted with one to three substituent(s) wherein said substituents are independently selected from halo, C_1 – C_4 alkyl, hydroxyl, C_1 – C_4 alkoxy, halo-substituted C_1 – C_4 alkyl, \Box ydroxyl-substituted C₁ -C₄ alkyl, (C₁ -C₄ alkoxy)C₁ -C₄ alkyl, halosubstituted C₁ -C₄ alkoxy, amino, N-(C₁ -C₄ alkyl)amino, N, N-di(C₁ -C₄ alkyl)amino, [N-(C_1 – C_4 alkyl)ami no] C_1 – C_4 alkyl, [N, N-di(C_1 – C_4 alkyl)amino] $C_1 - C_4$ alkyl, $N-(C_1 - C_4$ alkanoyl)amino, $N-[C_1 - C_4$ alkyl) $(C_1 - C_4)$ C₄ alkanovl)]amino, N-[(C₁ -C₄ a lkyl)sulfony]amino, N-[(halo-substituted C₁ $-C_4$ alkyl)sulfonyl]amino, C_1 $-C_4$ alkanoyl, carboxy, $(C_1$ $-C_4$ alkoxy)carbonyl, carbomoyl, $[N-(C_1-C_4 \text{ alky})]$ amino]carbonyl, $[N, N-di(C_1-C_4 \text{ alky})]$ C_4 alkyl)aminolcarbonyl, cyano, mitro, mercapto, $(C_1 - C_4$ alkyl)thio, $(C_1 - C_4)$

alkyl)sulfinyl, $(C_1 - C_4 \text{ alkyl})$ sulfonyl, aminosulfonyl, $[N-(C_1 - C_4 \text{ alkyl})]$ amino]sulfonyl and $[N, N-\text{di}(C_1 - C_4 \text{ alkyl})]$ amino]sulfonyl; and heteroaryl selected from: a 5-membered monocyclic aromatic ring having one hetero atom selected from O, S and N and optionally containing one to three N atom(s) in addition to said hetero atom; or a 6-membered monocyclic aromatic ring having one N atom and optionally containing one to four N atom(s) in addition to said N atom; and said heteroaryl being optionally substituted with one to three substituent(s) selected from X^{20} ;

 R^{139} and R^{140} are independently selected from: hydrogen; halo; $C_1 - C_4$ alkyl; phenyl optionally substituted with one to three substituent(s) wherein said substituents are independently selected from halo, $C_1 - C_4$ alkyl, hydroxyl, $C_1 - C_4$ alkoxy, amino, N-($C_1 - C_4$ alkyl)amino and N, N-di($C_1 - C_4$ alkyl)amino; or R^{138} and R^{139} can form, together with the carbon atom to which they are attached, a $C_3 - C_7$ cycloalkyl ring;

m is 0, 1, 2, 3, 4 or 5; and n is 0, 1, 2, 3 or 4.

[0131] Compounds that may be employed as a Cox-2 selective inhibitor of the present invention include indole compounds that are described in U.S. Patent No. 6,300,363. Such indole compounds have the formula shown below in formula **XXVII**:



and the pharmaceutically acceptable salts thereof, wherein:

L⁴ is oxygen or sulfur;

Y³ is a direct bond or C₁ –C₄ alkylidene;

 Q^6 is:

5

10

15

20

(a) $C_1 - C_6$ alkyl or halosubstituted $C_1 - C_6$ alkyl, said alkyl being optionally substituted with up to three substituents independently selected from hydroxyl, $C_1 - C_4$ alkoxy, amino and mono- or di-($C_1 - C_4$ alkyl)amino, (b) $C_3 - C_7$ cycloalkyl optionally substituted with up to three substituents independently selected from hydroxyl, $C_1 - C_4$ alkyl and $C_1 - C_4$ alkoxy, (c) phenyl or naphthyl, said phenyl or naphthyl being optionally substituted with up to four substituents independently selected from:

5

10

15

20

25

30

(c-1) halo, C_1 – C_4 alkyl, halosubstituted C_1 – C_4 alkyl, hydroxyl, C_1 – C_4 alkoxy, halosubstituted C_1 – C_4 alkoxy, $S(O)_m$ R^{143} , SO_2 NH_2 , SO_2 $N(C_1$ – C_4 alkyl)₂, amino, mono- or di-(C_1 – C_4 alkyl)amino, $NHSO_2$ R^{143} , $NHC(O)R^{143}$, CN, CO_2 H, CO_2 (C_1 – C_4 alkyl), C_1 – C_4 alkyl-OH, C_1 – C_4 alkyl-OR¹⁴³, $CONH_2$, $CONH(C_1$ – C_4 alkyl), $CON(C_1$ – C_4 alkyl)₂ and — O—Y-phenyl, said phenyl being optionally substituted with one or two substituents independently selected from halo, C_1 – C_4 alkyl, CF_3 , hydroxyl, OR^{143} , $S(O)_mR^{143}$, amino, mono- or di-(C_1 – C_4 alkyl)amino and CN;

(d) a monocyclic aromatic group of 5 atoms, said aromatic group having one heteroatom selected from O, S and N and optionally containing up to three N atoms in addition to said heteroatom, and said aromatic group being substituted with up to three substitutents independently selected from:

(d-1) halo, C_1 – C_4 alkyl, halosubstituted C_1 – C_4 alkyl, hydroxyl, C_1 – C_4 alkoxy, halosubstituted C_1 – C_4 alkoxy, C_1 – C_4 alkyl-OH, $S(O)_m$ R^{143} , SO_2 NH_2 , SO_2 $N(C_1$ – C_4 alkyl)₂, amino, mono- or di-(C_1 – C_4 alkyl)amino, $NHSO_2$ R^{143} , $NHC(O)R^{143}$, CN, CO_2 H, CO_2 (C_1 – C_4 alkyl), C_1 – C_4 alkyl-OR¹⁴³, $CONH_2$, $CONH(C_1$ – C_4 alkyl), $CON(C_1$ – C_4 alkyl)₂, phenyl, and mono-, di- or tri-substituted phenyl wherein the substituent is independently selected from halo, CF_3 , C_1 – C_4 alkyl, hydroxyl, C_1 – C_4 alkoxy, CF_3 , SR^{143} , SO_2 CH_3 , SO_2 NH_2 , amino, C_{1-4} alkylamino and $NHSO_2$ R^{143} ;

(e) a monocyclic aromatic group of 6 atoms, said aromatic group having one heteroatom which is N and optionally containing up to three atoms in

addition to said heteroatom, and said aromatic group being substituted with up to three substituents independently selected from the above group (d-1);

 R^{141} is hydrogen or C_1 – C_6 alkyl optionally substituted with a substituent selected independently from hydroxyl, OR^{143} , nitro, amino, mono- or di-(C_1 – C_4 alkyl)amino, CO_2 H, CO_2 (C_1 – C_4 alkyl), $CONH_2$, $CONH(C_1$ – C_4 alkyl) and $CON(C_1$ – C_4 alkyl)₂;

R¹⁴² is:

5

15

- (a) hydrogen,
- 10 (b) $C_1 C_4$ alkyl,
 - (c) $C(O)R^{145}$,

wherein R¹⁴⁵ is selected from:

(c-1) C_1 – C_{22} alkyl or C_2 – C_{22} alkenyl, said alkyl or alkenyl being optionally substituted with up to four substituents independently selected from:

(c-1-1) halo, hydroxyl, OR^{143} , $S(O)_m$ R^{143} , nitro, amino, mono- or di-(C_1 — C_4 alkyl)amino, NHSO₂ R^{143} , CO_2 H, CO_2 (C_1 — C_4 alkyl), CONH₂, CONH(C_1 — C_4 alkyl), CON(C_1 — C_4 alkyl)₂, OC(O)R¹⁴³, thienyl, naphthyl and groups of the following formulas:

$$(X^{22})_n$$

$$(X^$$

(c-2) C_1 $-C_{22}$ alkyl or C_2 $-C_{22}$ alkenyl, said alkyl or alkenyl being optionally substituted with five to forty-five halogen atoms, (c-3) $-Y^5$ — C_3 $-C_7$ cycloalkyl or $-Y^5$ — C_3 $-C_7$ cycloalkenyl, said cycloalkyl or cycloalkenyl being optionally substituted with up to three substituent independently selected from:

5

10

(c-3-1) C_1 – C_4 alkyl, hydroxyl, OR^{143} , $S(O)_m$ R^{143} , amino, mono- or di- (C_1 – C_4 alkyl)amino, $CONH_2$, $CONH(C_1$ – C_4 alkyl) and $CON(C_1$ – C_4 alkyl)₂,

(c-4) phenyl or naphthyl, said phenyl or naphthyl being optionally substituted with up to seven (preferably up to seven) substituents independently selected from:

(c-4-1) halo, C_1 – C_8 alkyl, C_1 – C_4 alkyl-OH, hydroxyl, C_1 – C_8 alkoxy, halosubstituted C_1 – C_8 alkyl, halosubstituted C_1 – C_8 alkoxy, CN, nitro, $S(O)_m$ R^{143} , SO_2 NH $_2$, SO_2 NH(C_1 – C_4 alkyl), SO_2 N(C_1 — C_4 alkyl) $_2$, amino, C_1 – C_4 alkylamino, di-(C_1 – C_4 alkyl)amino, CONH $_2$, CONH(C_1 – C_4 alkyl), CON(C_1 – C_4 alkyl) $_2$, OC(O) R^{143} , and phenyl optionally substituted with up to three substituents independently selected from halo, C_1 – C_4 alkyl, hydroxyl, OCH $_3$, CF $_3$, OCF $_3$, CN, nitro, amino, mono- or di-(C_1 – C_4 alkyl)amino, CO $_2$ H, CO $_2$ (C_1 – C_4 al kyl) and CONH $_2$,

(c-5) a monocyclic aromatic group as defined in (d) and (⊜) above, said aromatic group being optionally substituted with up to three substituents independently selected from:

(c-5-1) halo, C_1 – C_8 alkyl, C_1 – C_4 alkyl-OH, hydroxyl, C_1 – C_8 alkoxy, CF_3 , OCF_3 , CN, nitro, $S(O)_m$ R^{143} , amino, mono- or di-(C_1 – C_4 alkyl)amino, $CONH_2$, $CONH(C_1$ – C_4 alkyl), $CON(C_1$ – C_4 alkyl)₂, CO_2 H and CO_2 (C_1 – C_4 alkyl), and —Y-phenyl, said phenyl being optionally substituted with up to three substituents inderpendently selected halogen, C_1 – C_4 alkyl, hydroxyl, C_1 – C_4 alkoxy, CF_3 , CF_3 , CN, nitro, $S(O)_m$ R^{143} , amino, mono- or di-(C_1 – C_4 alkyl) amino, CO_2 H, CO_2 (C_1 – C_4 alkyl), $CONH_2$, $CONH(C_1$ – C_4 alkyl) and $CON(C_1$ – C_4 alkyl)₂,

(c-6) a group of the following formula:

5

10

15

20

25

 X^{22} is halo, C_1 – C_4 alkyl, hydroxyl, C_1 – C_4 alkoxy, halosubstitutued C_1 – C_4 alkoxy, $S(O)_m$ R^{143} , amino, mono- or di-(C_1 – C_4 alkyl)amino, NHSO₂ R^{143} , nitro, halosubstitutued C_1 – C_4 alkyl, CN, CO₂ H, CO₂ (C_1 – C_4 alkyl), C_1 – C_4 alkyl-OH, C_1 – C_4 alkylOR¹⁴³, CONH₂, CONH(C_1 – C_4 alkyl) o Γ CON(C_1 – C_4 alkyl)₂;

 R^{143} is C_1 – C_4 alkyl or halosubstituted C_1 – C_4 alkyl;

30 m is 0, 1 or 2; n is 0, 1, 2 or 3; p is 1, 2, 3, 4 or 5; q is 2 or 3;

Z¹¹ is oxygen, sulfur or NR¹⁴⁴; and

 R^{144} is hydrogen, C_1 – C_6 alkyl, halosubstitutued C_1 – C_4 alkyl or – Y^5 -phenyl, said phenyl being optionally substituted with up to two substituents independently selected from halo, C_1 – C_4 alkyl, hydroxyl, C_1 – C_4 alkoxy, $S(O)_m$ R^{143} , amino, mono- or di-(C_1 – C_4 alkyl)amino, CF_3 , OCF_3 , CN and nitro;

with the proviso that a group of formula $-Y^5$ —Q is not methyl or ethyl when X^{22} is hydrogen;

L⁴ is oxygen;

10 R¹⁴¹ is hydrogen; and R¹⁴² is acetyl.

[0132] Aryl phenylhydrazides that are described in U.S. Patent No. 6,077,869 can serve as Cox-2 selective inhibitors of the present invention. Such aryl phenylhydrazides have the formula shown below in formula

15 XXVIII:

5

wherein:

 χ^{23} and Υ^{6} are selected from hydrogen, halogen, alkyl, nitro, amino, hydroxy, methoxy and methylsulfonyl;

or a pharmaceutically acceptable salt thereof,.

[0133] Materials that can serve as a Cox-2 selective inhibitor of the present invention include 2-aryloxy, 4-aryl furan-2-ones that are described in U.S. Patent No. 6,140,515. Such 2-aryloxy, 4-aryl furan-2-ones have the formula shown below in formula **XXIX**:

or a pharmaceutical salt thereof, wherein:

5

10

15

 R^{146} is selected from the group consisting of SCH₃, —S(O)₂ CH₃ and — S(O)₂ NH₂;

R¹⁴⁷ is selected from the group consisting of OR¹⁵⁰, mono or di-substituted phenyl or pyridyl wherein the substituents are selected from the group consisting of methyl, chloro and F;

 R^{150} is unsubstituted or mono or di-substituted phenyl or pyridyl wherein the substituents are selected from the group consisting of methyl, chloro and F;

 R^{148} is H, C_1 – C_4 alkyl optionally substituted with 1 to 3 groups of F, Cl or Br; and

 R^{149} is H, C_1 – C_4 alkyl optionally substituted with 1 to 3 groups of F, Cl or Br, with the proviso that R^{148} and R^{149} are not the same.

[0134] Materials that can serve as a Cox-2 selective inhibitor of the present invention include bisaryl compounds that are described in U.S. Patent No. 5,994,379. Such bisaryl compounds have the formula shown below in formula **XXX**:

$$R^{151}$$
 R^{152}
 R^{153}
 R^{154}
 CO_2H

or a pharmaceutically acceptable salt, ester or tautomer thereof, wherein: Z^{13} is C or N:

when Z¹³ is N, R¹⁵¹ represents H or is absent, or is taken in conjunction with R¹⁵² as described below:

10

15

20

when Z^{13} is C, R^{151} represents H and R^{152} is a moiety which has the following characteristics:

- (a) it is a linear chain of 3-4 atoms containing 0-2 double bonds, which can adopt an energetically stable transoid configuration and if a double bond is present, the bond is in the trans configuration,
- (b) it is lipophilic except for the atom bonded directly to ring A, which is either lipophilic or non-lipophilic, and
- (c) there exists an energetically stable configuration planar with ring A to within about 15 degrees;

or R¹⁵¹ and R¹⁵² are taken in combination and represent a 5- or 6membered aromatic or non-aromatic ring D fused to ring A, said ring D containing 0-3 heteroatoms selected from O, S and N;

said ring D being lipophilic except for the atoms attached directly to ring A, which are lipophilic or non-lipophilic, and said ring D having available an

energetically stable configuration planar with ring A to within about 15 degrees;

said ring D further being substituted with 1 R^a group selected from the group consisting of C_1 – C_2 alkyl, — OC_1 – C_2 alkyl, — NHC_1 – C_2 alkyl, — NHC_1 – C_2 alkyl, —C(O) C_1 – C_2 alkyl, — C_1 – C_2 alkyl, and —C(S) C_1 – C_2 alkyl;

 Y^7 represents N, CH or C—OC₁ –C₃ alkyl, and when Z^{13} is N, Y^7 can also represent a carbonyl group;

R¹⁵³ represents H, Br, Cl or F; and

R¹⁵⁴ represents H or CH₃.

5

10

15

20

[0135] Compounds useful as Cox-2 selective inhibitors of the present invention include 1,5-diarylpyrazoles that are described in U.S. Patent No. 6,028,202. Such 1,5-diarylpyrazoles have the formula shown below in formula **XXXI**:

$$R^{158}$$
 R^{160}
 R^{160}
 R^{161}
 R^{161}
 R^{161}
 R^{161}
 R^{161}
 R^{162}
 R^{162}
 R^{162}

wherein:

 R^{155} , R^{156} , R^{157} , and R^{158} are independently selected from the groups consisting of hydrogen, $C_1 - C_5$ alkyl, $C_1 - C_5$ alkoxy, phenyl, halo, hydroxyl, $C_1 - C_5$ alkylsulfonyl, $C_1 - C_5$ alkylthio, trihalo $C_1 - C_5$ alkyl, amino, nitro and 2-quinolinylmethoxy;

 R^{159} is hydrogen, $C_1 - C_5$ alkyl, trihalo $C_1 - C_5$ alkyl, phenyl, substituted phenyl where the phenyl substitutents are halogen, $C_1 - C_5$ alkoxy,

trihaloC₁ –C₅ alkyl or nitro or R¹⁵⁹ is heteroaryl of 5-7 ring members where at least one of the ring members is nitrogen, sulfur or oxygen; R^{160} is hydrogen, $C_1 - C_5$ alkyl, phenyl $C_1 - C_5$ alkyl, substituted phenyl $C_1 - C_5$ C_5 alkyl where the phenyl substitutents are halogen, $C_1 - C_5$ alkoxy, trihalo $C_1 - C_5$ alkyl or nitro, or R^{160} is $C_1 - C_5$ alkoxycarbonyl, phenoxycarbonyl, substituted phenoxycarbonyl where the phenyl substitutents are halogen, C₁ –C₅ alkoxy, trihaloC₁ –C₅ alkyl or nitro; R^{161} is $C_1 - C_{10}$ alkyl, substituted $C_1 - C_{10}$ alkyl where the substituents are halogen, trihalo C_1 – C_5 alkyl, C_1 – C_5 alkoxy, carboxy, C_1 – C_5 alkoxycarbonyl, amino, $C_1 - C_5$ alkylamino, di $C_1 - C_5$ alkylamino, di $C_1 - C_5$ alkylamino $C_1 - C_5$ alkylamino, $C_1 - C_5$ alkylamino $C_1 - C_5$ alkylamino or a heterocycle containing 4-8 ring atoms where one more of the ring atoms is nitrogen, oxygen or sulfur, where said heterocycle may be optionally substituted with C₁ -C₅ alkyl; or R¹⁶¹ is phenyl, substituted phenyl (where the phenyl substitutents are one or more of C₁ -C₅ alkyl, halogen, C₁ -C₅ alkoxy, trihalo C_1 – C_5 alkyl or nitro), or R^{161} is heteroaryl having 5-7 ring atoms where one or more atoms are nitrogen, oxygen or sulfur, fused heteroaryl where one or more 5-7 membered aromatic rings are fused to the heteroaryl; or R¹⁶¹ is NR¹⁶³ R¹⁶⁴ where R¹⁶³ and R¹⁶⁴ are independently selected from hydrogen and C_{1-5} alkyl or R^{163} and R^{164} may be taken together with the depicted nitrogen to form a heteroaryl ring of 5-7 ring members where one or more of the ring members is nitrogen, sulfur or oxygen where said heteroaryl ring may be optionally substituted with C_1 – C_5 alkyl; R^{162} is

5

10

15

20

25

30

[0136] Materials that can serve as a Cox-2 selective inhibitor of the present invention include 2-substituted imidazoles that are described in U.S. Patent No. 6,040,320. Such 2-substituted imidazoles have the formula shown below in formula XXXII:

hydrogen, C₁ -C₅ alkyl, nitro, amino, and halogen;

and pharmaceutically acceptable salts thereof.

wherein:

R¹⁶⁴ is phenyl, heteroaryl wherein the heteroaryl contains 5 to 6 ring atoms, or

5 substituted phenyl;

10

20

wherein the substituents are independently selected from one or members of the group consisting of C₁₋₅ alkyl, halogen, nitro, trifluoromethyl and nitrile;

R¹⁶⁵ is phenyl, heteroaryl wherein the heteroaryl contains 5 to 6 ring atoms,

substituted heteroaryl;

wherein the substituents are independently selected from one or more members of the group consisting of C_1 – C_5 alkyl and halogen, or substituted phenyl,

wherein the substituents are independently selected from one or members of the group consisting of C_1 – C_5 alkyl, halogen, nitro, trifluoromethyl and nitrile;

 R^{166} is hydrogen, 2-(trimethylsilyl)ethoxymethyl), C_1 – C_5 alkoxycarbonyl, aryloxycarbonyl, aryl C_1 – C_5 alkyloxycarbonyl, aryl C_1 – C_5 alkyl, phthalimido C_1 – C_5 alkyl, amino C_1 – C_5 alkyl, diamino C_1 – C_5 alkyl, succinimido C_1 – C_5 alkyl, C_1 – C_5 alkylcarbonyl, aryloarbonyl, C_1 – C_5

alkylcarbonyl C_1 – C_5 alkyl, aryloxycarbonyl C_1 – C_5 alkyl, heteroaryl C_1 – C_5 alkyl where the heteroaryl contains 5 to 6 ring atoms, or

substituted arylC₁ –C₅ alkyl,

wherein the aryl substituents are independently selected from one or more members of the group consisting of C_1 – C_5 alkyl, C_1 – C_5 alkoxy, halogen, amino, C_1 – C_5 alkylamino, and di C_1 – C_5 alkylamino; R^{167} is $(A^{11})_n$ – $(CH^{165})_a$ – X^{24} wherein:

A¹¹ is sulfur or carbonyl; n is 0 or 1; q is 0-9;

 X^{24} is selected from the group consisting of hydrogen, hydroxyl, halogen, vinyl, ethynyl, C_1 – C_5 alkyl, C_3 – C_7 cycloalkyl, C_1 – C_5 alkoxy, phenoxy, phenyl, aryl C_1 – C_5 alkyl, amino, C_1 – C_5 alkylamino, nitrile, phthalimido, amido, phenylcarbonyl, C_1 – C_5 alkylaminocarbonyl, phenylaminocarbonyl, aryl C_1 – C_5 alkylaminocarbonyl, C_1 – C_5 alkylaminocarbonyl, phenylsulfonyl,

10 substituted sulfonamido,

5

25

- wherein the sulfonyl substituent is selected from the group consisting of C_1 $-C_5$ alkyl, phenyl, ara C_1 $-C_5$ alkyl, thienyl, furanyl, and naphthyl; substituted vinyl,
- wherein the substituents are independently selected from one or members of the group consisting of fluorine, bromine, chlorine and iodine, substituted ethynyl,
 - wherein the substituents are independently selected from one or more members of the group consisting of fluorine, bromine chlorine and iodine, substituted $C_1 C_5$ alkyl,
- wherein the substituents are selected from the group consisting of one or more C_1 – C_5 alkoxy, trihaloalkyl, phthalimido and amino, substituted phenyl,
 - wherein the phenyl substituents are independently selected from one or more members of the group consisting of C_1 – C_5 alkyl, halogen and C_1 – C_5 alkoxy,
 - substituted phenoxy,
 - wherein the phenyl substituents are independently selected from one or more members of the group consisting of C_1 – C_5 alkyl, halogen and C_1 – C_5 alkoxy,
- 30 substituted C_1 – C_5 alkoxy, wherein the alkyl substituent is selected from the group consisting of phthalimido and amino,

substituted aryl C_1 – C_5 alkyl, wherein the alkyl substituent is hydroxyl, substituted aryl C_1 – C_5 alkyl,

wherein the phenyl substituents are independently selected from one or more members of the group consisting of C_1 – C_5 alkyl, halogen and C_1 – C_5 alkoxy,

substituted amido,

5

wherein the carbonyl substituent is selected from the group consisting of C_1 – C_5 alkyl, phenyl, aryl C_1 – C_5 alkyl, thienyl, furanyl, and naphthyl,

substituted phenylcarbonyl,
wherein the phenyl substituents are independently selected from one or
members of the group consisting of C₁ –C₅ alkyl, halogen and C₁ –C₅
alkoxy,

substituted C₁ –C₅ alkylthio,

- wherein the alkyl substituent is selected from the group consisting of hydroxyl and phthalimido, substituted C₁ –C₅ alkylsulfonyl, wherein the alkyl substituent is selected from the group consisting of hydroxyl and phthalimido,
- substituted phenylsulfonyl, wherein the phenyl substituents are independently selected from one or members of the group consisting of bromine, fluorine, chlorine, C_1 – C_5 alkoxy and trifluoromethyl, with the proviso:
- if A¹¹ is sulfur and X²⁴ is other than hydrogen, C₁ –C₅ alkylaminocarbonyl, phenylaminocarbonyl, arylC₁ –C₅ alkylaminocarbonyl, C₁ –C₅ alkylsulfonyl or phenylsulfonyl, then q must be equal to or greater than 1; if A¹¹ is sulfur and q is 1, then X²⁴ cannot be C₁ –C₂ alkyl; if A¹¹ is carbonyl and q is 0, then X²⁴ cannot be vinyl, ethynyl, C₁ –C₅ alkylaminocarbonyl, phenylaminocarbonyl, arylC₁ –C₅ alkylaminocarbonyl, C₁ –C₅ alkylsulfonyl or phenylsulfonyl;

if A^{11} is carbonyl, q is 0 and X^{24} is H, then R^{166} is not 2-(trimethylsilyl)ethoxymethyl;

if n is 0 and q is 0, then X^{24} cannot be hydrogen; and pharmaceutically acceptable salts thereof.

[0137] Materials that can serve as a Cox-2 selective inhibitor of the present invention include 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles that are described in U.S. Patent No. 6,083,969. Such 1,3- and 2,3-diarylpyrazole compounds have the general formulas shown below in formulas XXXIII and XXXIV:

10

5

wherein:

15

 R^{168} and R^{169} are independently selected from the group consisting of hydrogen, halogen, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, nitro, amino, \square ydroxyl,

trifluoro, — $S(C_1 - C_6)$ alkyl, — $SO(C_1 - C_6)$ alkyl and — SO_2 ($C_1 - C_6)$ alkyl; and

the fused moiety M is a group selected from the group consisting of an optionally substituted cyclohexyl and cycloheptyl group having the formulae:

$$R^{173}$$
 , or R^{173} R^{172} R^{171}

wherein:

5

10

15

20

25

R¹⁷⁰ is selected from the group consisting of hydrogen, halogen, hydroxyl and carbonyl;

or R¹⁷⁰ and R¹⁷¹ taken together form a moiety selected from the group consisting of —OCOCH₂ —, —ONH(CH₃)COCH₂ —, —OCOCH= and —O—;

R¹⁷¹ and R¹⁷² are independently selected from the group consisting of hydrogen, halogen, hydroxyl, carbonyl, amino, $(C_1 - C_6)$ alkyl, $(C_1 - C_6)$ alkoxy, =NOH, —NR¹⁷⁴ R¹⁷⁵, —OCH₃, —OCH₂ CH₃, —OSO₂ NHCO₂ CH₃, =CHCO₂ CH₂ CH₃, —CH₂ CO₂ H, —CH₂ CO₂ CH₃, —CH₂ CO₂ CH₂ CH₃, —CH₂ CO₁ CH₂ CO₂ CH₃, —CH₂ CO₂ CH₃, —CH₂ CO₂ CH₃, —OCON(CH₃)₂, —CH₂ CO₂ NHCH₃, —CHCHCO₂ CH₂ CH₃, —OCON(CH₃)OH, —C(COCH₃)₂, di(C₁ -C₆)alkyl and di(C₁ -C₆)alkoxy; R¹⁷³ is selected from the group consisting of hydrogen, halogen, hydroxyl, carbonyl, amino, (C₁ -C₆)alkyl, (C₁ -C₆)alkoxy and optionally substituted carboxyphenyl, wherein substituents on the carboxyphenyl group are selected from the group consisting of halogen, hydroxyl, amino, (C₁ - C₆)alkyl and (C₁ -C₆)alkoxy;

or R¹⁷² and R¹⁷³ taken together form a moiety selected from the group consisting of —O—and

 R^{174} is selected from the group consisting of hydrogen, OH, —OCOCH₃, —COCH₃ and (C₁ –C₆)alkyl; and

 R^{175} is selected from the group consisting of hydrogen, OH, —OCOCH₃, —COCH₃, (C₁ –C₆)alkyl, —CONH₂ and —SO₂ CH₃; with the proviso that

if M is a cyclohexyl group, then R^{170} through R^{173} may not all be hydrogen; and

pharmaceutically acceptable salts, esters and pro-drug forms thereof.

[0138] Esters derived from indolealkanols and novel amides derived from indolealkylamides that are described in U.S. Patent No. 6,306,890 can serve as Cox-2 selective inhibitors of the present invention. Such compounds have the general formula shown below in formula XXXV:

15

5

10

$$R^{177}$$
 R^{178}
 R^{179}
 R^{178}

wherein:

 R^{176} is C_1 – C_6 alkyl, C_1 – C_6 branched alkyl, C_4 – C_8 cycloalkyl, C_1 – C_6 hydroxyalkyl, branched C_1 – C_6 hydroxyalkyl, hydroxyl substituted C_4 – C_8

aryl, primary, secondary or tertiary C_1 – C_6 alkylamino, primary, secondary or tertiary branched C_1 – C_6 alkylamino, primary, secondary or tertiary C_4 – C_8 arylamino, C_1 – C_6 alkylamino, branched C_1 – C_6 alkylamino, branched C_1 – C_6 alkylamino, caid, caid,

10 R¹⁷⁷ is C₁ –C₆ alkyl, C₁ –C₆ branched alkyl, C₄ –C₈ cycloalkyl, C₄ –C₈ aryl, C₄ –C₈ aryl-substituted C₁ –C₆ alkyl, C₁ –C₆ alkoxy, C₁ –C₆ branched alkoxy, C₄ –C₈ aryloxy, or halo-substituted versions thereof or R¹⁷⁷ is halo where halo is chloro, fluoro, bromo, or iodo;

 R^{178} is hydrogen, $C_1 - C_6$ alkyl or $C_1 - C_6$ branched alkyl;

R¹⁷⁹ is C₁ –C₆ alkyl, C₄ –C₈ aroyl, C₄ –C₈ aryl, C₄ –C₈ heterocyclic alkyl or aryl with O, N or S in the ring, C₄ –C₈ aryl-substituted C₁ –C₆ alkyl, alkyl-substituted or aryl-substituted C₄ –C₈ heterocyclic alkyl or aryl with O, N or S in the ring, alkyl-substituted C₄ –C₈ aroyl, or alkyl-substituted C₄ –C₈ aryl, or halo-substituted versions thereof where halo is chloro, bromo, or iodo;

n is 1, 2, 3, or 4; and

5

25

 X^{25} is O, NH, or N—R¹⁸⁰, where R¹⁸⁰ is C₁ –C₆ or C₁ –C₆ branched alkyl.

[0139] Materials that can serve as a Cox-2 selective inhibitor of the present invention include pyridazinone compounds that are described in U.S. Patent No. 6,307,047. Such pyridazinone compounds have the formula shown below in formula **XXXVI**:

or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein:

 X^{26} is selected from the group consisting of O, S, —NR¹⁸⁵, —NOR^a, and – NNR^b R^c;

R¹⁸⁵ is selected from the group consisting of alkenyl, alkyl, aryl, arylalkyl, cycloalkenyl, cycloalkenyl, cycloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclic, and heterocyclic alkyl;

R^a, R^b, and R^c are independently selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, and cycloalkylalkyl;

R¹⁸¹ is selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxyiminoalkoxy, alkyl, alkylcarbonylalkyl, alkylsulfonylalkyl, alkynyl, aryl,

arylalkenyl, arylalkoxy, arylalkyl, arylalkynyl, arylhaloalkyl, arylhydroxyalkyl, aryloxyhaloalkyl, aryloxyhydroxyalkyl, arylcarbonylalkyl, carboxyalkyl, cyanoalkyl, cycloalkenyl, cycloalkyl, cycloalkyl, cycloalkyl, haloalkenyl,

haloalkoxyhydroxyalkyl, haloalkyl, haloalkynyl, heterocyclic, heterocyclic alkoxy, heterocyclic alkyl, heterocyclic oxy, hydroxyalkyl,

hydroxyiminoalkoxy, — $(CH_2)_n C(O)R^{186}$, — $(CH_2)_n CH(OH)R^{186}$, — $(CH_2)_n CH(OH)R^{186}$, — $(CH_2)_n CH(NOR^d)R^{186}$, — $(CH_2)_n CH(NR^d R^e)R^{186}$, — $(CH_2)_n C=CR^{188}$, — $(CH_2)_n [CH(CX^{26'}_3)]_m (CH_2)_p R^{188}$, — $(CH_2)_n (CH_2)_n (CH_2)_n$

20 R¹⁸⁶ is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkenyl, haloalkyl, haloalkynyl, heterocyclic, and heterocyclic alkyl;

R¹⁸⁷ is selected from the group consisting of alkenylene, alkylene, haloalkylene, haloalk

R¹⁸⁷ is selected from the group consisting of alkenylene, alkylene, halosubstituted alkenylene, and halo-substituted alkylene;

25 R¹⁸⁸ is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

R^d and R^e are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl,

30 haloalkyl, heterocyclic, and heterocyclic alkyl;

X^{26'} is halogen;

5

15

m is an integer from 0-5;

n is an integer from 0-10;

p is an integer from 0-10;

5

10

15

20

25

R¹⁸², R¹⁸³, and R¹⁸⁴ are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyiminoalkoxy, alkoxyiminoalkyl, alkyl, alkynyl, alkylcarbonylalkoxy, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminoalkoxy, aminoalkylcarbonyloxyalkoxy aminocarbonylalkyl, aryl, arylalkenyl, arylalkyl, arylalkynyl, carboxyalkylcarbonyloxyalkoxy, cyano, cycloalkenyl, cycloalkyl, cycloalkylidenealkyl, haloalkenyloxy, haloalkoxy, haloalkyl, halogen, heterocyclic, hydroxyalkoxy, hydroxyiminoalkoxy, hydroxyiminoalkyl, mercaptoalkoxy, nitro, phosphonatoalkoxy, Y⁸, and Z¹⁴; provided that one of R¹⁸², R¹⁸³, or R¹⁸⁴ must be Z¹⁴, and further provided that only one of R¹⁸², R¹⁸³, or R¹⁸⁴ is Z¹⁴;

 Z^{14} is selected from the group consisting of

 X^{28} X^{27} X^{27} X^{27} X^{29} X^{27} X^{29} X^{27} X^{29} X^{29} X^{27} X^{29} X^{29}

 X^{27} is selected from the group consisting of S(O)₂, S(O)(NR¹⁹¹), S(O), Se(O)₂, P(O)(OR¹⁹²), and P(O)(NR¹⁹³ R¹⁹⁴);

X²⁸ is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl and halogen;


R¹⁹⁰ is selected from the group consisting of alkenyl, alkoxy, alkyl, alkylamino, alkylcarbonylamino, alkynyl, amino, cycloalkenyl, cycloalkyl, dialkylamino, —NHNH₂, and —NCHN(R¹⁹¹)R¹⁹²; R¹⁹¹, R¹⁹², R¹⁹³, and R¹⁹⁴ are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl, or R¹⁹³ and R¹⁹⁴ can be taken together, with the nitrogen to which they are attached, to form a 3-6 membered ring containing 1 or 2 heteroatoms selected from the group consisting of O. S. and NR¹⁸⁸;

Y⁸ is selected from the group consisting of $-OR^{195}$, — SR^{195} , — $C(R^{197})(R^{198})R^{195}$, — $C(O)R^{195}$, — $C(O)OR^{195}$, — $C(O)OR^{195}$, — $C(O)R^{197}$) R¹⁹⁵, and — $C(R^{197})R^{195}$;

R¹⁹⁵ is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkylthioalkyl, alkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, heterocyclic alkyl, hydroxyalkyl, and NR¹⁹⁹ R²⁰⁰; and

R¹⁹⁷, R¹⁹⁸, R¹⁹⁹, and R²⁰⁰ are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, cycloalkenyl, cycloalkyl, aryl, arylalkyl, heterocyclic, and heterocyclic alkyl.

[0140] Benzosulphonamide derivatives that are described in U.S. Patent No. 6,004,948 are useful as Cox-2 selective inhibitors of the present invention. Such benzosulphonamide derivatives have the formula shown below in formula **XXXVII**:



15

20

5

10

wherein:

A¹² denotes oxygen, sulphur or NH;

R²⁰¹ denotes a cycloalkyl, aryl or heteroaryl group optionally mono- or polysubstituted by halogen, alkyl, CF₃ or alkoxy;

D⁵ denotes a group of formula **XXXVIII** or **XXXIX**:

or

$$S(O)_m$$
 $N \longrightarrow R^{202'}$
XXXIX

 R^{202} and R^{203} independently of each other denote hydrogen, an optionally polyfluorinated alkyl radical, an aralkyl, aryl or heteroaryl radical or a radical (CH₂)_n – X^{29} ; or

5

 R^{202} and R^{203} together with the N-atom denote a three- to seven-membered, saturated, partially or totally unsaturated heterocycle with one or more heteroatoms N, O, or S, which may optionally be substituted by oxo, an alkyl, alkylaryl or aryl group or a group $(CH_2)_n - X^{29}$, R^{202} , denotes hydrogen, an optionally polyfluorinated alkyl group, an aralkyl, aryl or heteroaryl group or a group $(CH_2)_n - X^{29}$,

10

15

wherein:

aralkyl or aryl;

20

n is an integer from 0 to 6;

 R^{206} is a straight-chained or branched C_1 – C_4 alkyl group which may optionally be mono- or polysubstituted by halogen or alkoxy, or R^{206} denotes CF_3 ; and

m denotes an integer from 0 to 2;

with the proviso that A^{12} does not represent O if R^{206} denotes CF_3 ; and the pharmaceutically acceptable salts thereof.

[0141] Materials that can serve as Cox-2 selective inhibitors of the present invention include methanesulfonyl-biphenyl derivatives that are described in U.S. Patent No. 6,583,321. Such methanesulfonyl-biphenyl derivatives have the formula shown below in formula XXXX:

10

15

5

wherein:

R²⁰⁷ and R²⁰⁸ are respectively a hydrogen;

C₁ –C₄-alkyl substituted or not substituted by halogens;

C₃ -C₇-cycloalkyl;

 C_1 – C_5 -alkyl containing 1-3 ether bonds and/or an aryl substitute; substituted or not substituted phenyl;

or substituted or not substituted five or six ring-cycled heteroaryl containing more than one hetero atoms selected from a group consisting of nitrogen, sulfur, and oxygen (wherein phenyl or heteroaryl can be one-or multi-substituted by a substituent selected from a group consisting of hydrogen, methyl, ethyl, and isopropyl).

[0142] Cox-2 selective inhibitors such as 1H-indole derivatives described in U.S. Patent No. 6,599,929 are useful in the present invention. Such 1H-indole derivatives have the formula shown below in formula XXXXI:

wherein:

5

10

15

20

 χ^{30} is $-NHSO_2R^{209}$ wherein R^{209} represents hydrogen or C_1 $-C_3$ alkyl;

 Y^9 is hydrogen, halogen, C_1 – C_3 –alkyl substituted or not substituted by halogen, NO₂, NH₂, OH, OMe, CO₂H, or CN; and

 Q^7 is C=O, C=S, or CH₂.

[0143] Compounds that are useful as Cox-2 selective inhibitors of the present invention include prodrugs of Cox-2 inhibitors that are described in U.S. Patent Nos. 6,436,967 and 6,613,790. Such prodrugs of Cox-2 inhibitors have the formula shown below in formula XXXXII:

wherein:

A¹³ is a ring substituent selected from partially unsaturated heterocyclic, heteroaryl, cycloalkenyl and aryl, wherein A¹³ is unsubstituted or substituted with one or more radicals selected from alkylcarbonyl,

formyl, halo, alkyl, haloalkyl, oxo, cyano, nitro, carboxyl, alkoxy, aminocarbonyl, alkoxycarbonyl, carboxyalkyl, cyanoalkyl, hydroxyalkyl, haloalkylsulfonyloxy, alkoxyalkyloxyalkyl, carboxyalkoxyalkyl, cycloalkylalkyl, alkenyl, alkynyl, heterocycloxy, alkylthio, cycloalkyl, aryl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, alkylamino, -arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylaminoalkyl, N-arylaminoalkyl, N-arylaminoalkyl, N-arylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, and N-alkyl-N-arylaminosulfonyl;

15

5

10

R²¹⁰ is selected from heterocyclyl, cycloalkyl, cycloalkenyl, and aryl, wherein R²¹⁰ is unsubstituted or substituted with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy, and alkylthio;

20

R²¹¹ is selected from hydrido and alkoxycarbonylalkyl;

R²¹² is selected from alkyl, carboxyalkyl, acyl, alkoxycarbonyl, heteroarylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylcarbonyl, amino acid residue, and alkylcarbonylaminoalkylcarbonyl;

25

provided A¹³ is not tetrazolium, or pyridinium; and further provided A¹³ is not indanone when R²¹² is alkyl or carboxyalkyl; further provided A¹³ is not thienyl, when R²¹⁰ is 4-fluorophenyl, when R²¹¹ is hydrido, and when R²¹² is methyl or acyl; and

R²¹³ is hydrido;

or a pharmaceutically-acceptable salt thereof.

30

[0144] Specific non-limiting examples of substituted sulfonamide prodrugs of Cox-2 inhibitors disclosed in U.S. Patent No. 6,436,967 that are useful in the present invention include:

N-[[4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]phen yl]sulfonyl]propanamide;
N-[[4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]phen yl]sulfonyl]butanamide;

- N-[[4-[1,5-dimethyl)-3-phenyl-1H-pyrazol-4-yl]phenyl]sulfonyl]acetamide;
 N-[[4-(2-(3-pyridinyl)-4-(trifluoromethyl)-1H-imidazol-1yl)phenyl]sulfonyl]acetamide;
 N-[[4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1yl]phenyl]sulfonyl]acetamide;
- N-[[4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide;
 N-[[4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]butanamide;
 N-[[4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-
- yl]phenyl]sulfonyl]butanamide;
 N-[[4-[2-(3-chloro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1yl]phenyl]sulfonyl]acetamide;
 N-[[4-[3-(3-fluorophenyl)-5-methylisoxazol-4-yl]phenyl]sulfonyl]acetamide;
 2-methyl-N-[[4-(5-methyl-3-phenylisoxazol-4-
- yl)phenyl]sulfonyl]propanamide;
 N-[[4-(5-methyl-3-phenylisoxazol-4-yl]phenyl]sulfonyl]propanamide;
 N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]benzamide;
 2,2-dimethyl-N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]propanamide;
- N-[[4-5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]butanamide;
 N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]pentanamide;
 N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]hexanamide;
 3-methoxy-N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]propanamide;
- 2-ethoxy-N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]acetamide; N-[[4-[5-methyl-3-phenylisoxazol-4-yl]phenyl]sulfonyl]acetamide;

N-[[4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H pyrazol-1-yl]phenyl]sulfonyl]propanamide;

N-[[4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]butanamide;

- 5 N-[[4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]acetamide;
 - N-[[4-[3-(difluoromethyl)-6-fluoro-1,5-dihydro-7-methoxy-
 - [2]benzothiopyrano [4,3-c]pyrazol-1-yl)phenyl]sulfonyl]acetamide;
 - N-[[4-[6-fluoro-1,5-dihydro-7-methoxy-3-(trifluoromethyl)-[2]benzothiopyran
- 10 o[4,3-c]pyrazol-1-yl]phenyl]sulfonyl]acetamide;
 - N-[[4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]acetamide;
 - N-[[4-(2-methyl-4-phenyloxazol-5-yl)phenyl]sulfonyl]acetamide; methyl[[[4-(5-methyl-3-phenylisoxazol-4-
- 15 yl)phenyl]sulfonyl]amino]oxoacetate;
 - 2-methoxy-N-[[4-(5-methyl-3-phenylisoxazol-4-
 - yl)phenyl]sulfonyl]acetamide;
 - N-[[4-[5-(difluoromethyl)-3-phenylisoxazol-4-
 - yl]phenyl]sulfonyl]propanamide;
- 20 N-[[4-[5-(difluoromethyl)-3-phenylisoxazol-4-yl]phenyl]sulfonyl]butanamide;
 - N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]formamide;
 - 1,1-dimethylethyl-N-[[4-(5-methyl-3-phenylisoxazol-4-
 - yl)phenyl]sulfonyl]carbamate;
 - N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]glycine;
- 25 2-amino-N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]acetamide;
 - 2-(acetylamino)-N-[[4-(5-methyl-3-phenylisoxazol-4-
 - vI)phenyllsulfonyllacetamide;
 - methyl 4-[[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]amino]-4-oxobutanoate;
- methyl N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]carbamate; N-acetyl-N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]glycine, ethyl ester;

N-[[4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl]sulfonyl]acetamide; methyl 3-[[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]amino]-3-oxopropanoate;

- 5 4-[5-(3-bromo-5-fluoro-4-methoxyphenyl)-2-(trifluoromethyl)oxazol-4-yl]-N-methylbenezenesulfonamide;
 - N-(1,1-dimethylethyl)-4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide;
 - 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-
- 10 methylbenzenesulfonamide;
 - N-methyl-4-(5-methyl-3-phenylisoxazol-4-yl)benezenesulfonamide; N-[[4-[5-(hydroxymethyl)-3-phenylisoxazol-4-yl]phenyl]sulfonyl]acetamide: N-[[4-[5-(acetoxymethyl)-3-phenylisoxazol-4-yl]phenyl]sulfonyl]acetamide;
 - N-[[4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-
- 15 yl)phenyl]sulfonyl]acetamide;
 - 4-[2-(4-fluorophenyl)-1H-pyrrol-1-yl]-N-methylbenzenesulfonamide;
 - N-[[4-(3,4-dimethyl-1-phenyl-1H-pyrazol-5-yl]phenyl]sulfonyl]propanamide;
 - N-[[4-[2-(2-methylpyridin-3-yl)-4-trifluoromethylimidazol-1-
 - yl]phenyl]sulfonyl]propanamide;
- 4-[2-(4-fluorophenyl)cyclopenten-1-yl]-N-methylbenezenesulfonamide; and N-[[4-(3-phenyl-2,3-dihydro-2-oxofuran-4-yl)phenyl]sulfonyl]propanamide.
 - [0145] Those prodrugs disclosed in U.S. Patent No. 6,613,790 have the general formula shown above in formula **XXXXII** wherein:
- A¹³ is a pyrazole group optionally substituted at a substitutable
 25 position with one or more radicals independently selected at each
 occurrence from the group consisting of alkylcarbonyl, formyl, halo, alkyl,
 haloalkyl, oxo, cyano, intro, carboxyl, alkoxy, aminocarbonyl,
 alkoxycarbonyl, carboxyalkyl, cyanoalkyl, hydroxyalkyl,
 haloalkylsulonyloxy, alkoxyalkyloxyalkyl, carboxyalkoxyalkyl, alkenyl,
 alkynyl, alkylthio, alkylthioalkyl, alkoxyalkyl, alkoxycarbonylalkyl,
 aminocarbonylalkyl, alkylaminocarbonyl, alkylaminocarbonylalkyl,

alkylamino, aminoalkyl, alkylaminoalkyl, alkylsutfinyl, alkylsulfonyl, aminosulfonyl, and alkylaminosulfonyl;

5

10

15

20

R²¹⁰ is a phenyl group optionally substituted at a substitutable position with one or more radicals independently selected at each occurrence from the group consisting of alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy, and alkylthio;

 R^{211} and R^{212} are independently selected from the group consisting of hydroxyalkyl and hydrido but at least one of R^{211} and R^{212} is other than hydrido; and

R²¹³ is selected from the group consisting of hydrido and fluoro.

[0146] Examples of prodrug compounds disclosed in U.S. 6,613,790 that are useful as Cox-2 inhibitors of the present invention include, but are not limited to, N-(2-hydroxyethyl)-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, N,N-bis(2-hydroxyethyl)-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyraz ol-1-yl]benzenesulfonamide, or pharmaceuticaly-acceptable salts thereof.

[0147] Cox-2 selective inhibitors such as sulfamoylheleroaryl pyrazole compounds that are described in U.S. Patent No. 6,583,321 may serve as Cox-2 inhibitors of the present invention. Such sulfamoylheleroaryl pyrazole compounds have the formula shown below in formula XXXXIII:

wherein:

5

10

15

R²¹⁴ is furyl, thiazolyl or oxazolyl;

R²¹⁵ is hydrogen, fluoro or ethyl; and

 X^{31} and X^{32} are independently hydrogen or chloro.

[0148] Heteroaryl substituted amidinyl and imidazolyl compounds such as those described in U.S. Patent No. 6,555,563 are useful as Cox-2 selective inhibitors of the present invention. Such heteroaryl substituted amidinyl and imidazolyl compounds have the formula shown below in formula XXXXIV:

$$\begin{array}{c} N \\ N \\ N \\ R^{218} \end{array}$$
 XXXXIV wherein:

-16 . .

Z¹⁶ is O or S,

R²¹⁶ is optionally substituted aryl,

R²¹⁷ is aryl optionally substituted with aminosulfonyl, and

 $\mbox{\ensuremath{R^{218}}}$ and $\mbox{\ensuremath{R^{219}}}$ cooperate to form an optionally substituted 5-membered ring.

5

10

15

20

25

[0149] Materials that can serve as Cox-2 selective inhibitors of the present invention include substituted hydroxamic acid derivatives that are described in U.S. Patent Nos. 6,432,999, 6,512,121, and 6,515,014. These compounds also act as inhibitors of the lipoxygenase-5 enzyme. Such substituted hydroxamic acid derivatives have the general formulas shown below in formulas XXXXV and XXXXVI:

$$R^{221}$$
 A^{14}
 Y^{10}
 R^{222}
 R^{222}
 R^{222}

$$R^{224}$$
 $OH O H$ A^{15} A^{15}

[0150] Pyrazole substituted hydroxamic acid derivatives described in U.S. Patent No. 6,432,999 have the formula shown above in formula XXXXV, wherein:

A¹⁴ is pyrazolyl optionally substituted with a substituent selected from acyl, halo, hydroxyl, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;

Y¹⁰ is selected from lower alkenylene and lower alkynylene;

R²²⁰ is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R²²⁰ is optionally substituted at a substitutable position with one or more substituents selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino,

phenylmino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;

R²²¹ is selected from lower alkyl and amino; and

R²²² is selected from hydrido, lower alkyl, phenyl, 5- and 6-membered heterocyclo and lower cycloalkyl; or a pharmaceutically-acceptable salt thereof.

[0151] Pyrazole substituted hydroxamic acid derivatives described in U.S. Patent No. 6,432,999 may also have the formula shown above in formula **XXXXVI**, wherein:

10

15

20

25

5

A¹⁵ is pyrazolyl optionally substituted with a substituent selected from acyl, halo, hydroxyl, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;

Y¹¹ is selected from lower alkylene, lower alkenylene and lower alkynylene;

R²²³ is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R²²³ is optionally substituted at a substitutable position with one or more substituents selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylmino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;

R²²⁴ is selected from lower alkyl and amino; and

R²²⁵ is selected from hydrido, lower alkyl;

or a pharmaceutically-acceptable salt thereof.

[0152] Heterocyclo substituted hydroxamic acid derivatives described in U.S. Patent No. 6,512,121 have the formula shown above in formula **XXXXV**, wherein:

30

A¹⁴ is a ring substituent selected from oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isochiazolyl, isoxazolyl, cyclopentenyl, phenyl, and pyridyl; wherein A¹⁴ is optionally substituted with a substituent selected

from acyl, halo, hydroxy, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;

Y¹⁰ is lower alkylene, lower alkenylene, and lower alkynylene;

5

R²²⁰ is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R²²⁰ is otionally substituted at a substitutable position with one or more substituents selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;

10

R²²¹ is selected from lower alkyl and amino; and

15

R²²² is selected from hydrido, lower alkyl, phenyl, 5- and 6membered heterocyclo and lower cycloalkyl; or a pharmaceuticallyacceptable salt thereof.

[0153]

Heterocyclo substituted hydroxamic acid derivatives described in U.S. Patent No. 6,512,121 may also have the formula shown above in formula XXXXVI, wherein:

20

A¹⁵ is a ring substituent selected from oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, cyclopentenyl, phenyl, and pyridyl; wherein A is optionally substituted with a substituent selected from acyl, halo, hydroxy, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarboryl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;

25

Y¹¹ is selected from lower alkyl, lower alkenyl and lower alkynyl; R²²³ is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R²²³ is optionally substituted at a substitutable position with one or more substituents selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl,

30

lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino,

phenylamino, nitto, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;

R²²⁴ is selected from lower alkyl and amino; and

5

10

15

20

25

30

R²²⁵ is selected from hydrido and alkyl; or a pharmaceutically-acceptable salt thereof.

[0154] Thiophene substituted hydroxamic acid derivatives described in U.S. Patent No. 6,515,014 have the formula shown above in formula **XXXXV**, wherein:

A¹⁴ is thienyl optionally substituted with a substituent selected from acyl, halo, hydroxy, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;

Y¹⁰ is ethylene, isopropylene, propylene, butylene, lower alkenylene, and lower alkynylene;

R²²⁰ is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R²²⁰ is optionally substituted at a substitutable position with one or more substituents selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;

R²²¹ is selected from lower alkyl and amino; and

R²²² is selected from hydrido, lower alkyl, phenyl, 5- and 6-membered heterocyclo and lower cycloalkyl; or a pharmaceutically-acceptable salt thereof.

[0155] Thiophene substituted hydroxamic acid derivatives described in U.S. Patent No. 6,515,014 may also have the formula shown above in formula XXXXV, wherein:

A¹⁵ is thienyl optionally substituted with a substituent selected from acyl, halo, hydroxy, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl,

lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;

Y¹¹ is selected from lower alkyl, lower alkenyl and lower alkynyl;

R²²³ is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R²²³ is optionally substituted at a substitutable position with one or more substituents selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;

R²²⁴ is selected from lower alkyl and amino; and R²²⁵ is selected from hydrido and alkyl; or a pharmaceutically-

acceptable salt thereof.

[0156] Compounds that are useful as Cox-2 selective inhibitors of the present invention include pyrazolopyridine compounds that are described in U.S. Patent No. 6,498,166. Such pyrazolopyridine compounds have the formula shown below in formula XXXXVII:

20 wherein:

5

10

15

 R^{226} and R^{227} are independently selected from the group consisting of H, halogen, C_1 – C_6 alkyl, C_1 – C_6 alkoxy, and C_1 – C_6 alkoxy substituted by one or more fluorine atoms;

 R^{228} is halogen, CN, CON R^{230} $\mathsf{R}^{231},$ CO $_2$ H, CO $_2$ C $_1$ –C $_6$ alkyl, or NHSO $_2\mathsf{R}^{230};$

 R^{229} is $C_1 - C_6$ alkyl or NH_2 ; and

 R^{225} and R^{225} are independently selected from the group consisting of H, C_1 – C_6 alkyl, phenyl, phenyl substituted by one or more atoms or groups selected from the group consisting of halogen, C_1 – C_6 alkyl, C_1 – C_6 alkoxy, and C_1 – C_6 alkoxy substituted by one or more fluorine atoms, or a pharmaceutically acceptable salt, solvate, ester, or salt or solvate of such ester thereof.

10 **[0157]** Materials that are useful as Cox-2 selective inhibitors of the present invention include 4,5-diaryl-3(2H)-furanone derivatives that are described in U.S. Patent No. 6,492,416. Such 4,5-diaryl-3(2H)-furanone derivatives have the formula shown below in formula **XXXXVIII**:

15 wherein:

20

5

X³³ represents halo, hydrido, or alkyl;

Y¹² represents alkylsulfonyl, aminosulfonyl, alkylsulfinyl, (N-acylamino)-sulfonyl, (N-alkylamino)sulfonyl, or alkylthio;

Z¹⁷ represents oxygen or sulfur atom;

R²³³ and R²³⁴ are selected independently from lower alkyl radicals; and

R²³² represents a substituted or non-substituted aromatic group of 5 to 10 atoms;

or a pharmaceutically-acceptable salt thereof.

[0158] Cox-2 selective inhibitors that can be used in the present invention include 2-phenyl-1,2-benzisoselenazol-3(2H)-one derivatives and 2-phenylcarbomyl-phenylselenyl derivatives that are described in U.S. Patent No. 6,492,416. Such 2-phenyl-1,2-benzisoselenazol-3(2H)-one derivatives and 2-phenylcarbomyl-phenylselenyl derivatives have the formulas shown below in formulas XXXXIX or XXXXIX':

wherein:

5

10

15

20

R²³⁵ is a hydrogen atom or an alkyl group having 1-3 carbon atoms;

 R^{236} is a hydrogen atom, a hydroxyl group, an organothiol group that is bound to the selenium atom by its sulfur atom, or R^{235} and R^{236} are joined to each other by a single bond;

R²³⁷ is a hydrogen atom, a halogen atom, an alkyl group having 1-3 carbon atoms, an alkoxyl group having 1-3 carbon atoms, a trifluoromethyl group, or a nitro group;

 R^{238} and R^{239} are identical to or different from each other, and each is a hydrogen atom, a halogen atom, an alkoxyl group having 1-4 carbon atoms, a trifluoromethyl group, or R^{238} and R^{239} are joined to each other to form a methylenedioxy group,

a salt thereof, or a hydrate thereof.

[0159] Pyrones such as those disclosed in U.S. Patent No. 6,465,509 are also useful as Cox-2 inhibitors of the present invention. These pyrone compounds have the general formula shown below in formula XXXXX:

wherein:

5

15

20

25

X³⁴ is selected from the group consisting of

10 (a) a bond,

(b) $--(CH_2)_m$ --, wherein m 1 or 2,

(c) --C(O)--,

(d) --O--,

(e) --S--, and

(f) --N(R²⁴⁴)--;

 R^{240} is selected from the group consisting of

- (a) C_1 – C_{10} alkyl, optionally substituted with 1-3 substituents independently selected from the group consisting of hydroxy, halo, C_1 – C_{10} alkylthio, and CN,
 - (b) phenyl or naphthyl, and
- (c) heteroaryl, which is comprised of a monocyclic aromatic ring of 5 atoms having one hetero atom which is S, O or N, and optionally 1, 2, or 3 additional N atoms; or

a monocyclic ring of 6 atoms having one hetero atom which is N, and optionally 1, 2, or 3 additional N atoms, wherein groups (b) and (c)

above are each optionally substituted with 1-3 substituents independently selected from the group consisting of halo, $C_1 - C_{10}$ alkoxy, $C_1 - C_{10}$ alkylthio, CN, $C_1 - C_{10}$ alkyl, optionally substituted to its maximum with halo, and N_3 ;

5

R²⁴¹ is selected from the group consisting of

- (a) C₁ −C₆ alkyl, optionally substituted to its maximum with halo,
- (b) NH_2 , and
- (c) NHC(O)C₁ -C₁₀ alkyl, optionally substituted to its maximum with halo;

10

 R^{242} and R^{243} are each independently selected from the group consisting of hydrogen, halo, and C_1 – C_6 a lkyl, optionally substituted to its maximum with halo; and

 R^{244} is selected from the group consisting of hydrogen and C_1 – C_6 alkyl, optionally substituted to its maximum with halo.

15

[0160] Examples of pyrone compounds that are useful as Cox-2 selective inhibitors of the present invention include, but are not limited to: 4-(4-Methylsulfonyl)phenyl-3-phenyl-pyran -2-one,

- 3-(4-Fluorophenyl)-6-methyl-4-(4-methylsulfonyl)phenyl-pyran-2-one,
- 3-(3-Fluorophenyl)-6-methyl-4-(4-methylsulfonyl)phenyl-pyran-2-one,
- 6-Methyl-4-(4-methylsulfonyl)phenyl-3-phenyl-pyran-2-one,
 - 6-Difluoromethyl-4-(4-methylsulfonyl)phen yl-3-phenyl-pyran-2-one,
 - 6-Fluoromethyl-4-(4-methylsulfonyl)pheny I-3-phenyl-pyran-2-one,
 - 6-Methyl-4-(4-methylsulfonyl)phenyl-3-phenylthio-pyran-2-one,
 - 6-Methyl-4-(4-methylsulfonyl)phenyl-3-phenoxy-pyran-2-one,
 - 6-Methyl-4-(4-methylsulfonyl)phenyl-3-pyridin-3-yl-pyran-2-one,
 - 3-Isopropylthio-6-methyl-4-(4-methylsulfornyl)phenyl-pyran-2-one,
 - 4-(4-Methylsulfonyl)phenyl)-3-phenylthio-6-trifluoromethyl-pyran-2-one,
 - 3-Isopropylthio-4-(4-methylsulfonyl)pheny 1-6-trifluoromethyl-pyran-2-one,
 - 4-(4-Methylsulfonyl)phenyl-3-phenyl-6-(2,2,2-trifluoroethyl)-pyran-2-one,

30

and

25

3-(3-Hydroxy-3-methylbutyl)-6-methyl-4-(**4**-methylsulfonyl)phenyl-pyran-2-one.

[0161] Organically synthesized or purified from plant sources, free-B-ring flavanoids such as those described in U.S. Published Application No. 2003/0165588, are useful as Cox-2 selective inhibitors of the present invention. Such free-B-ring flavanoids have the general structure shown in formula XXXXXI:

wherein:

5

10

15

20

 R^{246} , R^{247} , R^{248} , R^{249} , and R^{250} are independently selected from the group consisting of --H, --OH, --SH, --OR, --SR, --NH₂, --NHR²⁴⁵, --N(R^{245})₂,

--N(R²⁴⁵)₃+X³⁵⁻, a carbon, oxygen, nitrogen or sulfur, glycoside of a single or a combination of multiple sugars including, aldopentoses, methylaldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; wherein R²⁴⁵ is an alkyl group having between 1-10 carbon atoms; and X³⁵ is selected from the group of pharmaceutically acceptable counter anions including, hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride and carbonate.

[0162] Heterocyclo-alkylsulfonyl pyrazoles such as those described in European Patent Application No. EP 1312367 are useful as Cox-2 selective inhibitors of the present invention. Such heterocyclo-alkylsulfonyl pyrazoles have the general formula shown below in formula XXXXXII:

or a pharmaceutically acceptable salt thereof, wherein the ring of the formula (R²⁵⁵)-A-(SO_mR²⁵⁴) is selected from the group consisting of

5

10

 R^{251} is a radical selected from the group consisting of H,

$$\begin{split} NO_2,\ CN,\ (C_1-C_6)alkyl,\ (C_1-C_6)alkyl-SO_2-,\ (C_6-C_{10})aryl-SO_2-,\ H-(C=O)-,\\ (C_1-C_6)alkyl-(C=O)-,\ (C_1-C_6)alkyl-)-(C=O)-,\ (C_1-C_9)heteroaryl-(C=O)-,\\ (C_1-C_9)heterocyclyl-(C=O)-,\ H_2N-(C=O)-,\ (C_1-C_6)alkyl-NH-(C=O)-,\ [(C_1-C_6)alkyl-NH-(C=O)-,\ (C_1-C_6)alkyl-NH-(C=O)-,\ [(C_1-C_6)alkyl-NH-(C=O)-,\ (C_1-C_6)alkyl-NH-(C=O)-,\ (C_1-C_6)alkyl-NH-(C=O)-,\ (C_1-C_6)alkyl-NH-(C=O)-,\ [(C_1-C_6)alkyl-NH-(C=O)-,\ (C_1-C_6)alkyl-NH-(C=O)-,\ (C_1-C_6)alkyl-NH-$$

 C_6)alkyl]₂-N-(C=O)-, [(C_6 - C_{10})aryl]₂-NH-(C=O)-, [(C_1 - C_6)alkyl]-[((C_6 - C_{10})aryl-N]-(C=O)-, HO-NH-(C=O)-, and (C_1 – C_6)alkyl-O-NH-(C=O)-; R²⁵² is a radical selected from the group consisting of H, -NO₂, -CN, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₇)cycloalkyl, (C₆-C₁₀)aryl, (C₁- C_9)heteroaryl, (C_1-C_9) heterocyclyl, (C_1-C_6) alkyl-O-, (C_3-C_7) cycloalkyl-O-, 5 (C_6-C_{10}) aryl-O-, (C_1-C_9) heteroaryl-O-, (C_6-C_9) heterocyclyl-O-, H-(C=O)-, (C_1-C_6) alkyl-(C=O)-, (C_3-C_7) cycloalkyl-(C=O)-, (C_6-C_{10}) aryl-(C=O)-, (C_1-C_1) C_9)heteroaryl-(C=O)-, (C_1 - C_9)heterocyclyl-(C=O)-, (C_1 - C_6)alkyl-O-(C=O)-. (C_3-C_7) cycloalkyl-O-(C=O)-, (C_6-C_{10}) aryl-O-(C=O)-, (C_1-C_9) heteroaryl-O- $(C=O)_{-}$, $(C_1-C_9)_{+}$ heterocyclyl-O- $(C=O)_{-}$, $(C_1-C_6)_{+}$ alkyl- $(C=O)_{-}$, $(C_3-C_6)_{+}$ 10 C_7)cycloalkyl-(C=O)-O-, (C₆-C₁₀)aryl-(C=O)-O-, (C₁-C₉)heteroaryl-(C=O)-O-, (C_1-C_9) heterocyclyl-(C=O)-O-, (C_1-C_6) alkyl-(C=O)-NH-, (C_3-C_6) alkyl-(C=O)-NH-, (C_3-C_6) alkyl-(C=O)-NH-, (C_3-C_6) alkyl-(C=O)-NH-, (C_3-C_6) alkyl-(C=O)-NH-, (C_3-C_6) -NH-, (C_5-C_6) -NH-, (C_5-C_6) -NH-, (C_5-C_6) -NH-, (C_5-C_6) -NH-, (C_5-C_6) -NH-, (C_7)cycloalkyl-(C=0)-NH-, (C₆-C₁₀aryl-(C=O)-NH-. (C₁-C₉)heteroaryl-(C=O)-NH-, (C_1-C_9) heterocyclyl-(C=O)-NH-, (C_1-C_6) alkyl-O-(C=O)-NH-, (C_1-C_6) alkyl-O-(C=O)-NH-, (C_1-C_6) alkyl-O-(C=O)-NH-, (C_1-C_6) alkyl-O-(C=O)-NH-, (C_1-C_6) alkyl-O-(C=O)-NH-, (C_1-C_6) alkyl-O-(C=O)-NH-, (C_1-C_6) -NH-, $(C_1-C_6$ C_6)alkyl-NH, [(C_1 - C_6)alkyl]₂-N-, (C_3 - C_7)cycloalkyl-NH-. [(C_3 - C_7)cycloalkyl]₂-15 N-, $[(C_6-C_{10})aryl]-NH-$, $[(C_6-C_{10})aryl]_2-N-$, $[(C_1-C_6)alkyl]-[((C_6-C_{10})aryl)-N]-$, $[(C_1-C_9)heteroaryl]-NH-, [(C_1-C_9)heteroaryl]_2-N-, [(C_1-C_9)heterocycly]-NH-, [(C_1-C_9)heteroaryl]_2-N-, [$ (C=O)-, $[(C_1-C_6)alkyl]$ -NH-(C=O)-, $[(C_1-C_6)alkyl]_2$ -N-(C=O)-, $[(C_3-C_6)alkyl]_2$ -N-(C=O)- $C_7) cycloalkyl]-NH-(C=O)-, \\ [(C_3-C_7) cycloalkyl]_2-N-(C=O)-, \\ [(C_6-C_{10}) aryl]-NH-(C=O)-, \\ [(C_6-C_{10}) aryl]-NH-(C=O)-,$ 20 $(C=O)-, \ [(C_6-C_{10}aryl]_2-N-(C=O)-, \ [(C_1-C_6)alkyl]-[((C_6-C_{10})aryl)-N]-(C=O)-, \ [(C_6-C_{10})aryl]-N]-(C=O)-, \$ C_9)heterocyclyl]-NH-(C=O)-, (C_1 - C_6)alkyl-S- and (C_1 - C_6)alkyl optionally substituted by one -OH substituent or by one to four fluoro substituents; R²⁵³ is a saturated (3- to 4-membered)-heterocyclyl ring 25

R²⁵³ is a saturated (3- to 4-membered)-heterocyclyl ring radical; or a saturated, partially saturated or aromatic (7- to 9-membered)-heterocyclyl ring radical;

wherein said saturated (3- to 4-membered)-heterocyclyl ring radical orsaid saturated, partially saturated or aromatic (7- to 9-membered)-heterocyclyl ring radical; may optionally contain one to four ring heteroatoms independently selected from the groups consisting of - N=, -NH-, -O-, and -S-;

30

wherein said saturated (3- to 4-membered)-heterooyclyl ring radical; or said saturated, partially saturated or aromatic (7- to 9nembered)-heterocyclyl ring radical; may optionally be substituted on any ring carbon atom by one to three substituents per ring independently selected from the group consisting of halo, -OH, -CN, -NO2, (C2-5 C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₇)cycloalkyl, (C₆-C₁₀)aryl, (C₂- C_9)hetorocyclyl, $(C_1 - C_6)$ alkyl-O-, H-(C=0)-, $(C_1 - C_6)$ alkyl-(C=O)-, HO- $(C=O)_{-}$, $(C_1-C_6)alkyl-O-(C=O)_{-}$, $-NH_2$, $(C_1-C_6)alkyl-NH_{-}$, $[(C_1-C_6)alkyl]_2-N_{-}$, (C_3-C_7) cycloalkyl-NH-, (C_6-C_{10}) aryl-NH-, $[(C_1-C_6)$ alkyl]- $[((C_6-C_{10})$ aryl)-N]-, (C_1-C_9) heteroaryl-NH-, H_2 N-(C=O)- $[(C_1-C_6)$ alkyl]-NH-(C=O)-, $[(C_1-C_6)]$ 10 C_6)alkyl]₂-N-(C=O)-, [(C_6 - C_{10})aryl]-NH-(C=O)-, [(C_1 - C_6)alkyl]-[((C_6 - C_{10})aryl)-N]-(C=O)-, (C₁-C₆)alkyl-O-NH-(C=O)-, (C₁-C₆)alkyl-(C=O)-HN-, (C₁- C_6)alkyl-(C=O)-[(C₁-C₆)alkyl-N]-, -SH, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-(S=0)-, (C₁-C₆)alkyl-SO₂- and (C₁-C₆)alkyl optionally substituted with one to 15 fourfluoro moieties:

wherein said saturated (3- to 4-membered)-heterocyclyl ring radical; or said saturated, partially saturated or aromatic (7- to 9-membered)-heterocyclyl ring radical; may also optionally be substituted on any ring nitrogen atom by one to three substituents per ring independently selected from the group consisting of (C_3-C_7) cyoloalkyl, (C_6-C_{10}) aryl, (C_2-C_9) heterocyclyl, H-(C=O)-, (C_1-C_6) alkyl-(C=O)-, (C_1-C_6) alkyl-O-(C=O)-, (C_1-C_6) alkyl-NH-(C=O)-, (C_1-C_6) alkyl]-NH-(C=O)-, (C_1-C_6) alkyl]-NH-(C=O)-, (C_1-C_6) alkyl]-[((C₆-C₁₀)aryl)-N]-(C=O)-, (C_1-C_6) alkyl-O-NH-(C=O)-, and (C_1-C_6) alkyl optionally substituted with one to four fluoro moieties;

20

25

30

 R^{254} is an (C₁-C₆)alkyl radical optionally substituted by one to four fluoro substituents; and

 $R^{255} \text{ is a radical selected from the group consisting of H,} \\ \text{halo, -OH, } (C_1\text{-}C_6) \text{alkyl-O-, } (C_2\text{-}C_6) \text{alkenyl, } (C_2\text{-}C_6) \text{ alkynyl, } (C_3\text{-}C_7) \text{cycloalkyl, -CN, H-(C=O)-, } (C_1\text{-}C_6) \text{alkyl-(C=O)-, } (C_1\text{-}C_6) \text{alkyl-(C=O)-, } (C_1\text{-}C_6) \text{alkyl-NH-. } [(C_1\text{-}C_6) \text{alkyl-NH-. } [(C_1\text{-}C_6) \text{alkyl-NH-, } (C_3\text{-}C_7) \text{cycloalkyl-NH-, } (C_6\text{-}C_{10}) \text{aryl-NH-, } [(C_1\text{-}C_6) \text{alkyl-} [((C_6\text{-}C_{10}) \text{aryl-N})\text{-}N]\text{-}, } \\ \text{(C_3-C_7) cycloalkyl-NH-, } (C_6\text{-}C_{10}) \text{aryl-NH-, } [(C_1\text{-}C_6) \text{alkyl-} [((C_6\text{-}C_{10}) \text{aryl-N})\text{-}N]\text{-}, } \\ \text{(C_3-C_7) cycloalkyl-NH-, } (C_6\text{-}C_{10}) \text{aryl-NH-, } [(C_1\text{-}C_6) \text{alkyl-} [(C_6\text{-}C_{10}) \text{aryl-N}]\text{-}N]\text{-}, } \\ \text{(C_3-C_7) cycloalkyl-NH-, } (C_6\text{-}C_{10}) \text{aryl-NH-, } [(C_1\text{-}C_6) \text{alkyl-} [(C_6\text{-}C_{10}) \text{aryl-N}]\text{-}N]\text{-}, } \\ \text{(C_3-C_7) cycloalkyl-NH-, } (C_6\text{-}C_{10}) \text{aryl-NH-, } [(C_1\text{-}C_6) \text{alkyl-} [(C_6\text{-}C_{10}) \text{aryl-N}]\text{-}N]\text{-}, } \\ \text{(C_3-C_7) cycloalkyl-NH-, } (C_6\text{-}C_{10}) \text{-}N \text$

 (C_1-C_9) heteroaryl-NH-, $H_2N-(C=O)$ -, (C_1-C_6) alkyl-NH-(C=O)-. $[(C_1-C_6)$ alkyl]₂-N-(C=O)-, (C_6-C_{10}) aryl-(C=O)-, $[(C_1-C_6)$ alkyl]- $[((C_6-C_{10})$ aryl)-N]-(C=O)-, (C_1-C_6) alkyl-O-NH-(C=O)-, (C_1-C_6) alkyl-S-, and (C_1-C_6) alkyl optionally substituted by one to four fluoro substituents.

[0163] 2-phenylpyran-4-one derivatives such as those described in U.S. Patent No. 6,518,303 are also useful as Cox-2 selective inhibitors of the present invention. Such 2-phenylpyran-4-one derivatives have the general formula shown below in formula XXXXXIII:

wherein:

5

10

15

20

R²⁵⁶ represents an alkyl or –NR²⁵⁹ R²⁶⁰ group, wherein R²⁵⁹ and R²⁶⁰ each independently represents a hydrogen atom or an alkyl group; R²⁵⁷ represents an alkyl, C₃ –C₇ cycloalkyl, naphthyl, tetrahydronaphthyl or indanyl group, or a phenyl group which may be unsubstituted or substituted by one or more halogen atoms or alkyl, trifluorom ethyl, hydroxy, alkoxy, methylthio, amino, mono- or dialkylamino, hydroxyalkyl or hydroxycarbonyl groups;

Ĵ

12

 R^{258} represents a methyl, hydroxymethyl, alkoxymethyl, $C_3 - C_7$ cycloalkoxymethyl, benzyloxymethyl, hydroxycarbonyl, nitrile, trifluoromethyl or difluoromethyl group or a $CH_2 - R^{261}$ group wherein R^{261} represents an alkyl group; and

X³⁶ represents a single bond, an oxygen atom, a sulfur atom or a methylene group;

or a pharmaceutically acceptable salt thereof.

Examples of 2-phenylpyran-4-one derivatives useful in the [0164] present invention include, but are not limited to: 3-(4-fluorophenyl)-2-(4-methanesulfonylphenyl)-6-methylpyran-4-one, 3-(2-fluorophenyl)-2-(4-methanesulfonylphenyl)-6-methylpyran-4-one, 3-(4-chlorophenyl)-2-(4-methanesulfonylphenyl)-6-methylpyran-4-one, 5 3-(4-bromophenyl)-2-(4-methylsulfonylphenyl)-6-methylpyran-4-one, 3-(2,4-difluorophenyl)-2-(4-methanesulfonylphenyl)-6-methylpyran-4-one, 3-(3,4-dichlorophenyl)-2-(4-methanesulfonylphenyl)-6-methylpyran-4-one, 3-(3-chloro-4-methylphenyl)-2-(4-methanesulfonylphenyl)-6-methylpyran-10 4-one, 2-(4-methanesulfonylphenyl)-6-methyl-3-phenoxypyran-4-one, 3-(4-fluorophenoxy)-2-(4-methanesulfonylphenyl)-6-methylpyran-4-one, 3-(2-fluorophenoxy)-2-(methanesulfonylphenyl)-6-methylpyran-4-one, 3-(4-chlorophenoxy)-2-(methanesulfonylphenyl)-6-methylpyran-4-one, 3-(2-chlorophenoxy)-2-(methanesulfonylphenyl)-6-methylpyran-4-one, 15 3-(4-bromophenoxy)-2-(4-methanesulfonylphenyl)-6-methylpyran-4-one, 2-(4-methanesulfonylphenyl)-6-methyl-3-(4-methylphenoxy)pyran-4-one, 3-(2,4-difluorophenoxy)-2-(4-methanesulfonylphenyl)-6-methylpyran-4one, 3-(2,5-difluorophenoxy)-2-(methanesulfonylphenyl)-6-methylpyran-4-one, 20 3-(4-chlorophenyl)-2-(4-methanesulfonylphenyl)-6-methoxymethylpyran-4one, 3-(4-chlorophenyl)-6-difluoromethyl-2-(4-methanesulfonylphenyl)pyran-4one, and pharmaceutically acceptable salts thereof. 25 Cox-2 selective inhibitors that are useful in the subject [0165] method and compositions can include the compounds that are described in U.S. Patent No. 6,472,416 (sulfonylphenylpyrazoles); U.S. Patent No. 6.451,794 (2.3-diaryl-pyrazolo[1,5-b]pyridazines); U.S. Patent Nos.

6,169,188, 6,020,343, and 5,981,576 ((methylsulfonyl)phenyl furanones);

U.S. Patent No. 6,222,048 (diaryl-2-(5H)-furanones); U.S. Patent No. 6.057.319 (3.4-diaryl-2-hydroxy-2,5-dihydrofurans); U.S. Patent No.

30

6,046,236 (carbocyclic sulfonamides); U.S. Patent Nos. 6,002,014 and 5,945,539 (oxazole derivatives); and U.S. Patent Nos. 6,359,182 and 6,538,116 (C-nitroso compounds).

- **[0166]** Examples of specific compounds that are useful as Cox-2 selective inhibitors include, without limitation:
- a1) 8-acetyl-3-(4-fluorophenyl)-2-(4-methylsulfonyl)phenyl-imidazo(1,2-a)pyridine;
- a2) 5,5-dimethyl-4-(4-methylsulfonyl)phenyl-3-phenyl-2-(5H)-furanone;
- a3) 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-
- 10 (trifluoromethyl)pyrazole;

5

- a4) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)pyrazole;
- a5) 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
- a6) 4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
 - a7) 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide;
 - a8) 4-(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
 - a9) 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1-
- 20 yl)benzenesulfonamide;
 - a10) 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
 - b1) 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide;
- 25 b2) 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide
 - b3) 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
 - b4) 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
 - b5) 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
- 30 yl]benzenesulfonamide;
 - b6) 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

b7) 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

- b8) 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 5 b9) 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
 - b10) 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-vl]benzenesulfonamide;
 - c1) 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
- 10 c2) 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
 - c3) 4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
 - c4) 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 15 c5) 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
 - c6) 4-[4-chloro-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
 - c7) 4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 20 c8) 4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
 - c9) 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
 - c10) 4-[6-(4-fluorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide;
 - d1) 6-(4-fluorophenyl)-7-[4-(methylsulfonyl)phenyl]spiro[3.4]oct-6-ene;
- d2) 5-(3-chloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
 - d3) 4-[6-(3-chloro-4-methoxyphenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide;
 - d4) 5-(3,5-dichloro-4-methoxyphenyl)-6-[4-
- 30 (methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;
 - d5) 5-(3-chloro-4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hept-5-ene;

d6) 4-[6-(3,4-dichlorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide;

- d7) 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole;
- 5 d8) 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole;
 - d9) 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole;
 - d10) 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole;
- e1) 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole;
 - e2) 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylaminothiazole;
 - e3) 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1-propylamino)thiazole;
- e4) 2-[(3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]thiazole;
 - e5) 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole;
 - e6) 1-methylsulfonyl-4-[1,1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3-yl]benzene;
 - e7) 4-[4-(4-fluorophenyl)-1,1-dimethylcyclopenta-2,4-dien-3-yl]benzenesulfonamide;
 - e8) 5-(4-fluorophenyl)-6-[4-(methylsulfonyl)phenyl]spiro[2.4]hepta-4,6-diene;
- e9) 4-[6-(4-fluorophenyl)spiro[2.4]hepta-4,6-dien-5-yl]benzenesulfonamide;

20

- e10) 6-(4-fluorophenyl)-2-methoxy-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile;
- f1) 2-bromo-6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-pyridine-3-carbonitrile;
 - f2) 6-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyl-pyridine-3-carbonitrile;

f3) 4-[2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;

- f4) 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
- 5 f5) 4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;

10

20

- f6) 3-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
- f7) 2-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
- f8) 2-methyl-4-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
- f9) 2-methyl-6-[1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
- f10) 4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
 - g1) 2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole;
 - g2) 4-[2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
 - g3) 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-methyl-1H-imidazole;
 - g4) 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-imidazole;
- g5) 2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-1+imidazole;
 - g6) 2-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl-4-(trifluoromethyl)-1H-imidazole;
 - g7) 1-[4-(methylsulfonyl)phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole;
 - g8) 2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole;

g9) 4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;

- g10) 2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole;
- 5 h1) 4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
 - h2) 2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole;
 - h3) 4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1-
- 10 yl]benzenesulfonamide;
 - h4) 1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazole;
 - h5) 4-[2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
- 15 h6) 4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
 - h7) 4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
 - h8) 1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 20 h9) 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
 - i1) N-phenyl-[4-(4-luorophenyl)-3-[4-(methylsulfonyl)phenyl]-5- (trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
 - i2) ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-
- 25 (trifluoromethyl)-1H-pyrazol-1-yl]acetate;
 - i3) 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;
 - i4) 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole;
- 30 i5) 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

i6) 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethyl-1H-imidazole;

- i7) 4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-(trifluoromethyl)-1H-imidazole;
- 5 i8) 5-(4-fluorophenyl)-2-methoxy-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine;
 - i9) 2-ethoxy-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine;
 - i10) 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-(2-propynyloxy)-6-(trifluoromethyl)pyridine;
 - j1) 2-bromo-5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine;
 - j2) 4-[2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl]benzenesulfonamide;
- 15 j3) 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]benzene;
 - j4) 5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole;
 - j5) 4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
 - j6) 4-[5-difluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
 - j7) 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
- 20 j8) 4-[5-methyl-3-phenyl-isoxazol-4-yl]benzenesulfonamide;
 - j9) 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
 - j10) 1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
 - k1) 1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 25 k2) 1-[2-(2,4-dichlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
 - k3) 1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
 - k4) 1-[2-(4-methylthiophenyl)cyclopenten-1-yl]-4-
- 30 (methylsulfonyl)benzene;

10

k5) 1-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;

k6) 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;

- k7) 1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 5 k8) 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;
 - k9) 4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
 - k10) 4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide;
 - 11) 1-[2-(4-methoxyphenyl)cyclopenten-1-yl]-4-
- 10 (methylsulfonyl)benzene;
 - 12) 1-[2-(2,3-difluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
 - 4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl]benzenesulfonamide;
- 15 l4) 1-[2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl]-4- (methylsulfonyl)benzene;
 - 15) 4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
 - 16) 4-[2-(2-methylpyridin-5-yl)cyclopenten-1-yl]benzenesulfonamide;
 - 17) ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl) phenyl]oxazol-2-yl]-
- 20 2-benzyl-acetate;
 - 18) 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid;
 - 19) 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
 - 110) 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole;
- 25 m1) 4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole; and
 - m2) 4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-oxazolyl]benzenesulfonamide;
 - m3) 6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- 30 m4) 6-chloro-7-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;

m5) 8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;

- m6) 6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- 5 m7) 6-chloro-8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - m8) 2-trifluoromethyl-3H-naphthopyran-3-carboxylic acid;
 - m9) 7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- 10 m10) 6-bromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - n1) 8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - n2) 6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - n3) 5,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- 15 n4) 8-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - n5) 7,8-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - n6) 6,8-bis(dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - n7) 7-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic
- 20 acid;
 - n8) 7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - n9) 6-chloro-7-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - n10) 6-chloro-8-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic
- 25 acid;
 - o1) 6-chloro-7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - o2) 6,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - o3) 6,8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- 30 o4) 2-trifluoromethyl-3H-naptho[2,1-b]pyran-3-carboxylic acid;
 - o5) 6-chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;

06)	8-chloro-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic
acid;	

- o7) 8-chloro-6-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- 5 o8) 6-bromo-8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - o9) 8-bromo-6-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - o10) 8-bromo-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic
- 10 acid;

20

- p1) 8-bromo-5-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- p2) 6-chloro-8-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- p3) 6-bromo-8-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - p4) 6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - p5) 6-[(dimethylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - p6) 6-[(methylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - p7) 6-[(4-morpholino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- p8) 6-[(1,1-dimethylethyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - p9) 6-[(2-methylpropyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - p10) 6-methylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - q1) 8-chloro-6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;

q2) 6-phenylacetyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;

- q3) 6,8-dibromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- q4) 8-chloro-5,6-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
- 5 q5) 6,8-dichloro-(S)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - q6) 6-benzylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - q7) 6-[[N-(2-furylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - q8) 6-[[N-(2-phenylethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - q9) 6-iodo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid;
 - q10) 7-(1,1-dimethylethyl)-2-pentafluoroethyl-2H-1-benzopyran-3-carboxylic acid;
 - r1) 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methyl-sulphonyl-2(5H)-fluranone;
 - r2) 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid;
 - r3) 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
- 20 yl]benzenesulfonamide;

10

15

- r4) 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- r5) 4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 25 r6) 3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;
 - r7) 2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;
 - r8) 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
 - r9) 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
 - r10) 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

s1) [2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide;

5

10

15

20

25

30

- s2) 4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide; or
- s3) 4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4-oxazolyl]benzenesulfonamide;

or a pharmaceutically acceptable salt or prodrug thereof.

[0167] Cox-2 inhibitors that are useful in the methods and compositions of present invention can be supplied by any source as long as the Cox-2 inhibitor is pharmaceutically acceptable. Likewise, Cox-2 inhibitors that are useful in the compositions and methods of present invention can by synthesized, for example, according to the description in Example 1. Several Cox-2 inhibitors that are suitable for use with the compositions and methods of the present invention may be synthesized by the methods described in, for example, U.S. Patent No. 5,466,823 to Talley, et al. Cox-2 inhibitors can also be isolated and purified from natural sources. Cox-2 inhibitors should be of a quality and purity that is conventional in the trade for use in pharmaceutical products.

[0168] Preferred Cox-2 selective inhibitor compounds are those compounds selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, etoricoxib, meloxicam, rofecoxib, lumiracoxib, RS 57067, T-614, BMS-347070 (Bristol Meyers Squibb, described in U.S. Patent No. 6,180,651), JTE-522 (Japan Tabacco), S-2474 (Shionogi), SVT-2016, CT-3 (Atlantic Pharmaceutical), ABT-963 (Abbott), SC-58125 (GD Searle), nimesulide, flosulide, NS-398 (Taisho Pharmaceutical), L-745337 (Merck), RWJ-63556, L-784512 (Merck), darbufelone (Pfizer), CS-502 (Sankyo), LAS-34475 (Almirall Prodesfarma), LAS-34555 (Almirall Prodesfarma), S-33516 (Servier), SD-8381 (Pharmacia, described in U.S. Patent No. 6,0340256), MK-966 (Merck), L-783003 (Merck), T-614 (Toyama), D-1376 (Chiroscience), L-748731 (Merck), CGP-28238 (Novartis), BF-389 (Biofor/Scherer), GR-253035 (Glaxo Wellcome), prodrugs of any of them, and mixtures thereof.

[0169] More preferred is that the Cox-2 selective inhibitor is selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, lumiracoxib, etoricoxib, rofecoxib, prodrugs of any of them, and mixtures thereof.

[0170] Even more preferred still is that the Cox-2 selective inhibitor is celecoxib.

5

20

- [0171] Cox-2 inhibitors that are useful in the methods and compositions and methods of present invention can be supplied by any source as long as the Cox-2 inhibitor is pharmaceutically acceptable.
- Likewise, Cox-2 inhibitors that are useful in the compositions and methods of present invention can by synthesized, for example, according to the description in Example 1. Several Cox-2 inhibitors that are suitable for use with the compositions and methods of the present invention may be synthesized by the methods described in, for example, U.S. Patent No. 5,466,823 to Talley, *et. al.*
 - [0172] Various classes of Cox-2 inhibitors useful in the present invention can be prepared as follows. Pyrazoles can be prepared by methods described in WO 95/15316. Pyrazoles can further be prepared by methods described in WO 95/15315. Pyrazoles can also be prepared by methods described in WO 96/03385.
 - [0173] Thiophene analogs useful in the present invention can be prepared by methods described in WO 95/00501. Preparation of thiophene analogs is also described in WO 94/15932.
 - [0174] Oxazoles useful in the present invention can be prepared by the methods described in WO 95/00501. Preparation of oxazoles is also described in WO 94/27980.
 - [0175] Isoxazoles useful in the present invention can be prepared by the methods described in WO 96/25405.
- [0176] Imidazoles useful in the present invention can be prepared by the methods described in WO 96/03388. Preparation of imidazoles is also described in WO 96/03387.

[0177] Cyclopentene Cox-2 inhibitors useful in the present invention can be prepared by the methods described in U.S. Patent No. 5,344,991. Preparation of cyclopentene Cox-2 inhibitors is also described in WO 95/00501.

- 5 **[0178]** Terphenyl compounds useful in the present invention can be prepared by the methods described in WO 96/16934.
 - [0179] Thiazole compounds useful in the present invention can be prepared by the methods described in WO 96/03392.
 - [0180] Pyridine compounds useful in the present invention can be prepared by the methods described in WO 96/03392. Preparation of pyridine compounds is also described in WO 96/24585.

10

- **[0181]** Benzopyranopyrazolyl compounds useful in the present invention can be prepared by the methods described in WO 96/09304.
- [0182] Chromene compounds useful in the present invention can be prepared by the methods described in WO 98/47890. Preparation of chromene compounds is also described in WO 00/23433. Chromene compounds can further be prepared by the methods described in U.S. Patent No. 6,077,850. Preparation of chromene compounds is further described in U.S. Patent No. 6,034,256.
- 20 **[0183]** Arylpyridazinones useful in the present invention can be prepared by the methods described in WO 00/24719. Preparation of arylpyridazinones is also described in WO 99/10332. Arylpyridazinones can further be prepared by the methods described in WO 99/10331.
 - [0184] 5-Alkyl-2-arylaminophenylacetic acids and derivatives useful in the present invention can be prepared by the methods described in WO 99/11605.
 - **[0185]** Diarylmethylidenefuran derivative Cox-2 selective inhibitors useful in the present invention can be prepared by the methods described in U.S. Patent No. 6,180,651.
- The celecoxib used in the compositions and methods of the present invention can be prepared in the manner set forth in U.S. Patent No. 5,466,823.

[0187] The valdecoxib used in the compositions and methods of the present invention can be prepared in the manner set forth in U.S. Patent No. 5,633,272.

[0188] The parecoxib used in the compositions and methods of the present invention can be prepared in the manner set forth in U.S. Patent No. 5,932,598.

5

10

15

20

25

30

[0189] The rofecoxib used in the compositions and methods of the present invention can be prepared in the manner set forth in U.S. Patent No. 5,474,995.

[0190] The deracoxib used in the compositions and methods of the present invention can be prepared in the manner set forth in U.S. Patent No. 5,521,207.

[0191] The etoricoxib used in the compositions and methods of the present invention can be prepared in the manner set forth in WO 98/03484.

[0192] The meloxicam used in the compositions and methods of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,233,299.

[0193] The compound 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide used in the compositions and methods of the present invention can be prepared in the manner set forth in U.S. Patent No. 5,994,381.

[0194] The compound 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone used in the compositions and methods of the present invention can be prepared in the manner set forth in WO 00/24719.

[0195] The compound 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one used in the compositions and methods of the present invention can be prepared in the manner set forth in EP 863134.

[0196] The compound 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-benzeneacetic acid used in the compositions and methods of the present invention can be prepared in the manner set forth in WO 99/11605.

[0197] The compound N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide used in the compositions and methods of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,885,367.

5

20

25

- [0198] The compound (3Z)-3-[(4-chlorophenyl)[4-(methylsulfonyl)phenyl]methylene]dihydro-2(3H)-furanone used in the compositions and methods of the present invention can be prepared in the manner set forth in U.S. Patent No. 6,180,651.
 - [0199] Cox-2 inhibitors can also be isolated and purified from natural sources. Cox-2 inhibitors should be of a quality and purity that is conventional in the trade for use in pharmaceutical products.
- 15 **[0200]** An optional component of the combination therapy embodiments of the present invention is an antidepressant agent.
 - [0201] As used herein, the phrase "antidepressant agent" means an agent or compound, or a combination of two or more of such agents or compounds, which treat or prevent psychiatric disorders or symptoms of a psychiatric disorder in a subject in need of such treatment.
 - [0202] Antidepressant agents display a wide range of chemical structures. Some of the structural classes of antidepressant agents that are encompassed by the present invention include tricyclics, tetracylics, hydrazides/hydrazines, bicyclics, benzodiazepines, and pyrrolidones.
 - [0203] Antidepressant agents also perform a wide range of functions within the subject's body. Some of the functional classes of antidepressant agents that are encompassed by the present invention include selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, noradrenaline reuptake inhibitors, selective serotonin and noradrenaline reuptake inhibitors, dual-action serotonin norepinephrine reuptake inhibitors, norepinephrine antagonist serotonin antagonists, selective serotonin and noradrenaline reuptake inhibitors, serotonin

antagonist and reuptake inhibitors, norepinephrine dopamine reuptake inhibitor, and serotonin reuptake accelerators.

5

10

In one embodiment, sertraline (Zoloft®), in particular, has been found to be a preferred antidepressant agent. Sertraline was initially introduced for the treatment of depression, but it is now used to treat a wide variety of psychiatric disorders. See Khouzam H., et al., Compr Ther 29(1):47-53 (2003). Sertraline acts as a selective serotonin reuptake inhibitor (SSRI) through oral administration. However, it is chemically unrelated to other SSRIs, tricyclic, tetracyclic, or other available antidepressant agents.

[0205] In another embodiment, the present invention encompasses one or more of the antidepressant agents described in Table 3 below.

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents			
No.	Compound Name	Trade Name(s)	Drug Class	Dose	Manufacturer	Reference	
	Sertraline HCI	Zoloft®	Selective	50-200	Pfizer Inc.	U.S. Patent No.	
		Altruline®	Serotonin	mg/day	,	4,045,488 and	
	(1S-cis)-4-(3,4-	Sercerin®	Reuptake			4,556,676 and	
	dichlorophenyl)-1,2,3,4-	Lustral®	Innibitor (35KI), Bicvelic	***		4,330,310.	····
	nanphthalenamine						
	hydrochloride						
							
	\$						
	<u></u>				,		
			,				
) }						
2	Citalopram HBr	Celexa® Cioramil®	SSRI, bicyclic	40 mg/day	Forest Pharmaceuti	U.S. Patent No. 4,943,590.	
	(±)-1-(3-	Prisdal®		·)	cals, lnc		
	dimethylaminopropyl)-1- (4-fluorophenyl)-1,3-						
	dihydroisobenzofuran-5-						
	carbonitrie ndi						
	O. John M. Co.						
	\{\bar{\}}						
	- June 2						
	L.					and the second s	

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
က	Escitalopram oxalate	Lexapro®	SSRI	10-50	Forest	U.S. Patent No.
	5			mg/day	Pharmaceuti	6,455,710
	S-(+)-1-[3- : : : : : : : : : : : : : : : : : : :				cals, Inc	
	dimethylamino)propyl]-1-					
	(p-fluorophenyl)-5-					
	phthalancarbonitrile oxalate					
4	Fluvoxamine	Luvox®	SSRI	100-300	Solvay	Martin, A., et al., J
		Faverin®		mg/day	Pharmaceuti	Autism Dev Disorder
	5-methoxy-4'-	Floxyfral®			cals, Inc	33(1):77-85 (2003).
	(trifluoromethyl)		······			
	valerophenone (E)-O-(2-					
	aminoethyl)oxime					
	maleate (1:1)					
	MeO					
	:					
	Z-N-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-					
	-{_					
	>					
	CF ₃					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

	U.S. Patent Nos.	2,680,743; 2,734,063;	2,904,551; and	3,024,244							U.S. Patent No.	4,030,410.					
	III.	Kline 2,6									 Eli Lilly and	Company					
Agents	20-50	mg/day									20-150	mg/day					
Table 3: Antidepressant Agents	SSRI, bicyclic										SSRI					÷	
Table 3	Paxil®	Aropax®	Seroxat®	Aroxat®							Prozac®	Deprax® F∷far®	Eulol⊛ Psiquial® Lovan®				
	Paroxetine HCI		(-) - (3S,4R)-4-[(p-	fluorophenyl)-3-[(3,4-	methylenedioxy)	phenoxy]methyl]piperidin	hemihydrate	•	I	○ { } }	Fluoxetine HCI	C. Linda C. L. Altania	(±)-lv-metnyl-3-pnenyl-3- [(a,a,a-trifluoro-p-tolyl)- oxvloropvlamine	hydrochloride	ew_NH	-ra-	
	5					-					9						

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

8	Amitriptyline HCI 3-(10,11-dihydro-5 <i>H</i> -dibenzo [a, <i>d</i>] cycloheptene-5-ylidene)- <i>N,N</i> -dimethyl-1- propanamine hydrochloride Coloheptene-5-ylidene)- Coloheptene-5-ylidene)- Mydrochloride Coloheptene-5-ylidene)- All Dispanamine Desipramine Desipramine Desipramine 10, 11-	Table 3: Elavil® Endep® Sarotex® Typtanol® Typtizol® Norpramine® Pertofrane®	Table 3: Antidepressant Agents ndep® Tricyclic 50-30 sx® nol® ol® ol® ane® Tricyclic 100-30 mg/de mg/de mg/de	Agents 50-300 mg/day 100-300 mg/day	Astrazeneca	U.S. Patent No. 4,495,281 Swann, A., et al., J Clin Psychopharmacol 17(2):78-83 (1997).
	dihydro-N-methyl Monohydrochloride		# :			

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		7- 0
Imipra	Imipramine	Tofranil® Jaminine	Tricyclic	50-300 mg/day		Van Amerongen, A., et al., J Affect Disord
5-[3-(imethylamino),11- ihydro-5 [b,1-azep Monohydroc	5-[3-(Dimethylamino)propyl]- 10,11- ihydro-5H-dibenz [b,1-azepine] Monohydrochloride			,		72(1):21-31 (2002).
Mapr	Maprotiline	Ludiomil®	tetracyclic	25-150	Novartis	Kudoh, A., et al.,
N-metl ethanoal 9(10H)-pr	N-methyl-9,10- ethanoanthracene- 9(10H)-propanamine			mg/day		Pharmacopsychiatry 36(2):57-60 (2003).
			١			
Rebo	Reboxetine	Edronax®, Vestra®	Noradrenaline Reuptake	4-12 mg/day		Montgomery, S., et al., J Clin
(E L		Inhibitor			Psychopharmacol 23(1):45-50 (2003).

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents	
12	Nortriptyline	Aventyl®,	Tricyclic	50-150	Nierenberg, A., et al., J
	1-Propanamine, 3-(10,11-dihydro, 5H-dibenzo fa. dl	Pamelor® Nortilen®		mg/day	Clin Psychiatry 64(1):35-9 (2003).
	cyclohepten- 5-ylidene)- N-methyl-, hydrochloride				
	STATION STATIONS				
13	Amineptine	Survector®	Tricyclic	100-200	Ferreri, M., et al., Int
man.	7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid	Maneon®		IIIg/uay	 Ulin Psychopharmacol 12 Suppl 3:S39-45 (1997).
4	Zimelidine	Zelmid®		75-300	Merck Index, 12th ed,
	(Z)-3-(4-bromophenyl)- N,N-dimethyl-3-(3- pyridinyl)-2-propen-1- amine		5	mg/day	No. 10254

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

			1 amile 5: 1 minus 5: 0 com: 1 diamile	2	
15	Venlafaxine	Effexor®	Dual-action	75-300	U.S. Patent Nos.
		EffexorXR®	serotonin	mg/day	6,274,171 and
	(R/S)-1-[2-	Dobupal®	norepinephrine		4,535,186
	(dimethylamino)-1-(4		reuptake		
	methoxyphenyl)ethyl]		inhibitor		
	cyclohexanol			-	
	hydrochloride or (±)-1-[a				
	[(dimethylamino)methyl]				
	p-methoxybenzyl]				
	cyclohexanol			***************************************	
	hydrochloride				
	•				
	Me Me				
	<u></u>		•		
		*			
	<u> </u>				
	ОМе				

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

Table 3: Antidepressant Agents	3 Tetracyclic	Norset® hg/day 4,002,646 and Zipsin® 4,515,792					50-200	serotonin and mg/day al., J Alieu Disord noradrenaline 72(1):21-31 (2002).	reuptake inhihitor (SNRI)			, , , , , , , , , , , , , , , , , , , ,	
	Mirtazapine	1,2,3,4,10,14b-	hexahydro-2-	meunyipyrazino[z, ı-a] pyrido [2,3-c]	benzazepine		Milnacipran	Cis-(+)-2-(aminomethyl)-	N,N-diethyl-1-	piletiyicyclopiopariecarbo xamide	HN.	NEt,	ā
	16				,		17						

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
18	Phenelzine	Nardil®	Monoamine	30-90	Parke-Davis	Swann, A., et al., J Clin
_			oxidase	mg/day		Psychopharmacol
	(2-phenethyl)hydrazine		inhibitor,			17(2):78-83 (1997).
			hydrazides/hydr			
	IN NH2		azines			
	<u></u> ====================================					
19	Tranylcypromine	Parnate®	Monoamine	20-120	Smithkline	Joffe, R., Int Clin
			oxidase inhibitor	mg/day	Beecham	Psychopharmacol
	(±)- trans -2-					11(4):287-8 (1996).
	phenylcyclopropylamine					
	sulfate (2:1)					
	I					
	2,1,2					
	>@					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
7	Nefazodone	Serzone®	Serotonin		Bri	Grunze H, et al.,
		Dutonin®	Antagonist and	mg/day	Squibb	Neuropsychobiology
,	2-[3-[4-(3-chlorophenyl)-	Nefadar®	Reuptake			46 Suppl 1:31-5
	1-piperazinyl]propyl]-5-		inhibitor (SARI)			(2002).
	ether-2,4-dihydro-4-(2-					
	phenoxyethyl)-3H-1,2,4-					
	triazol-3-one					
	monohydrochloride					
	å					
	, and the second					
	7					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

	U.S. Patent No. 4,613,600	U.S. Patent Nos. 6,391,875 and 4,347,176
	Apothecon, Princeton, NJ	GlaxoSmith Kline
Agents	100-600 mg/day	300-450 mg/day, 150-300 mg/day
Table 3: Antidepressant Agents	Serotonin Antagonist and Reputake inhibitor (SARI), bicyclic	Norepinephrine dopamine reuptake inhibitor
Table 3	Desyrel®	Wellbutrin® Zyban®
	Trazodone 2-[3-{4 -(m-Chlorophenyl)-1-piperazinyl] propyl]s-triazol[4,3-a]-pyridine-3(2H)-onemonohydrochloride	Bupropion (±)-1-(3-chlorophenyl)-2- [(1,1- dimethylethyl)amino]-1- propanone hydrochloride
	21	22

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

Table 3: Antidepressant Agents	ranil®, Tricyclic 25-2500 Ackerman, D., <i>et al.</i> , <i>J</i> mg/day Clin Psychopharmacol 22(3):309-17 (2002).	U.S. Patent Nos. 5,011,841 and 4,507,303
Table 3: Antide	Anafranil®, Tri	
	Clomipramine 3-chloro-5-[3- (dimethylamino)propyl]- 10.11-dihydro-5H- dibenz[b.f]azepine monohydrochloride	Tandospirone 4,7-methano-1H- isoindole-1,3(2H)-dione, hexahydro-2>4->-(2- pyrimidinyl)-1- piperazinyl!butyl!- (3a.alpha.,4.beta.,7. beta.,7a.alpha.)-2- hydroxy-1,2,3- propanetricarboxylate (1:1) or as N->4->4-(2- pyrimidinyl)-1- piperazinyl!butyl-2,3- norbornanedicarboximide
	53	24

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
25	Isocarboxazid	Marplan®	Monoamine	30-80	Roche	Davidson, J., et al.,
	5-methyl-3-		oxidase inhibitor	mg/day		Arch Gen Psychiatry 45(2):120-7 (1988).
···	isoxazolecarboxylic acid 2-benzylhydrazide					
	Me					
	ZI					
26	Lithium Carbonate	Eskalith®,				
		Lithobid®				
	L ₂ CO ₃	LIIIOGADS				
27	Lithium Citrate	Cibalith®-Sr				
28	Doxepin	Adapin® Sinequan®	tricyclic	75-300 mg/day		Ayd, F., Jr., <i>J Clin</i> Psychiatry 45(3 Pt
~~~~	1-Propanamine,3- dibenz[b,e] oxepin-					2):39-46 (1984).
	1,1(oH) ylldene IN, IN- dimethyl-hydrochloride					
				,		-
	NMe ₂					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents			_
1	Amoxapine	Asendin®	Tricyclic	75-400		Schmultz, J., et al.,	r
	2-chloro-11-(1- piperazinyldibenz- [b,f][1,4]oxapine	Asendas@		mg/day		15:245 (1967).	
					,		TOM:
30	Moclobemide	Manerix,	Serotonin and	150-600		Kimura, M., et al.,	
	4-chloro-N-[2-(4- morpholinyl)- ethyl}benzamide	Auronx, Moclamine	Notepinepinite Reuptake Inhibitors (SNRI).	ilig/day		Psychopharmacology 17: 121-125 (2002).	
	<b>€</b>						
	- H				l.		
	-\						

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
31	Trimipramine	Surmontil, Rhotrimine	Tricylic	50-300 ma/day	Berger, M.	Berger, M., et al., Eur
	5-[3-(dimethylamino)-2- methylpropyl]-10,11- dihydro-5H- dibenz[b,f]azepine			ָ 	Neurosci 27 (190	(1996).
	ow W			•		
	NMe2					
32	Selegiline	l-deprenyl, Fidenryl	Monoamine oxidase inhibitor	5-30 mg/day	Mann JJ, e	Mann JJ, et al., Arch Gen Psychiatry
	(-)Deprenyl, or (R)-(-)-N,2-dimethyl-N-2- propynylphenethylamine hydrochloride	Jumex, Carbex		ָּהָ בַּ	46(1):45-50 (1989).	50 (1989).
	€-					
	DH+HD=CHON					
	- ch. ch.					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

Protriptyline		Table 3 Vivactii, Triptil	Table 3: Antidepressant Agents til, Tricylic 15-6(	Agents 15-60 mg/day	U.S. Pat. Nos. 3,244,748 and
dibenzo[a,d]cycloheptene -5-propamine	<u>—</u>				- C.
NHMe					
Viloxazine Vii 2-[(2- ethoxyphenoxy)methyl]m orpholine		Vivalan	,	15-30 mg/day	Merck Index, 12th ed, no 10116
n hyl-6- olo [4,3- zepine		Xanex, Helix	benzodiazepine	.75-10 mg/day	U.S. Patent No. 4,595,684.
Me N N N N N N N N N N N N N N N N N N N			i		

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

1	-	Table 3	Table 3: Antidepressant Agents	Agents		
Pargyline		Eutonyl,		06		Merck Index, 12th ed.,
N-methyl-N-2-		Eudatine, Tenalin		mg/day		no 7172
propynylbenzenemethan amine						
Dextroamphetamine		Dexedrine®		Up to	GlaxoSmith	
		(Adderail®)		40 ma/day	Kline	
methylphenethylamine				iiig/uay		
(Combination of the						
neutral sulfate salts of						
dextroamphetamine and						
amphetamine, with the						
dextroisomer of						
amphetamine saccharate						
and 6, I-amphetamine						
aspartate)						
Methylphenidate		Ritalin®		Up to 60	CIBA-Geigy Corporation	Kimko, H., <i>et al.</i> , <i>Clin</i> <i>Pharmacokine</i>
methyl a-phenyl-2-piperi-				mg/day		37(6):457-70 (1999).
dineeacetate						
hydrochloride						
Ph			-			
COOMe						

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

	Diszenem	Valium	Table 3: Antidepressant Agents	Agents	Roche	II.S. Patent No
בֿ ב	azepam	vallum, Dizac	penzodiazepine	ng/day	Kocne	0.5. Faterit No. 3,932,325.
7-chlord methyl-5	7-chloro-1,3-dihydro-1- methyl-5-phenyl-2H-1,4-					
neuzo(	penzodiazepin-z-one			v.		
	Me					
	Ta ta					
Bus	Buspirone HCI	BuSpar		15 - 60 ma/dav		Mahmood, I., et al., Clin Pharmacokinet
8-[4-[4-(	8-[4-(2-pyrimidinyl)-1- piperazinyl) butyl)-8-					36(4):277-87 (1999).
azaspir 7	azaspiro [4,5] decane- 7,9- dione					
mono	monohydrochloride					
	×					
0	~~					
	_/{					
	<u> </u>					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
41	Tianeptine	Stablon®,	serotonin	25-50		Wagstaff, A., et al.,
		Ardix	reuptake	mg/day		CNS Drugs 15(3):231-
			accelerator,			59 (2001).
			Tricyclic			
	W.					
	,					
42	Binodaline		Bicyclic	50-150		Merck Index, 12th ed,
				mg/day	-	no 1266
	N,N,N'-trimethyl-N'-(3-					
	ethanediamine					_
43	Caroxazone		a reversible			Merck Index, 12th ed,
			monoamine			no 1907
	2-oxo-2H-1,3-		oxidase			
	benzoxazine-3(4H)-		inhibitor, Bicyclic			
	acetamide					
44	Dimethazan		Bicyclic			Merck Index, 12th ed,
	7-[2-					- 0 1 0
	(dimethylamino)ethyl]-					
	3,7-dihydro-1,3-dimethyl-					,
	1H-purine-2,6-dione					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents	
45	Fencamine		Bicyclic		Merck Index, 12th ed,
	3,7-dihydro-1,3,7- trimethyl-8-[[2-[methyl(1-				
	neuryl-z- phenylethyl)amino]ethyl]a mino]-1H-purine-2,6- dione				
46	Indalpine	Upstene	Bicyclic	100-150 mg/day	Merck Index, 12th ed, no 4965
	3-[2-(4-piperidinyl)ethyl]- 1H-indole				
47	Indeloxazine	Elen	Bicyclic	40-120	Merck Index, 12th ed,
	nydrocnioride			mg/day	NO 4972
	yloxy)methyl]morpholine		٠		
	hydrochloride				
48	Nefopam		Bicyclic		Merck Index, 12th ed, no 6529
	3,4,5,6-tetrahydro- 5methyl-1-phenyl-1H-2,5-				
	benzoxazocine				

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
53	Benmoxine	Neuralex,	Hydrazides /	50-75	Merck Index, 12th ed,	th ed,
		Nerusil	Hydrazines	mg/day	no 1072	
	Benzoic acid 2-(1-					
54	Iproclozide	Sursum	Hydrazides /	10-30	Merck Index, 12th ed,	th ed,
			Hydrazines	mg/day	no 5092	
	4-(chlorophenoxy)acetic					
	acid 2-(1-					
	methylethyl)hydrazide					
22	Iproniazid	lprozid,	Hydrazides /	50-150	Merck Index, 12th ed,	th ed,
		Marsilid	Hydrazines	mg/day	no 5094	
	4-pyridinecarboxylic acid					***
	2-(1-				-	
	methylethyl)hydrazide					
26	L-Tryptophan			,	Merck Index, 12th ed,	th ed,
					no 9929	
	(S)-α-amino-1H-indole-3-					
	propanoic acid					
22	Nialamide	Niamid	Hydrazides /	100-200	Merck Index, 12th ed,	th ed,
	4-pvridinecarboxylic acid		riyarazırıes	IIIg/uay	C /CO OII	
	2-[3-0xo-3-					•
	[(phenylmethyl)amino]pro					
	pyl]hydrazide					
28	Octamoxin		Hydrazides /		Merck Index, 12th ed,	th ed,
	3		Hydrazines		no 6845	
	<u>-</u>					
	methylheptyl)hydrazine					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
29	Toloxatone	Humory, Perenum				Merck Index, 12th ed, no 9659
	5-(hydroxymethyl)-3-(3- methylphenyl)-2- oxazolidinone					
09	Cotinine		Pyrrolidones			Merck Index, 12th ed, no 2619
	1-methyl-5-(3-pyridinyl)2- pyrrolidinone		,,			
61	Rolicyprine		Pyrrolidones			Merck Index, 12th ed, no 8409
	5-oxo-N-(2-					
	prienyicyciopropyi)-z- pyrrolidinecarboxamide					
62	Rolipram		Pyrrolidones	.75-1.5 ma/day	-	Merck Index, 12th ed,
	4-[3-(cyclopentyloxy)-4-			) )		
	methoxyphenyl]-2- pyrrolidinone					
63	Metralindole		Tetracyclic			Merck Index, 12th ed, no 6238
	2,4,5,6-tetrahydro-9- methoxy-4-methyl-1H-					
	3,4,6a-triazafluoranthene					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table	Table 3: Antidepressant Agents	Arente	
64	Mianserin	Athymil,	Tetracyclic	30-90	Merck Index 12th ed
		Bolvidon,	•	mg/dav	no 6260
	1,2,3,4,10,14b-	Norval,			0010
	hexahydro-2-methyl-	Tolvin			
	dibenzo[c,f]pyrazino[1,2-				
,	ajazepine				
65	Adinazolam	Deracyn	Tricyclic	30-90	Merck Index, 12th ed,
	8-chorola M-chorola			mg/day	no 159
	phenvi-4H-				
	[1,2,4]triazolo[4,3-				
	a][1,4]benzodiazepine-1-				
	methanamine				-
99	Amitriptylinoxide		Tricyclic		Merck Index, 12th ed,
	3-(10,11-dihydro-5H-				no 512
	dibenzo[a,d]cyclohepten-				
	5-ylidene)-N,N-dimethyl-				
	1-propanamine N-oxide				
29	Butriptyline	Evadyne,	Tricyclic		Merck Index, 12th ed,
	10,11-dihydro-N,N,β-	Centrolyse			no 1568
	trimethyl-5H-	•			
	dibenzo[a,d]cycloheptene				
	-5-propanamine				

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

89	Dibenzenin	Noveril	Table 3: Antidepressant Agents	Agents	Marck Index 12th ed
8	Dipenzepin	Ecotril,	i licyciic	240-460 mg/day	Merck Index, 1ztri ed, no 3055
	10-[2-	Victoril			
	(dimethylamino)ethyl]- 5,10-dihydro-5-methyl-				
	11H-				
	dibenzo[b,e][1,4]diazepin- 11-one				
69	Dimetacrine		Tricyclic		Merck Index, 12th ed,
					no 3258
-	N,N,9,9-tetramethyl-				
	10(9H)-				
	acridinepropanamine				
02	Dothiepin	Prothiaden,	Tricyclic	50-225	Merck Index, 12th ed,
**		Arpin,		mg/day	no 3485
	3-dibenzo[b,e]thiepin-	ldom			
	11(6H)-ylidene-N,N-				
	dimethyl-1-propanamine				
71	Fluacizine		Tricyclic		Merck Index, 12th ed,
				•	no 4149
	10-[3-diethylamino)-1-				
	oxopropyi]-2-				
	(trifluoromethyl)-10H-				
	phenothiazine				

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

	Merck Index, 12th ed,	10 4630				Merck Index, 12th ed,	no 5091	1.0			Merck Index, 12th ed,	no 5587								
Agents											70-210	mg/day				-				
Table 3: Antidepressant Agents	Tricyclic					Tricyclic		•			Tricyclic		·							:
Table 3	Transaction of the Control of the Co									:	Emdalen,	Gamanii,	Lomont, Tvmelvt							
	Imipramine N-Oxide	10,11-dihydro-N,N-	dimethyl-5H-	dibenz[b,f]azepine-5-	propanamine N-oxide	Iprindole	6.7.8.9.10.11-hexahvdro-	N.N-dimethyl-5H-	cyclooct[b]indole-5-	propanamine	Lofepramine		1-(4-cnlorophenyl)-2-[[3- (10.11-dihvdro-5H-	dibenz[b,f]azepin-5-	yl)propyl]methylaminojeth	anone	8	 The state of the s	<b>}</b> —{	
	72					73					74			-						

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
75	Melitracen	Dixoran,	Tricyclic	75-225		Merck Index, 12th ed,
		Melixeran,		mg/day		no 5866
	3-(10,10-dimethyl-	Trausabun				
,	9(10H)-					
	anthracenylidene)-N,N-					
	dimethyl-1-propanamine					
9/	Metapramine	Timaxil	Tricyclic	150-450		Merck Index, 12th ed,
,				mg/day		no 5991
	10,11-dihyrdo-N,5-				,	
	dimethyl-5H-					
	dibenz[b.flazepin-10-					
	amine					
	Noxiptilin	Nogedal	Tricyclic	25-200		Merck Index, 12th ed,
				mg/day		no 6821
	10,11-dihydro-5H-					
	dibenzo[a,d]cyclohepten-					
	5-one O-[2-					
	(dimethylamino)ethyl]oxi					
	me					
78	Opipramol	Insidon, Oprimol	Tricyclic	150-300 mg/day		Merck Index, 12th ed, no 6985
	4-[3-(5H-					
	dibenz[b,f]azepin-					
	5yl)propyl]-1-					
	piperazineethanol					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents	
79	Pizotyline		Tricyclic		Merck Index, 12th ed,
	4-(9,10-dihydro-4H-				1707.011
	benzo[4,5]cyclohepta[1,2-				
	b]thien-4-ylidene)-1- methylpiperidine				
80	Propizepine	Vagran	Tricyclic	50-200	Merck Index, 12th ed,
	6-[2-			IIIg/uay	0000
	(dimethylamino)propyl]-				
	1,6-dihydro-5H-				
	b][1,5]benzodiazepin-5-				
	one				
<u>8</u>	Quinupramine	Adeprim, Kevopril	Tricyclic		Merck Index, 12th ed, no 8267
· ·	5-(1-azabicyclo[2.2.2]oct-	<b>-</b>			
	3-yl)-10,11-dihydro-5H-				
	dibenz[b,f]azepine				
82	Tofenacin	-			Merck Index, 12th ed, no 9641
	N-methyl-2-[(2-				
	methylphenyl)phenylmeth				
	oxy]ethanamine		,		

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3: An	<b>Table 3: Antidepressant Agents</b>	ıts	
83	Adrafinil	Olmifon	96   61	600- 1200	Merck Index, 12th ed, no 168
	2-		mg	mg/day	
	[(diphenylmethyl)sulfinyl]-				
	IN-riyaroxyacelarnide				
	Ph NHOH				
8	Benactyzine				Merck Index, 12th ed,
	1-[7-[2-hydroxy-3-[(1-				0
	methylethyl)amino]propox	1	··•		
	yj-2- benzofuranyl]ethanone				
85	Butacetin				Merck Index, 12th ed, no 1532
	N-[4-(1,1- dimethylethoxy)phenyl]ac				
98	Dioxadrol				Merck Index, 12th ed,
	2-(2,2-diphenyl-1,3-dioxolan-4-vl)biperidine				1
87	Duloxetine	Cymbalta	40- ma	40-120 mg/dav	Merck Index, 12th ed, no 3518
	(S)-N-methyl- $\gamma$ -(1-naophthalenyloxy)-2-thiophenepropanamine				

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3: Antidepressant Agents	
88	Etoperidone	Merck Index, 12th ed,	12th ed,
		0585 OU	
	2-[3-[4-(3-chlorophenyl)-		
	1-piperazinyl]propyl]-4,5-		
	diethyl-2,4-dihydro-3H-		
·FIU	1,2,4-triazol-3-one		
89	Febarbamate	Merck Index, 12th ed,	12th ed,
	1	No 3983	
	1-[2-		
	[(aminocarbonyl)oxy]-3-		
	butoxypropyl]-5-ethyl-5-		
	phenyl-2,4,6(1H,3H,5H)-		
	pyrimidinetrione		
06	Femoxetine	400-600 Merck Index, 12th ed, mg/day no 3993	12th ed, 3
	(3R-trans)-3-[(4-		<u>-</u> -
	methoxyphenoxy)methyl]-		
	1-methyl-4-		
	phenylpiperidine		
91	Fenpentadiol	Merck Index, 12th ed,	12th ed,
		8704 011	ກ
	2-(4-chlorophenyl)-4-		
	methyl-2,4-pentanediol		

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

		Table 3	Table 3: Antidepressant Agents	Agents		
92	Hematoporphyrin				Me	Merck Index, 12th ed, no 4669
	7,12-bis(1-hydroxyethyl)-					
	5,6,13,1/-tetrametnyl-					
	21H,23H-porphine-2,18-					
93	Hypericin				Me	Merck Index, 12th ed,
	,					no 4911
	1,3,4,6,8,13-					
	hexahydroxy-10,11-					
	dimethylphenanthro[1,10,					
	9,8-opgra]perylene-7,14-					
94	Levophacetoperane				Me	Merck Index, 12th ed, no 5493
	αphenyl-2-					
	piperidinemethanol acetate					
92	Medifoxamine	Cledial,		100-150	Me	Merck Index, 12th ed,
		Gerdasyl		mg/day		no 5834
	N,N-dimethyl-2,2-			1		
	diphenoxyethanamine					
96	Minaprine	Cantor		100-250 mg/day	Me	Merck Index, 12th ed,
	N-(4-methyl-6-phenyl-3-			( S.		) ) )
	pyridazinyl)-4-					
	morpholineethanamine					

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

	Merck Index, 12th ed,	no 8399				Merck Index, 12th ed,	no 8432				Merck Index, 12th ed,	no 8441	Merck Index, 12th ed, no 9163				Merck Index, 12th ed,	no 9521	
essant Agents	5-30	mg/day				7.5-30	mg/day						50-200 mg/dav						
Table 3: Antidepressant Agents	Tisterton	***************************************											Sulparex, Dogmatil.	Dolmatil,	Valirem				
	Ritanserin		6-[2-[4-[bis(4- fluorophenyl)methylene]-	1-piperidinyl]ethyl]-7-	methyl-5H-thiazolo[3,2-	Roxindole		3-[4-(3,6-dihydro-4-	pnenyl-1(ZH)-	pyridinyl)butyl]-1H-indol- 5-ol	Rubdium Chloride	Rubinorm	Sulpiride	5-(aminosulfonyl)-N-[(1-	ethyl-2-	pyrrolidinyl)methyl]-2- methoxybenzamide	Thozalinone	2-(dimethylamino)-5-	phenyl-4(5H)-oxazolone
	101					102					103		104				105		

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

Table 3: Antidepressant Agents	100-300	mg/day				reversible MAO- A inhibitor	50-200 mg/dav	5-40	mg/day	•			15-30	mg/day	20-120	mg/day	10-40	mg/day	50-150	mg/day	2.5-40	mg/day
Table 3: An	Symmetrel,	Symandine,	Amantan,	Mantadan,	Virofral	.eo	Solian	Dexedrine,	DextroStat,	Benzadrine		Emend	Abilify,	Abilitat	Strattera				Consonar		Parlodel,	Ergoset
	Amantadine		E Z	$\leftarrow$		Amiflamine	Amisulpride	Amphetamine		NH ₂	Ph	Aprepitant	Aripiprazole		Atomoxetine		Befloxatone		Brofaromine		Bromocriptine	
	106					107	108	109				110	111		112		113		114		115	

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

sant Agents	1.2-3.2	mg/day		100-150 mg/day		5-30	100-300	IIIg/uay		5-20 mg/day		900- 1800 mg/day		
Table 3: Antidepressant Agents	esic,	nex, tex							an, ron	ui	981			
	Temgesic,	Buprenex, Subutex							Tinoran, Deparon	<b>e</b> Focalin	Monase			
	Buprenorphine		Cericlamine	Ciclazindol	Cimoxatone	Clorgyline	Clovoxamine	Dapoxetine	Demexiptiline	Dexmethylphenidate	Etryptamine	Fengabine	Flerobuterol	Flesinoxan
	116		117	118	119	120	121	122	123	124	125	126	127	128

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

int Agents	50-200 mg/day		10-90 mg/day	40-120 mg/day				5-20 mg/day	2-8 grams	50-500 mg/day	
Table 3: Antidepressant Agents											
Table 3	Ectris		Ariza					Dynacirc, Lomir, Icaz	Larodopa, Dopar	Lamictal	
	Flibanserin	Fluparoxan	Gepirone	Idazoxan	Igmesine	Incazane	Ipsapirone	Isradipine	Levodopa	Lamotrigine	Levoprotiline
	129	130	131	132	133	134	135	136	137	138	139

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

sant Agents	25-100 mcg/da	10-25 mg/dav	1-3 mg/day								75-225 mg/day
Table 3: Antidepressant Agents	Cytomel		Mazanor, Sanorex, Teronac	Actomol	Timodyne, Perneuron	Axura, Akatinol, Exiba, Neuroplus	Mifeprex	Provigil, Alertec, Modiodal			Sintamil
	Liothyronine	Litoxetine	Mazindol	Mebanazine	Mefexamide	Memantine	Mifepristone	Modafinil	Nemifitide	Nisoxetine	Nitroxazepine
	140	141	142	143	144	145	146	147	148	149	150

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

nts	5-20	mg/day		40-180	iig/uay	40-200	g/day	50-113	g/day				.25-5	mg/day				
Table 3: Antidepressant Agents		m				4	m							E				
Tab	Zyprexa,	Lanzac		Oxycontin,	Eubine,	Geodon,	Zeldox	Cylert,	Deltamine				Permax,	Celance	le Drazine	Adipex, Zantryl	Visken	Trivastal
	Olanzapine		Oxaprotiline	Oxycodone		Ziprasidone		Pemoline	2	N=	<u></u>	Å	Pergolide		Phenoxypropazine	Phentermine	Pindolol	Piribedil
	151		152	153		154		155					156		157	158	159	160

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

164	District of the state of the st	Table 3:	Table 3: Antidepressant Agents	Agents	
101	Firindole, or Pyrazidol				
162	Pramipexole	Mirapex, Sifrol		1.5-4.5 mg/day	
163	Pregabalin				
164	Pyrovalerone	Centroton, Thymergix			
165	Risperidone	Risperdal		.5-2 mg/day	
166	Ropinirole	Requip		.75-3 mg/day	
167	Sibutramine	Meridia, Reductil		5-15 mg/day	
168	Talipexole				
169	Tetrindole				
170	Thyroxine	Synthroid, Levoxyl, Levothroid			
171	Tolcapone	Tasmar			
172	Vilazodone		ţ		
173	Viqualine				

Attorney Docket: 6794-197/POA Client Ref.: 01430/1

Table 3: Antidepressant Agents	8.1-16.2 mg/day			
Table 3:	Aphrodyne, Procomil, Yocon			
	Yohimbine H H H H H H H H H H H H H H H H H H H	Asenapine	1-pyrimidinylpiperazine	6-hydroxy-buspirone
3	174	175	176	177

[0206] In a preferred embodiment, the class of antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of tricyclics, tetracylics, hydrazides/hydrazines, bicyclics, benzodiazepines, and pyrrolidones, and mixtures thereof.

In a preferred embodiment, the tricyclic antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of amitriptyline, desipramine, imipramine, nortriptyline, amineptine, clomipramine, doxepin, amoxapine, trimipramine, protriptyline, tianeptine, adinazolam, amitriptylinoxide, butriptyline, dibenzepin, dimetacrine, dothiepin, fluacizine, imipramine N-oxide, iprindole, lofepramine, melitracen, metapramine, noxiptilin, opipramol, pizotyline, propizepine, and quinupramine, and mixtures thereof.

[0208] In a preferred embodiment, the tetracyclic antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of maprotiline, mirtazapine, metralindole, and mianserin, and mixtures thereof.

[0209] In a preferred embodiment, the bicyclic antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of sertraline, citalopram, paroxetine, trazodone, binodaline, caroxazone, dimethazan, fencamine, indalpine, indeloxazine hydrochloride, nefopam, nomifensine, oxitriptan, oxypertine, and thiazesim, and mixtures thereof.

[0210] In a preferred embodiment, the benzodiazepine antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of alprazolam and diazepam, and mixtures thereof.

[0211] In a preferred embodiment, the class of antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, noradrenaline reuptake

inhibitors, selective serotonin and noradrenaline reuptake inhibitors, dualaction serotonin norepinephrine reuptake inhibitors, norepinephrine antagonist serotonin antagonists, selective serotonin and noradrenaline reuptake inhibitors, serotonin antagonist and reuptake inhibitors, norepinephrine dopamine reuptake inhibitor, and serotonin reuptake accelerators, and mixtures thereof.

[0212] In a preferred embodiment, the selective serotonin reuptake inhibitor antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of sertraline, citalopram, escitalopram oxalate, fluvoxamine, paroxetine, and fluoxetine, and mixtures thereof.

[0213] In a preferred embodiment, the selective serotonin reuptake inhibitor antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of phenelzine, tranylcypromine, isocarboxazid, selegiline, caroxazone, and amiflamine, and mixtures thereof.

[0214] In a preferred embodiment, the serotonin antagonist and reuptake inhibitor antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of nefazodone and trazodone, and mixtures thereof.

[0215] In a preferred embodiment, the serotonin and noradrenaline reuptake inhibitor antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of milnacipran and moclobemide, and mixtures thereof.

[0216] In a preferred embodiment, the antidepressant that is suitable for use with the methods and compositions of the present invention is selected from the group consisting of sertraline, citalopram, escitalopram oxalate, fluvoxamine, paroxetine, fluoxetine, amitriptyline, desipramine, imipramine, maprotiline, reboxetine, nortriptyline, amineptine, zimelidine, venlafaxine, mirtazapine, milnacipran, phenelzine, tranylcypromine, nefazodone, trazodone, bupropion, clomipramine, tandospirone, isocarboxazid, lithium carbonate, lithium citrate, doxepin,

amoxapine, moclobemide, trimipramine, selegiline, protriptyline, viloxazine, alprazolam, pargyline, dextroamphetamine, methylphenidate, diazepam, buspirone, tianeptine, binodaline, caroxazone, dimethazan, fencamine, indalpine, indeloxazine hydrochloride, nefopam, nomifensine. oxitriptan, oxypertine, thiazesim, benmoxine, iproclozide, iproniazid, Ltryptophan, nialamide, octamoxin, toloxatone, cotinine, rolicyprine. rolipram, metralindole, mianserin, adinazolam, amitriptylinoxide, butriptyline, dibenzepin, dimetacrine, dothiepin, fluacizine, imipramine Noxide, iprindole, lofepramine, melitracen, metapramine, noxiptilin, opipramol, pizotyline, propizepine, quinupramine, tofenacin, adrafinil, benactyzine, butacetin, dioxadrol, duloxetine, etoperidone, febarbamate, femoxetine, fenpentadiol, hematoporphyrin, hypericin, levophacetoperane, medifoxamine, minaprine, oxaflozane, piberaline, prolintane. pyrisuccideanol, ritanserin, roxindole, rubdium chloride, sulpiride, thozalinone, amantadine, amiflamine, amisulpride, amphetamine, aprepitant, aripiprazole, atomoxetine, befloxatone, brofaromine, bromocriptine, buprenorphine, cericlamine, ciclazindol, cimoxatone, clorgyline, clovoxamine, dapoxetine, demexiptiline, dexmethylphenidate, etryptamine, fengabine, flerobuterol, flesinoxan, flibanserin, fluparoxan, gepirone, idazoxan, igmesine, incazane, ipsapirone, isradipine, levodopa, lamotrigine, levoprotiline, liothyronine, litoxetine, mazindol, mebanazine. mefexamide, memantine, mifepristone, modafinil, nemifitide, nisoxetine, nitroxazepine, olanzapine, oxaprotiline, oxycodone, ziprasidone, pemoline, pergolide, phenoxypropazine, phentermine, pindolol, piribedil, pirlindole or pyrazidol, pramipexole, pregabalin, pyrovalerone, risperidone, ropinirole, sibutramine, talipexole, tetrindole, thyroxine, tolcapone, vilazodone, viqualine, asenapine, 1-pyrimidinylpiperazine, 6-hydroxy-buspirone, and yohimbine, prodrugs of any of them, and mixtures thereof.

[0217] Any combination that includes at least one of the Cox-2 inhibitors that are described alone and, optionally, at least one of the antidepressant agents that are described above can be used in the novel methods, compositions, pharmaceutical compositions and kits of the

present invention. For example, a Cox-2 inhibitor such as celecoxib can be combined with any of the aforementioned antidepressant agents described in Table 3, including, for example, the antidepressant agent, sertraline.

[0218] One of skill in the art will understand how to make the antidepressant agents described above by following the teachings of the corresponding references.

[0219] Cox-2 inhibitors and antidepressant agents that are useful in the present invention can be of any purity or grade, as long as the preparation is of a quality suitable for pharmaceutical use. The Cox-2 inhibitor or antidepressant agent can be provided in pure form, or it can be accompanied with impurities or commonly associated compounds that do not affect its physiological activity or safety.

[0220] The Cox-2 inhibitors and antidepressant agents can be supplied in the form of a pharmaceutically active salt, a prodrug, an isomer, a tautomer, a racemic mixture, or in any other chemical form or combination that, under physiological conditions, still provides for inhibition of the Cox-2 enzyme and any physiological function that the antidepressant agent may perform. The present invention includes all possible diastereomers as well as their racemic and resolved, enantiomerically pure forms.

[0221] The present invention also encompasses a novel therapuetic composition comprising at least one Cox-2 inhibitor and one or more antidepressant agents.

[0222] In the present invention, a composition comprising a Cox-2 inhibitor in combination with a antidepressant agent is administered to a subject in need of such treatment according to standard routes of drug delivery that are well known to one of ordinary skill in the art.

[0223] The present invention also encompasses a pharmaceutical composition for preventing or treating a psychiatric disorder in a subject that is in need of such prevention and treatment, the pharmaceutical

composition comprising at least one Cox-2 inhibitor, at least one antidepressant agent, and a pharmaceutically acceptable carrier. Thus, the combination of a Cox-2 inhibitor and an antidepressant agent can be provided in a pharmaceutically acceptable carrier or excipient to form a pharmaceutical composition.

The pharmaceutical compositions of the present invention comprise a Cox-2 inhibitor and an antidepressant agent as an active ingredient or a pharmaceutically acceptable salt, thereof, and also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. When the Cox-2 inhibitor and an antidepressant agent inhibitor are supplied along with a pharmaceutically acceptable carrier, a pharmaceutical composition is formed. A pharmaceutical composition of the present invention is directed to a composition suitable for the prevention, treatment, or amelioration of a psychiatric disorder. The pharmaceutical composition comprises a pharmaceutically acceptable carrier, a Cox-2 inhibitor, and an antidepressant agent.

[0225] The term "pharmaceutically acceptable" is used herein to mean that the modified noun is appropriate for use in a pharmaceutical product.

[0226] Pharmaceutically acceptable carriers and excipients include, but are not limited to, physiological saline, Ringer's solution, phosphate solution or buffer, buffered saline and other carriers known in the art. Pharmaceutical compositions may also include stabilizers, anti-oxidants, colorants, and diluents. Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective. In one embodiment the Cox-2 inhibitor alone or in combination with the antidepressant agent are administered to a subject together in one pharmaceutical carrier. In another embodiment, the Cox-2 inhibitor and the antidepressant agent are administered separately.

[0227] The pharmaceutically acceptable carrier can also be selected on the basis of the desired route of administration of the compound. For example, in a preferred embodiment the carrier is suitable for oral administration. In a more preferred embodiment, the composition includes a carrier or additional agent that is suitable for promoting delivery of the compound to the brain. Carriers that can promote delivery of the compound to the brain can include any carrier that promotes translocation across the blood-brain barrier and any carrier that promotes uptake of the compound by neural cells. Examples of such carriers include those disclosed in U.S. Pat. Nos. 5,604,198 (issued to Poduslo, *et al.*), 5,827,819 (issued to Yatvin, *et al.*), 5,919,815 (issued to Bradley, *et al.*), 5,955,459 (issued to Bradley, *et al.*), and 5,977,174 (issued to Bradley, *et al.*).

The terms "pharmaceutically acceptable salts" refer to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Illustrative pharmaceutically acceptable salts are prepared from formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, hydrochloric, trifluoroacetic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxybethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, β-hydroxybutyric, galactaric and galacturonic acids.

[0229] Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine,

caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

[0230] Pharmaceutically acceptable cations include metallic ions and organic ions. More preferred metallic ions include, but are not limited to, appropriate alkali metal salts, alkaline earth metal salts and other physiological acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc in their usual valences.

[0231] Preferred organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplary pharmaceutically acceptable acids include, without limitation, hydrochloric acid, hydroiodic acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.

[0232] All of the above salts and ions can be prepared by those skilled in the art by conventional means from the corresponding compound of the present invention.

[0233] In the present invention, a Cox-2 inhibitor and/or antidepressant agent are administered to a patient in need of such treatment or prevention according to standard routes of drug delivery that are well known to one of ordinary skill in the art. The particular route and dosage of the Cox-2 inhibitor and the antidepressant agent depend upon

the needs of the subject being treated, the type of treatment or prevention, the efficacy of the compound and the degree of disease severity in the subject.

[0234] The pharmaceutical compositions may be administered enterally and parenterally. Oral (intra-gastric) is a preferred route of administration. Pharmaceutically acceptable carriers can be in solid dosage forms for the methods of the present invention, which include tablets, capsules, pills, and granules, which can be prepared with coatings and shells, such as enteric coatings and others well known in the art. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.

[0235] Enteral administration includes solution, tablets, sustained release capsules, enteric-coated capsules, and syrups. When administered, the pharmaceutical composition may be at or near body temperature.

[0236] Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate. sodium carbonate, lactose, calcium phosphate or sodium phosphate, granulating and disintegrating agents, for example, maize starch, or alginic acid, binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid, or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time

delay material such as glyceryl monostearate or glyceryl distearate may be employed.

[0237] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredients are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients are present as such, or mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.

[0238] Aqueous suspensions can be produced that contain the active materials in a mixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone gum tragacanth and gum acacia; dispersing or wetting agents may be naturallyoccurring phosphatides, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, or one or more sweetening agents, such as sucrose or saccharin.

[0239] Oily suspensions may be formulated by suspending the active ingredients in an omega-3 fatty acid, a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.

[0240] Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

[0100] Syrups and elixirs containing the Cox-2 inhibitor and/or antidepressant agent may be formulated with sweetening agents, for example glycerol, sorbitol, or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

The subject method of prescribing a Cox-2 inhibitor and/or antidepressant agent and compositions comprising the same can also be administered parenterally, either subcutaneously, or intravenously, or intramuscularly, or intrasternally, or by infusion techniques, in the form of sterile injectable aqueous or olagenous suspensions. Parenteral administration includes subcutaneous, intramuscular, intradermal, intramammary, intravenous, and other administrative methods known in the art.

[0243] Administration of either one or both of the Cox-2 inhibitor and antidepressant agents can also be by inhalation, in the form of aerosols or solutions for nebulizers. Therefore, in one embodiment, the Cox-2 inhibitor and/or the antidepressant agent is administered by direct inhalation into the respiratory system of a subject for delivery as a mist or other aerosol or dry powder. Delivery of drugs or other active ingredients directly to the subject's lungs provides numerous advantages including, providing an extensive surface area for drug absorption, direct delivery of therapeutic agents to the disease site in the case of regional drug therapy,

eliminating the possibility of drug degradation in the subject's intestinal tract (a risk associated with oral administration), and eliminating the need for repeated subcutaneous injections.

[0244] Aerosols of liquid particles comprising the active materials may be produced by any suitable means, such as inhalatory delivery systems. Nebulizers are commercially available devices which transform solutions or suspensions of the active ingredient into a therapeutic aerosol mist either by means of acceleration of compressed gas, typically air or oxygen, through a narrow venturi orifice or by means of ultrasonic agitation. Suitable formulations for use in nebulizers consist of the active ingredient in a liquid carrier. The carrier is typically water, and most preferably sterile, pyrogen-free water, or a dilute aqueous alcoholic solution, preferably made isotonic, but may be hypertonic with body fluids by the addition of, for example, sodium chloride. Optional additives include preservatives if the formulation is not made sterile, for example, methyl hydroxybenzoate, as well as antioxidants, flavoring agents, volatile oils, buffering agents and surfactants, which are normally used in the preparation of pharmaceutical compositions.

[0245] Aerosols of solid particles comprising the active materials may likewise be produced with any solid particulate medicament aerosol generator. Aerosol generators for administering solid particulate medicaments to a subject produce particles which are respirable, as explained above, and generate a volume of aerosol containing a predetermined metered dose of a medicament at a rate suitable for human administration.

[0246] One type of solid particulate aerosol generator is an insufflator. Suitable formulations for administration by insufflation include finely comminuted powders which may be delivered by means of an insufflator or taken into the nasal cavity in the manner of a snuff. In the insufflator, the powder is contained in capsules or cartridges, typically made of gelatin or plastic, which are either pierced or opened *in situ* and the powder delivered by means of air drawn through the device upon

inhalation or by means of a manually-operated pump. The powder employed in the insufflator consists either solely of the active ingredient or of a powder blend comprising the active materials, a suitable powder diluent, such as lactose, and an optional surfactant.

[0247] A second type of aerosol generator is a metered dose inhaler. Metered dose inhalers are pressurized aerosol dispensers, typically containing a suspension or solution formulation of the Cox-2 inhibitor and/or the antidepressant agent in a liquified propellant. During use, the metered dose inhaler discharges the formulation through a valve, adapted to deliver a metered volume, to produce a fine particle spray containing the active materials. Any propellant may be used for aerosol delivery, including both chlorofluorocarbon-containing propellants and non-chlorofluorocarbon-containing propellants.

[0248] A third type of aerosol generator is a electrohydrodynamic (EHD) aerosol generating device, which has the advantage of being adjustable to create substantially monomodal aerosols having particles more uniform in size than aerosols generated by other devices or methods. Typical EHD devices include a spray nozzle in fluid communication with a source of liquid to be aerosolized, at least one discharge electrode, a first voltage source for maintaining the spray nozzle at a negative (or positive) potential relative to the potential of the discharge electrode, and a second voltage source for maintaining the discharge electrode at a positive (or negative) potential relative to the potential of the spray nozzle. Most EHD devices create aerosols by causing a liquid to form droplets that enter a region of high electric field strength. The electric field then imparts a net electric charge to these droplets, and this net electric charge tends to remain on the surface of the droplet. The repelling force of the charge on the surface of the droplet balances against the surface tension of the liquid in the droplet, thereby causing the droplet to form a cone-like structure known as a Taylor Cone. In the tip of this conelike structure, the electric force exerted on the surface of the droplet overcomes the surface tension of the liquid, thereby generating a stream

of liquid that disperses into a many smaller droplets of roughly the same size. These smaller droplets form a mist which constitutes the aerosol cloud that the user ultimately inhales.

[0249] Administration of the compositions of the present invention can also be rectally, in the form of suppositories prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperature, but liquid at the rectal temperature and will therefore, melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

[0250] Also encompassed by the present invention is buccal or "sub-lingual" administration, which includes lozenges or a chewable gum comprising the compounds, set forth herein. The compounds can be deposited in a flavored base, usually sucrose, and acacia or tragacanth, and pastilles comprising the compounds in an inert base such as gelatin and glycerin or sucrose and acacia.

[0251] The prevent invention further encompasses intranasal administration comprising the compounds set forth herein. Intranasal dosage forms include, but are not limited to, aerosols, drops, gels, powders, and mixtures thereof.

[0252] Other methods for administration of the Cox-2 inhibitor compound and/or the antidepressant agent include dermal patches that release the medicaments directly into a subject's skin.

[0253] Topical delivery systems are also encompassed by the present invention and include ointments, powders, sprays, creams, jellies, collyriums, solutions or suspensions.

[0254] The compositions of the present invention can optionally be supplemented with additional agents such as, for example, viscosity enhancers, preservatives, surfactants and penetration enhancers.

[0255] Viscosity is an important attribute of many medications. Drops that have a high viscosity tend to stay in the body for longer periods and thus, increase absorption of the active compounds by the target tissues or increase the retention time. Such viscosity-building agents

include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methylcellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents know to those skilled in the art. Such agents are typically employed at a level of from 0.01% to 2% by weight.

Preservatives are optionally employed to prevent microbial contamination during use. Suitable preservatives include polyquaternium-1, benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, or other agents known to those skilled in the art. The use of polyquaternium-1 as the antimicrobial preservative is preferred. Typically, such preservatives are employed at a level of from 0.001% to 1.0% by weight.

[0256] The solubility of the components of the present compositions may be enhanced by a surfactant or other appropriate co-solvent in the composition. Such co-solvents include polysorbate 20, 60, and 80, polyoxyethylene/polyoxypropylene surfactants (e.g. Pluronic F-68, F-84 and P-103), cyclodextrin, or other agents known to those skilled in the art. Typically, such co-solvents are employed at a level of from 0.01% to 2% by weight.

[0257] A penetration enhancer is an agent used to increase the permeability of the skin to an active agent to increase the rate at which the drug diffuses through the skin and enters the tissues and bloodstream. Thus, in one embodiment of the present invention, a penetration enhancer may be added to a Cox-2 inhibitor topical composition or a Cox-2 inhibitor and antidepressant agent or topical composition.

[0258] Examples of penetration enhancers suitable for use with the compositions of the present invention include: alcohols, such as ethanol and isopropanol; polyols, such as n-alkanols, limonene, terpenes, dioxolane, propylene glycol, ethylene glycol, other glycols, and glycerol; sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformamide, methyl dodecyl sulfoxide, dimethylacetamide; esters, such as isopropyl myristate/palmitate, ethyl acetate, butyl acetate, methyl proprionate, and

capric/caprylic triglycerides; ketones; amides, such as acetamides; oleates, such as triolein; various surfactants, such as sodium lauryl sulfate; various alkanoic acids, such as caprylic acid; lactam compounds, such as azone; alkanols, such as oleyl alcohol; dialkylamino acetates, and admixtures thereof.

[0259] Pharmaceutically acceptable excipients and carriers encompass all the foregoing and the like. The above considerations concerning effective formulations and administration procedures are well known in the art and are described in standard textbooks. See e.g. Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 20th Edition, (Lippincott, Williams and Wilkins), 2000; Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania, 1975; Liberman, et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Kibbe, et al., Eds., Handbook of Pharmaceutical Excipients (3rd Ed.), American Pharmaceutical Association, Washington, 1999.

[0260] For purposes of the present invention, it is preferred that the amount of a Cox-2 inhibitor and the amount of an antidepressant agent comprise an effective amount of each of the two treatment agents. In another embodiment of the present invention, the amount of the combination therapy with the Cox-2 inhibitor and antidepressant agent together comprises a therapeutically effective amount of the combined therapy.

[0261] As used herein, an "effective amount" means the dose or amount to be administered to a subject and the frequency of administration to the subject, which is readily determined by one having ordinary skill in the art, by the use of known techniques and by observing results obtained under analogous circumstances.

[0262] In determining the effective amount or dose, a number of factors are considered by the attending diagnostician, including, but not limited to, the potency and duration of action of the compounds used, the nature and severity of the illness to be treated, as well as the sex, age,

weight, general health and individual responsiveness of the patient to be treated, and other relevant circumstances.

[0263] As used herein, the terms "therapeutically effective" are intended to qualify the amount of an agent for use in therapy that will achieve the goal of preventing or improving the severity of the disorder being treated, while avoiding adverse side effects typically associated with alternative therapies. A psychiatric disorder symptom is considered ameliorated or improved if any benefit is achieved, no matter how slight.

As used herein, the terms "prophylactically effective" refer to an amount of a Cox-2 inhibitor alone or in combination with at least one antidepressant agents that causes a decrease in the frequency of incidence of psychiatric disorders or psychiatric disorder-related symptoms. The term "prophylactic" refers to the prevention of psychiatric disorders or a psychiatric disorder-related symptom, whereas the term "therapeutic" refers to the effective treatment of an existing disorder such as psychiatric disorders or a psychiatric disorder-related symptom.

[0265] It will be appreciated that the amount of the Cox-2 inhibitor alone or in combination with at least one antidepressant agent required for use in the treatment or prevention of psychiatric disorders and psychiatric disorder-related symptoms will vary within wide limits and will be adjusted to the individual requirements in each particular case. In general, for administration to adults, an appropriate daily dosage is described herein, although the limits that are identified as being preferred may be exceeded if expedient. The daily dosage can be administered as a single dosage or in divided dosages.

[0266] The appropriate dosage level of a Cox-2 inhibitor will generally be from about 0.01 mg per kg to about 140 mg per kg subject body weight per day, which may be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 mg/kg to about 25 mg/kg per day; more preferably about 0.5 mg/kg to about 10 mg/kg per day.

[0267] In larger mammals, for example humans, a typical inclicated dose is about 0.5 mg to 7 grams orally per day. A Cox-2 inhibitor compound may be administered on a regimen of several times per day, for example 1 to 4 times per day, preferably once or twice per day.

The amount of the Cox-2 inhibitor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 7 g of active agent compounded optionally with an appropriate and convenient amount of carrier material, which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms for the Cox-2 inhibitor will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

The dosage level of an antidepressant agent will necessarily depend on the particular antidepressant agent that is used. The appropriate dosage level of an antidepressant agent will generally be from about 0.001 mg per kg to about 50 mg per kg subject body weight per day, which may be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 mg/kg to about 25 mg/kg per day; more preferably about 1.0 mg/kg to about 10 mg/kg per day.

[0270] In larger mammals, for example humans, a typical indicated dose of an antidepressant agent is about 0.1 mg to 2 grams orally per day. An antidepressant agent may be administered on a regimen of several times per day, for example 1 to 4 times per day, preferably once or twice per day.

[0271] The exact dosage and regimen for administering a Cox-2 inhibitor alone or in combination with at least one antidepressant agent will necessarily depend upon the potency and duration of action of the compounds used, the nature and severity of the illness to be treated, as well as the sex, age, weight, general health, and individual respons iveness of the patient to be treated, and other relevant circumstances. Those

skilled in the art will appreciate that dosages may also be determined with guidance from Goodman & Goldman's <u>The Pharmacological Basis of Therapeutics</u>, Ninth Edition (1996), Appendix II, pp. 1707-1711.

[0272] The effectiveness of a particular dosage of a Cox-2 inhibitor alone or in combination with an antidepressant agent is determined by monitoring the effect of a given dosage on the progress or prevention of a particular psychiatric disorder. This monitoring may be done through outpatient therapy or in a hospitalized setting.

[0273] For example, monitoring the effectiveness of the methods and compositions of the present invention on a subject suffering from depression may involve evaluating the subject under out-patient therapy. In this setting, any changes in the subject's symptoms of depression are monitored and evaluated by a therapist.

Still other methods for monitoring the effectiveness of the methods and compositions of the present invention can include conducting an evaluation of a subject's limbic-diencephalic function/dysfunction. Such evaluation can be performed by utilizing such tests as the thyrotropin-releasing hormone (TRH) stimulation test, the dexamethasone suppression test (DST), and sleep EEG for rapid eye movement (REM) latency test. See The Merck Manual of Diagnosis & Therapy, Beers & Brakow, 17th edition, Published by Merck Research Labs, Sec. 15, Chap. 189, Psychiatric Disorders, Mood Disorders (1999).

[0275] As used herein, the term "subject" for purposes of treatment includes any subject, and preferably is a subject who is in need of the treatment of psychiatric disorders, or who needs treatment of a psychiatric disorder-related symptom. For purposes of prevention, the subject is any subject, and preferably is a subject that is at risk for, or is predisposed to, developing a psychiatric disorder or a psychiatric disorder-related symptom. The subject is typically an animal, and yet more typically is a mammal. "Mammal", as that term is used herein, refers to any animal classified as a mammal, including humans, domestic and farm animals, zoo, sports, or pet animals, such as dogs, horses, cats, cattle, etc.

Preferably, the mammal is a human. For purposes of the present invention, an adult human weighs approximately seventy kilograms.

[0276] As used herein, the terms "a subject who is predisposed to a psychiatric disorder" and "a subject who is at risk for a psychiatric disorder," both of which are used interchangeably herein, mean any subject at risk for developing psychiatric disorders or any psychiatric disorder-related symptoms. The subject may be a human subject who is at risk for developing psychiatric disorders or any psychiatric disorder-related symptoms. The subject may be at risk due to genetic predisposition, diet, age, exposure to traumatic life events, exposure to a separation such as death, and the like. The subject may also be at risk due to physiological factors such as abnormalities in the brain.

As used herein, the terms "subject is in need of the [0277] prevention or treatment of a psychiatric disorder or a psychiatric disorderrelated symptom" refer to any subject who is suffering from or is predisposed to psychiatric disorders or any psychiatric disorder-related symptoms described herein. The terms "subject is in need of the prevention or treatment of a psychiatric disorder or a psychiatric disorderrelated symptom" also refer to any subject that requires a lower dose of conventional antidepressant agents. In addition, the terms "subject is in need of the prevention or treatment of a psychiatric disorder or a psychiatric disorder-related symptom" mean any subject who requires a reduction in the side effects of a conventional antidepressant agent. Furthermore, the terms "subject is in need of the prevention or treatment of a psychiatric disorder or a psychiatric disorder-related symptom" mean any subject who requires improved tolerability to any conventional psychiatric disorder treatment agent for psychiatric disorders therapy.

[0278] The present invention encompasses the prevention and/or treatment of any pychiatric disorder including, but not limited to, depression (uni-polar disorder or major depressive disorder), manic depression (bipolar disorders), anxiety disorder, anxious depression, panic disorder, attention deficit disorder, attention deficit/hyperactivity disorder,

melancholia (endogenous depression), depressive pseudodementia, dysthymic disorder, cyclothymic disorder, somatization disorder, conversion disorder, hypochondriasis, pa in disorder, posttraumatic stress disorder, acute stress disorder, obsessive compulsive disorder, premenstrual dysphonic disorder, body dysmorphic disorder, schizophrenia, autism, agoraphobia, specific phobias, social phobia, acute stress disorder, dissociative amnesia, dissociative fugue, dissociative identity disorder, depersonalization disorder, and any combination of the above.

[0279] In one embodiment, the present invention encompasses the treatment or prevention of depression.

In other embodiments, the present invention encompasses a kit for preventing or treating psychiatric disorders or any psychiatric disorder-related symptoms in a subject that is in need of such prevention or treatment, the kit comprising one dosa ge form comprising a Cox-2 inhibitor and a second dosage form comprising at least one antidepressant agent.

Invention. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered to be exemplary only, with the scope and spirit of the invention being indicated by the claims, which follow the examples. In the examples, all percentages are given on a weight basis unless otherwise indicated.

## EXAMPLE 1

[0282] This example shows the preparation of the Cox-2 inhibitor, celecoxib.

[0283] Step 1: Preparation of 1-(4- methylphenyl)-4,4,4-trifluorobutane-1,3-dione.

[0284] Following the disclosure provided in U.S. Patent No. 5,760,068, 4'-Methylacetophenone (5.26 g, 39.2 mmol) was dissolved in 25 mL of methanol under argon and 12 mL (52.5 mmol) sodium methoxide in methanol (25%) was added. The mixture was stirred for 5 minutes and 5.5 mL (46.2 mmol) ethyl trifluoroacetate was added. After refluxing for 24 hours, the mixture was cooled to room temperature and concentrated. 100 mL 10% HCl was added and the mixture extracted with 4 x 75 mL ethyl acetate. The extracts were dried over MgSO4, filtered and concentrated to afford 8.47 g (94%) of a brown oil which was carried on without further purification.

[0285] Step 2: Preparation of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

absolute ethanol, 4.26 g (19.0 mmol) 4-sulphonamidophenylhydrazine hydrochloride was added. The reaction was refluxed under argon for 24 hours. After cooling to room temperature and filtering, the reaction mixture was concentrated to afford 6.13 g of an orange solid. The solid was recrystallized from methylene chloride/hexane to give 3.11 g (8.2 mmol, 46%) of the product as a pale yellow solid, having a melting point (mp) of 157°-159°C; and a calculated composition of C₁₇ H₁₄ N₃ O₂ SF₃; C, 53.54; H, 3.70; N, 11.02. The composition that was found by analysis was: C, 53.17; H, 3.81; N, 10.90.

## **EXAMPLE 2**

[0287] This example illustrates the production of a composition containing celecoxib and an antidepressant agent, and of a pharmaceutical composition containing the combination.

[0288] An antidepressant such as sertraline may be supplied by any one of several commercially available preparations. One such preparation of sertraline is the trade name Zoloft® 100mg (NDC: 00049-4910-66)

available from the Roerig Division of Pfizer Inc, NY, NY. Each tablet of Zoloft® contains 100mg of sertraline.

[0289] Alternatively, one of skill in the art may synthesize sertraline from a reading of the general synthesis outline disclosed in U.S. Patent Numbers 4,536,518 and 4,556,676.

[0290] A therapeutic composition of the present invention can be formed by intermixing sertraline, 100 g; and 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (200 g, as produced in Example 1, or as available from Pharmacia Corporation, Peapack, NJ, under the tradename Celebrex®), in a suspension or solution with a sterile pharmaceutically acceptable liquid.

**[0291]** After mixing, the combination of sertraline and celecoxib forms a therapeutic composition that is sufficient for the production of about 1000 human single dose units. Each single dose unit contains about 100 mg of sertraline and about 200 mg of celecoxib.

[0292] If desirable, a solid carrier and other materials may be intermixed with the therapeutic composition to form a pharmaceutical composition and the resulting pharmaceutical composition may be formed into capsules for human consumption, for example, by conventional capsule-forming equipment, where each capsule can contain about the same amount of the active ingredients as each of the single dose units of the liquid preparation described above.

[0293] Therapeutic and pharmaceutical compositions comprising a combination of any of the Cox-2 inhibitors alone and in combination with any of the sources of antidepressant agents that are described above can be formed by similar methods.

[0294] All references cited in this specification, including without limitation all papers, publications, patents, patent applications, presentations, texts, reports, manuscripts, brochures, books, internet postings, journal articles, periodicals, and the like, are hereby incorporated by reference into this specification in their entireties. The discussion of the references herein is intended merely to summarize the assertions made by

their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinency of the cited references.

[0295] In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results obtained.

[0296] As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense. In addition, it should be understood that aspects of the various embodiments may be interchanged both in whole or in part.